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Quantitative imaging biomarkers gain increasing importance in research and clinical 
medicine. Measurement of biomarkers compared to mere visual evaluation allows for more 
objective evaluation of disease, and more accurate assessment of the stage and develop-
ment of disease through time [1-6]. Low-dose computed tomography (CT) examinations, 
obtained as part of lung cancer screening, can provide quantitative information on bio-
markers for lung cancer, cardiovascular disease and chronic obstructive pulmonary disease 
(COPD) - the big three killers of the Western population [7-12].  
The Dutch-Belgian Randomized Lung Cancer Screening Trial (Dutch acronym: NEL-
SON) was launched in 2003. Details on participant recruitment and CT acquisition proto-
col were described elsewhere [8]. In short, four rounds of low-dose CT screening took place 
in the year 1, 2, 4, and 6 for heavy (ex-) smokers between 50 and 75 years of age. Evaluation 
of CT examinations in lung cancer screening can also include assessment of coronary calci-
fication, emphysema and airway wall, markers for abovementioned major diseases that 
share risk factors with lung cancer [13]. A practical approach to the radiological evaluation 
of CT lung cancer screening examinations is necessary, including evaluation of pulmonary 
nodules and non-nodular diseases.  
 
Lung nodule volumetry 
The most common cause of cancer-related death is lung cancer. In the year 2000, lung can-
cer accounted for 17% of total cancer mortality [14]. Low-dose CT was proposed as a prom-
ising method to screen for lung cancer. Several cohort studies and randomised clinical tri-
als using low-dose CT were started, aiming to investigate the effect of lung cancer screen-
ing on the distribution of tumour stages, and eventually the effect on survival [7, 15, 16]. In 
CT screening, an overwhelming number of small, indeterminate solid pulmonary nodules 
are detected [7, 9, 17]. The large majority of these nodules are benign. Optimal manage-
ment protocol of small pulmonary nodules is important for early identification of malig-
nant lesions in screening, while at the same time preventing too many false positive refer-
rals. Efficient lung cancer screening starts with sensitive observer detection of pulmonary 
nodules. There are only scarce validation data on the detectability of small pulmonary 
nodules by low-dose CT [18, 19].  
In lung cancer screening, treatment decisions usually depend on pulmonary nodule 
size at first detection, and on growth rate at follow-up [9]. Therefore, it is essential to as-
sess nodule size and growth rate accurately and reproducibly [20]. Unfortunately, variabil-
ity has been found in CT-derived nodule size assessment [21, 22]. In view of the current 
practice that patients frequently undergo follow-up examinations, sometimes on different 
scanners, reliable inter- and intra-scanner reproducibility of nodule volumetry is important. 
However, previous studies reported inconsistent results regarding the reproducibility of 
nodule volumetry. Some in-vitro studies have been performed in which artificial nodules 
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were placed at known locations in a thoracic phantom without pulmonary vessels [23-25]. 
Some of these studies were based on older generation CT scanners [23, 26]. These studies 
generally showed a small margin of variability in nodule volumetry for software from dif-
ferent vendors. On the other side, in-vivo studies have shown that variability can be con-
siderable, with variability up to 25% for 15 to 500 mm
3
 nodules [21, 27-29]. A new anthro-
pomorphic phantom with pulmonary background is ideal to validate the detectability and 
volumetry of nodules, as in this controlled setting, a known number of artificial nodules 
are inserted, all having a known volume. These validation studies are essential for optimi-
zation of the management protocol for small nodules in lung cancer screening [8, 30]. 
 
Coronary calcium scoring 
The CT-derived coronary artery calcium score is a strong predictive biomarker of cardio-
vascular events [31-34]. Calcium scoring has been found to improve cardiovascular risk 
stratification beyond cardiovascular risk factors [33, 35]. Due to the irregular and periodic 
movements of coronary arteries, electrocardiography (ECG)-triggered cardiac acquisition 
techniques are applied in CT to minimize motion artifacts and optimize calcium scoring 
[32]. Compared to ECG-triggered CT, nontriggered CT of the thorax is extensively utilized. 
In 2007, 13.6 million nontriggered thoracic CT examinations were performed in the United 
States alone, in contrast to 0.7 million ECG-triggered CT examinations for calcium scoring 
[36]. In lung cancer screening, coronary calcification is a frequent finding [11]. Age and 
smoking, the current selection criteria for lung cancer screening, are also correlated with 
coronary calcification and coronary heart disease [37]. If nontriggered CT can be used for 
calcium scoring, to stratify individuals in categories of cardiovascular risk and to identify 
those at high cardiovascular risk, there may be a substantial unused primary prevention 
potential [38]. Also, deriving the calcium score from the same examination as used in lung 
cancer screening may positively impact the cost-effectiveness of screening. Because motion 
of coronary arteries influences calcium scoring [39], the utilization of coronary calcium 
scoring in nontriggered CT is still being debated [40]. Variability in coronary calcium 
quantification between ECG-triggered and nontriggered CT can be substantial [39, 41]. 
Compared with the extensive publications regarding ECG-triggered cardiac CT, the litera-
ture on calcium scoring based on nontriggered thoracic CT is relatively limited. 
 
Emphysema and bronchial wall quantification 
COPD is characterized by airflow limitation that is not fully reversible [42]. The patho-
genesis of airflow limitation in COPD is mainly related to emphysema and small airway 
remodelling [43]. For COPD patients, quantitative morphological biomarkers based on CT 
could be important to understand pathogenesis and the effect of therapeutic interventions 
[44, 45], and could help to identify those most at risk for acute exacerbations [46]. In mul-
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tiple studies, multi-detector CT was found to accurately evaluate the extent of emphysema 
[47-50]. Different measures have been introduced to quantify the severity of emphysema 
[51-55]. Airway wall quantification started over a decade ago, mainly for large airways [44, 
56-58], but investigators have measured peripheral airways down to 0.5 mm lumen diame-
ter [59] and 2.8 mm outer diameter [60]. Measurement of narrowing of CT-detectable air-
ways may estimate the degree of small airway disease [59]. The assumption is that emphy-
sema and peripheral airway wall thickness, as CT-derived biomarkers, are correlated to 
airflow obstruction in COPD patients. Study results have been variable and sometimes 
conflicting. However, some individual studies have been small and underpowered [43, 61-
64].  
Nearly half of the smokers in lung cancer screening have chronic respiratory symp-
toms, i.e., chronic hyper secretion of mucus, combined with chronic cough, often accom-
panied by dyspnea and wheezing [65]. Smokers with these symptoms have a higher risk to 
develop chronic bronchitis, a disease associated with an accelerated decline in pulmonary 
function – a major risk factor for COPD and all-cause mortality [66, 67]. Despite the high 
prevalence in smokers, chronic bronchitis is often under-diagnosed or diagnosed late [68]. 
Histopathologically, chronic bronchitis characterized by bronchial wall thickening and 
airway luminal narrowing, commonly in large airways [69, 70]. Morphological biomarkers 
are important to understand pathogenesis and effect of therapeutic interventions for 
chronic bronchitis [71, 72]. In participants of lung cancer screening, it is important to know 
whether morphological changes of airway walls are related to chronic respiratory symp-
toms, since early detection of chronic bronchitis by CT could lead to earlier treatment. 
 
Outline thesis 
Quantitative CT biomarkers for lung cancer, cardiovascular disease and COPD were inves-
tigated in this thesis, in particular quantification of the pulmonary nodule, coronary calci-
fication, emphysema and the bronchial wall. In Chapter 2, a practical approach to evaluate 
these CT biomarkers in the NELSON trial is described. Chapter 3 - 5 describe studies on 
lung nodule validation based on an anthropomorphic phantom and on screening data. 
Here the focus is on the sensitivity of detection of nodules in low-dose CT, and the accu-
racy and variability of nodule volumetry by manual and semi-automated measurements. In 
Chapter 6, the diagnostic and prognostic significance of coronary calcification assessed on 
nontriggered thoracic CT is described in a systematic review and meta-analysis, while 
Chapter 7 evaluates the agreement in coronary calcium scoring between thoracic CT and 
dedicated cardiac CT. In Chapter 8, emphysema and airway measurements based on CT 
are correlated with airflow obstruction in COPD in a systematic review and meta-analysis. 
Finally, in Chapter 9, CT-derived airway wall thickness along the respiratory pathway is 
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Lung cancer is the most common cause of cancer-related death in the world. The Dutch-
Belgian Randomized Lung Cancer Screening Trial (Dutch acronym: NELSON) was 
launched to investigate whether screening for lung cancer by low-dose multi-detector 
computed tomography (CT) in high risk subjects will lead to a decrease of lung cancer 
mortality. The NELSON lung nodule management is based on volumetry and volume-
doubling time assessment. Evaluation of CT examinations in lung cancer screening can also 
include assessment of coronary calcification, emphysema and airway wall, markers for ma-
jor diseases that share risk factors with lung cancer. In this review, a practical approach to 






Lung cancer is the primary cancer in males and the second in females, comprising 18% of 
the total number of deaths [1]. Despite advances in treatment, the 5-year survival rate is 
still only 15% or even less, as many lung cancers are found at a relatively late stage [2]. Low-
dose computed tomography (CT) was proposed as a promising screening method for early 
detection of lung cancer.  
The Dutch-Belgian Randomized Lung Cancer Screening Trial (Dutch acronym: NEL-
SON) was launched in 2003. The hypothesis of the NELSON trial is that lung cancer 
screening by low-dose spiral CT will reduce 10-year lung cancer mortality by 25% in a high 
risk population. Details on participant recruitment and CT acquisition protocol were de-
scribed elsewhere [3]. In short, four rounds of low-dose CT screening took place in the year 
1, 2, 4, and 6 for heavy (ex-) smokers between 50 and 75 years of age. The NELSON lung 
nodule management is based on volumetry and volume-doubling time assessment. Thin-
slice thoracic CT images were acquired with a slice thickness of 1 mm, and a slice interval 
of 0.7 mm, allowing for volume measurements of pulmonary nodules.  
Evaluation of CT examinations in lung cancer screening can also include assessment 
of coronary calcification, emphysema and airway wall, markers for major diseases that 
share risk factors with lung cancer [4]. In this review, a practical approach to the radio-
logical evaluation of CT lung cancer screening examinations is described, including evalua-
tion of pulmonary nodules and nonnodular diseases.   
 
 
Figure 1   A complete calcified nodule is considered as benign (a). A very small (14 mm3) nodule is 
not further evaluated (b and c). 
 
a b c 
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Pulmonary nodule evaluation 
 
Initial assessment 
The assessment starts with evaluating whether a newly detected nodule has purely benign 
characteristics like benign calcifications or is very small (< 15 mm
3
) (Figure 1). If so, the 
nodule is categorized as benign, and not further evaluated. If the nodule cannot directly be 
defined as benign, the nodule is further evaluated. Next, the density of the lung nodule is 
assessed. A nodule can be solid, partial-solid, or nonsolid.   
 
 
Figure 2   Screen capture of dedicated software (LungCare, Siemens, Forchheim, Germany) to 
semi-automatically measure the volume of a solid nodule. 
 
Size-based evaluation 
Evaluation of nodule size is essential to determine nodule growth. Evaluation methods for 
solid, partial-solid and nonsolid nodules are different.  
Semi-automated volumetry measurements are utilized for segmentable nodules (Fig-
ure 2), e.g., solid nodules and the solid part of partial-solid nodules. In NELSON, approxi-
mately 98% of the total nodules have been found to be solid, thus are potential to be as-
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sessed using semi-automated software [5]. In case of inappropriate segmentation, the 
reader is allowed to manually modify the segmentation for more accurate segmentation, 
which therefore overrules the automatically generated volume.  
Manual measurement of diameters is performed for nonsegmentable nodules (Figure 
3), e.g., nonsolid nodules and the nonsolid part of partial-solid nodules. Although partial-
solid and nonsolid nodules constitute the minority of nodules that are detected, the fre-
quency of malignancy is higher [6].  
 
 
Figure 3   Semi-automated volumetry is performed for the solid part of a partial-solid nodule (a), and 
manual measurement of diameters is used for the nonsolid part of this partial-solid nodule (b). Man-
ual measurement of diameters is performed for a nonsolid nodule (c). 
 
In-vivo interscan variability for nodule size evaluation is inevitable. Based on valida-
tion studies with repeated low-dose CT on the same day, in which the measurement error 
was maximally 25%, nodule growth is defined as a change in volume of at least 25% be-
tween two subsequent examinations [7]. 
 
Additional nonsize based evaluation 
 
Besides the nodule density, attachment type, shape, margin and location should be taken 
into account when evaluating a pulmonary nodule (Figure 4). Firstly, the attachment of 
nodules (peri-fissural, vessel-attached, pleural-based and intraparenchymal) is evaluated. 
Although peri-fissural nodules may show growth at follow-up CT, the malignancy potential 
of peri-fissural nodules is low [8]. Secondly, the shape of nodules (spherical and nonspheri-
cal) is evaluated. Nonspherical shape has been found to increase the likelihood of malig-
nancy, rather than spherical shape [9]. Thirdly, the margin of nodules (smooth, lobulated, 
spiculated and others) is assessed. In a subgroup of NELSON with 469 solid intraparen-
b c a 
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chymal nodules, a lobulated or spiculated margin increased the likelihood for malignancy, 
rather than the smooth margin [10]. At last, nodule location is defined by the pulmonary 
segment and according to distance to pleura: peripheral nodules are defined as < 1/3 from 
total distance hilus-costal pleura, and central nodules are defined as > 2/3. In-between 




Figure 4   Example images of four nodule attachment types: peri-fissural (a), vessel-attached (b), 




A single CT lung cancer screening evaluation by an experienced reader seems sufficient. In 
the first to third round of the NELSON trial, images were evaluated twice. The second 
readers were unaware of the conclusion of the first reader. In case of discrepancy, a third 
reader made the final decision. However, based on the results from the first three rounds, 
no statistically significant benefit was found for consensus double reading for lung cancer 
a b c d 
e f g 
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with the use of a nodule management strategy based on semi-automated volumetry meas-
urements [11]. Thereafter, in the fourth round, only one reading was performed by one of 
the two radiologists with experiences of at least 8 years.  
Images are interpreted on a workstation for pulmonary nodules and nonnodular dis-
eases (in the NELSON trial: Leonardo, Siemens, Forchheim, Germany), both at lung win-
dow and mediastinal settings. When pulmonary nodules are identified, a dedicated soft-
ware package (in the NELSON trial: LungCare, Siemens, Forchheim, Germany) is utilized 
for semi-automated nodule volumetry measurements. In case of nonsegmentable nodules, 
the reader should manually measure the lesion in diameter. In the LungCare software 
package, previous and current images are displayed simultaneously on the same screen for 
comparison. Besides the evaluation of nodule size, nodule characteristics (attachment type, 
margin, etc.) are then also evaluated. 
 
Table 1   Nodule categorization based on size and density (new nodules) and growth rate (existing 
nodules) in the NELSON trial 
Category Definition 
NODCAT 1 A benign nodule (with fat/benign calcifications) or other benign abnormalities 
NODCAT 2 A nodule, smaller than NODCAT3, not belonging to NODCAT1 
 Solid Partial solid Nonsolid 
NODCAT 3 
50 ≤ V ≤ 500 mm3 
 
Pleural based: 5 ≤ dmin ≤ 10 mm  
Solid component: 50 ≤ V ≤ 500 mm3 
 
Nonsolid component: dmean ≥ 8 mm 
dmean ≥ 8 mm 
NODCAT 4 
V > 500 mm3 
 
Pleural based: dmin > 10 mm 
Solid component: V > 500 mm3 
(nonexisting 
category) 
GROWCAT A VDT > 600 days 
GROWCAT B 400 ≤ VDT ≤ 600 days 
GROWCAT C VDT < 400 days, or new solid component in nonsolid lesion 
V = volume; dmin = minimal diameter; dmean = mean diameter; VDT = volume doubling time. 
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Figure 6   Decision tree of second, third and fourth round examination in the NELSON trial. 
Part 1   Introduction 
 20 
Lung nodule decision management 
Newly detected lung nodules are divided into four categories (NODCAT 1 to 4), based on 
nodule density and size. In subsequent screening rounds, pre-existing nodules are defined 
as three categories (GROWCAT A to C), based on nodule growth in terms of volume-
doubling time (Table 1). For newly detected nodules, the test result (negative, indetermi-
nate and positive) is based on the highest NODCAT. For pre-existing nodules, the test re-
sult is based on highest GROWCAT. A negative result indicates that no further workup is 
needed. The participant is then invited to undergo the regular next-round CT. An indeter-
minate result requires a follow-up examination after 6 weeks (for incidence screening) to 3 
months (for baseline screening). A positive result necessitates referral to a pulmonologist 
for work-up and diagnosis. The decision trees for baseline, second, third and fourth round 
are shown in Figures 5 and 6. An example of a growing nodule resulting in lung cancer is 
shown in Figure 7. 
 
 
Figure 7   A new pulmonary nodule was found in apicoposterior segment of left superior lobe in the 
third round (a and b). The volume was 54 mm3 (NODCAT 3). The nodule was nonspherical, 
lobulated and solid. On the fourth round, 3 years later (c and d), the nodule volume increased to 249 
mm3, and the volume-doubling time was 284 days (GROWCAT C). Thus, this participant was 
considered as a positive case and was referred to a pulmonologist. Finally this nodule was 
confirmed as lung cancer. 
 
NELSON management system 
In the NELSON trial, evaluation results are exported into the web-based NELSON man-
agement system (Figure 8). Nodule characteristics, volume and diameter are recorded. 
Nodule volume is automatically compared to the previous data to calculate the percentage 
volume change and the volume-doubling time in days. Finally, the system makes a sugges-
tion for categorization of pulmonary nodules.   
 




Figure 8   Screen capture of the web-based NELSON management system. 
 
Table 2   Nonnodular radiological findings in lung cancer CT screening 
 Not clinically significant Clinically significant 
Aortic calcium  Adrenal lesion  
Bronchiectasis  Aortic aneurysm  
Coronary artery calcifications Bone destruction  
Emphysema Liver lesions  
Pulmonary fibrosis  Mass (thyroid, breast, abdominal, etc.) 
Lymph node enlargement  Pleural fluid  
Pleural calcifications Pneumonia  
Disease 




Besides lung cancer originating from pulmonary nodules, over 14% of participants in lung 
cancer screening have been found to have clinically significant diseases, such as cardiovas-
cular diseases and pulmonary diseases [12]. Aging and smoking, the two major risk factors 
for lung cancer, are also the main contributors to the development and progression of 
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coronary calcification and emphysema [13,14]. It is important to review the CT screening 
examination for coronary artery calcification and emphysema. These important thoracic 
findings can be evaluated quantitatively, see the description below.  
A list of nonnodular radiological findings that were initially reported in the NELSON 
trial is given in Table 2. Some severe diseases have been detected in the NELSON screen 
group, e.g., abdominal aortic aneurysm and renal cancer (Figure 9). However, the preva-
lence of clinically significant findings in the NELSON trial is only 1% and the benefit for 
systematically searching for these additional findings has been found to be neglectable [15].  
 
 
Figure 9   Incidentally found abdominal aortic aneurysm (a). The maximal diameter was measured 
as 6 cm. Incidentally found left renal mass (b), which was subsequently proved as renal carcinoma. 
 
Coronary artery calcification 
Coronary artery calcification is a frequent finding in the NELSON screening group, with a 
prevalence of over 70% [16]. Calcium scoring as part of low-dose CT lung cancer screening 
can be used as an independent predictor of cardiovascular death and events [16,17]. For the 
analysis of coronary calcification, the raw data should be reconstructed into 3 mm thick-
ness to improve interscan reproducibility and make the settings more comparable to the 
dedicated coronary calcium examination [18,19]. Then, calcium scoring can be per-formed 
using the method developed by Agatston [20]. An example of evaluating calcium score is 






Figure 10   Screen capture of dedicated software (Aquarius iNtuition Calcium Score, TeraRecon, 
Foster City, US) to evaluate calcium score.  
 
Emphysema and airway wall 
Emphysema is also a frequent finding in lung cancer screening. The two primary causes of 
chronic obstructive pulmonary disease (COPD) are emphysema and airway remodelling 
[21]. In a meta-analysis, CT measured emphysema and airway wall thickness were signifi-
cantly correlated with airflow obstruction in COPD [22]. CT examinations obtained for 
lung cancer screening can identify participants with COPD, with a sensitivity of 63% and a 
specificity of 88% [23]. Among the parameters that can be used to quantify emphysema, 
percentage of lung attenuation area under -950 HU (%LAA-950), mean lung density (MLD) 
and 15 percentile point of lung density (Perc 15) are the most commonly utilized. Among 
the parameters to quantify airway wall thick-ness, wall area percentage (WA%) and wall 
thickness (WT) are the most commonly utilized [22]. Dedicated software is needed to ob-
tain quantitative emphysema and airway wall measures (Figures 11 and 12). 
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Figure 11   Screen capture of dedicated software to assess emphysema (Aquarius iNtuition LowAtt, 
TeraRecon, Foster City, US). 
 
 
Figure 12   Screen capture of dedicated software to measure airway wall (Airway Examiner, 





The NELSON trial is the first lung cancer screening trial in which nodules management is 
based on semi-automated volumetry measurements. The high resolution images acquired 
in low-dose thin-slice CT in NELSON are potential for evaluation of not only nodule vol-
ume, but also for interpretation and measurement of other thoracic structures. A 10-step 
practical approach to evaluate a participant was summarized in Table 3.  
Cardiovascular diseases and COPD share risk factors, like aging and smoking, with 
lung cancer, and therefore, the incidence of these diseases in a lung cancer screening popu-
lation is high. Besides the evaluation of lung nodules, low-dose thoracic CT is feasible to 
evaluate cardiac artery calcium, emphysema and airway wall thickness, and thereby can 
evaluate the risk for cardiovascular diseases and COPD. An integrated evaluation for these 
diseases is potential for participants in lung cancer screening. 
 
Table 3   A 10-step approach to evaluate a participant in the NELSON trial 
Step Practical approach  
1  Evaluate the presence of nodules (new or existing)  
2 Exclude nodules with benign calcifications and nodules <15 mm3  
3 Determine the nodule density (solid, partial-solid, or nonsolid) 
4 Measure the nodule (volume and diameters)  
5 Determine the nodule characteristics (morphology, margin, location, lung segment) 
6 In case of an existing nodule, compare to the previous examination, and determine vol-
ume doubling time 
7 Categorize the nodule (for a new nodule based on size, for an existing nodule based on 
growth) 
8 Repeat step 3-7 for each additional nodule  
9 Review for coronary calcification, emphysema, and other findings 











1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: 
GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.  
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-
29.  
3. Ru Zhao Y, Xie X, de Koning HJ, et al. NELSON lung cancer screening study. Cancer 
imaging 2011; 11: S79-84.  
4. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes 
of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global 
Burden of Disease Study 2010. Lancet 2013; 380: 2095-2128.  
5. van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of lung nodules detected 
by volume CT scanning. New England Journal of Medicine 2009; 361: 2221-2229.  
6. Henschke CI, Yankelevitz DF, Mirtcheva R, et al. CT screening for lung cancer: 
frequency and significance of part-solid and nonsolid nodules. AJR Am J Roentgenol 
2002; 178: 1053-1057.  
7. Gietema HA, Schaefer-Prokop CM, Mali WPTM, et al. Pulmonary nodules: interscan 
variability of semiautomated volume measurements with multisection CT-influence of 
inspiration level, nodule size, and segmentation performance. Radiology 2007; 245: 
888-894.  
8. Ahn MI, Gleeson TG, Chan IH, et al. Perifissural nodules seen at CT screening for lung 
cancer. Radiology 2010; 254: 949-956.  
9. van't Westeinde SC, de Koning HJ, Xu DM, et al. How to deal with incidentally 
detected pulmonary nodules less than 10 mm in size on CT in a healthy person. Lung 
Cancer 2008; 60: 151-159.  
10. Xu DM, van Klaveren RJ, de Bock GH, et al. Limited value of shape, margin and CT 
density in the discrimination between benign and malignant screen detected solid 
pulmonary nodules of the NELSON trial. European Journal of Radiology 2008; 68: 347-
352.  
11. Wang Y, van Klaveren RJ, de Bock GH, et al. No benefit for consensus double reading 
at baseline screening for lung cancer with the use of semiautomated volumetry 
software. Radiology 2012; 262: 320-326.  
12. Jacobs PC, Mali WP, Grobbee DE, et al. Prevalence of incidental findings in computed 
tomographic screening of the chest: a systematic review. J Comput Assist Tomogr 2008; 
32: 214-221.  
13. McEvoy JW, Blaha MJ, Rivera JJ, et al. Mortality rates in smokers and nonsmokers in 
the presence or absence of coronary artery calcification. JACC-Cardiovascular Imaging 
2012; 5: 1037-1045.  
Chapter 2 
 27 
14. Maritz GS, Mutemwa M. Tobacco smoking: patterns, health consequences for adults, 
and the long-term health of the offspring. Global journal of health science 2012; 4: 62-
75.  
15. van de Wiel JCM, Wang Y, Xu DM, et al. Neglectable benefit of searching for 
incidental findings in the Dutch-Belgian lung cancer screening trial (NELSON) using 
low-dose multi-detector CT. Eur Radiol 2007; 17: 1474-1482. 
16. Jacobs PC, Gondrie MJA, van der Graaf Y, et al. Coronary artery calcium can predict 
all-cause mortality and cardiovascular events on low-dose CT screening for lung 
cancer. AJR American Journal of Roentgenology 2012; 198: 505-511.  
17. Jacobs PC, Gondrie MJ, Mali WP, et al. Unrequested information from routine 
diagnostic chest CT predicts future cardiovascular events. Eur Radiol 2011; 21: 1577-1585.  
18. Jacobs PC, Isgum I, Gondrie MJ, et al. Coronary artery calcification scoring in low-dose 
ungated CT screening for lung cancer: interscan agreement. AJR Am J Roentgenol 2010; 
194: 1244-1249.  
19. Isgum I, Prokop M, Jacobs PC, et al. Automatic coronary calcium scoring in low-dose 
non-ECG-synchronized thoracic CT scans. Proceedings of the SPIE - The International 
Society for Optical Engineering 2010; 7624: 76240M. 
20. Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium 
using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827-832.  
21. Huertas A, Palange P. COPD: a multifactorial systemic disease. Therapeutic Advances 
in Respiratory Disease 2011; 5: 217-224. 
22. Xie XQ, de Jong PA, Oudkerk M, et al. Morphological measurements in computed 
tomography correlate with airflow obstruction in chronic obstructive pulmonary 
disease: systematic review and meta-analysis. Eur Radiol 2012; 22: 2085-2093.  
23. Mets OM, Buckens CF, Zanen P, et al. Identification of chronic obstructive pulmonary 





























Sensitivity and Accuracy of Volumetry of Pulmonary 
Nodules on Low-Dose 16- and 64-Row Multi-Detector 
CT: an Anthropomorphic Phantom Study 
 




















/ Roland A. Snijder
1 
/ Peter M.A. van Ooijen
12 








/ Marcel J.W. Greuter
1 
 
University of Groningen, University Medical Center Groningen, 
1
Department of Radiology,  
2
Center for Medical Imaging – North East Netherland, 
4
Department of Epidemiology; 
 
3
Department of Radiology, University Medical Center Utrecht 
29 





To assess the sensitivity of detection and accuracy of volumetry by manual and semiauto-
mated quantification of artificial pulmonary nodules in an anthropomorphic thoracic 
phantom on low-dose CT. 
 
Materials and Methods 
Fifteen artificial spherical nodules (diameter 3, 5, 8, 10 and 12 mm; CT densities -800, -630 
and +100 HU) were randomly placed inside an anthropomorphic thoracic phantom. The 
phantom was examined on 16- and 64-row multidetector CT with a low-dose protocol. Two 
independent blinded observers screened for pulmonary nodules. Nodule diameter was 
measured manually, and volume calculated. For solid nodules (+100 HU), diameter and 
volume were also evaluated by semi-automated software. Differences in observed volumes 
between the manual and semi-automated method were evaluated by a t-test. 
 
Results 
Sensitivity was 100% for all nodules of > 5 mm and larger, 60 to 80% for solid and 0 to 20% 
for nonsolid 3-mm nodules. No false-positive nodules but high inter-observer reliability 
and inter-technique correlation were found. Volume was underestimated manually by 24.1 
± 14.0% for nodules of any density, and 26.4 ± 15.5% for solid nodules, compared with 7.6 ± 
8.5% (p < 0.01) semi-automatically. 
 
Conclusions 
In an anthropomorphic phantom study, the sensitivity of detection is 100% for nodules of > 
5 mm in diameter. Semi-automated volumetry yielded more accurate nodule volumes than 
















The most common cause of cancer-related death is lung cancer. In 2000, lung cancer ac-
counted for 17% of total cancer mortality [1].  Despite advances in treatment the 5-year 
survival rate is still only 15% or even less, as many lung cancers are found at a relatively late 
stage [2]. Potentially, screening for lung cancer may improve the prognosis. About a decade 
ago, low-dose computed tomography (CT) was proposed as a promising method to screen 
for lung cancer. Several cohort studies and randomised clinical trials using low-dose CT 
were started, aiming to investigate the effect of lung cancer screening on the distribution 
of tumour stages and eventually the effect on survival [3-5]. Recently, the initial, encoura-
ging results of one of the largest trial cohorts were published: lung cancer screening by 
low-dose CT reduced lung cancer-specific mortality by 20% compared with chest radio-
graphy [3].  
Efficient lung cancer screening depends on the accurate distinction between benign 
and malignant pulmonary lesions, but starts with sensitive observer detection of pulmo-
nary nodules. There are only scarce validation data on the detectability of small pulmonary 
nodules by low-dose CT [6,7]. In one previous study using older generation CT equipment 
with slightly thicker collimation, the sensitivity of the detection of pulmonary nodules was 
evaluated in a thoracic phantom without pulmonary vessels, in which artificial nodules 
were placed at known locations. Pulmonary nodules as small as 2.4 mm in diameter could 
be detected by conventional dose CT [8]. However, no data exist about the observer sensi-
tivity on current thin-slice low-dose CT for pulmonary nodules in an anthropomorphic 
pulmonary background with pulmonary vessels. In addition, limited data are available on 
the accuracy of volumetry of pulmonary nodules on low-dose CT. Therefore, the aim of this 
manuscript was to assess the sensitivity of detection of artificial pulmonary nodules on 
low-dose CT, randomly placed in an anthropomorphic pulmonary background with pul-
monary vessels, and to determine the accuracy of volumetry of detected nodules by manual 
and semi-automated measurements. 
 
Materials and Methods 
 
An anthropomorphic thoracic phantom (Lungman, Kyoto Kagaku, Tokyo, Japan) with arti-
ficial thoracic wall, heart, mediastinum, diaphragm and lung with pulmonary vessels was 
used (Figure 1). The phantom consisted of an accurate life-size anatomical model of a male 
thorax with soft tissue substitute materials made of polyurethane resin composites and 
synthetic bones made of epoxy resin with X-ray absorption rates very close to those of hu-
man tissue. The space between the pulmonary vessels in the thoracic cavity consisted of air. 
In addition, we used 15 artificial spherical pulmonary nodules with a smooth surface in five 
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diameters (3, 5, 8, 10 and 12 mm, corresponding to a volume of 14, 65, 268, 523 and 904 
mm
3
) and 3 CT densities (-800, -630 and +100 Hounsfield Units [HU]). The artificial solid 
nodules were made of polyurethane resin and the artificial nonsolid nodules were made of 




Figure 1  An anthropomorphic thoracic phantom (a and b) 
with artificial pulmonary nodules (c) with five different 
diameters (3, 5, 8, 10 and 12 mm, corresponding to 
volumes of 14, 65, 268, 523 and 904 mm3) and three 
different densities (-800, -630 and +100 HU). 
 
16-row multi-detector CT (16-MDCT) and 64-row multi-detector CT (64-MDCT) (Sen-
sation 16 and Sensation 64, respectively, Siemens, Forchheim, Germany) were used. A 
clinically used low-dose protocol for lung cancer screening was applied for image acquisi-
tion [9]: spiral acquisition at 120 kV, 20 mAs, 0.5 s rotation time, pitch 1.5 and collimation 
16 × 0.75 mm and 2 × 32 × 0.6 mm. The CT images were reconstructed with a slice thick-
ness of 1 mm and increment of 0.7 mm using a medium B30f kernel and a field of view 300 
mm.  
The artificial nodules were randomly positioned in both artificial lungs. All nodules 
were attached to pulmonary vessels. None of the nodules were attached to pleura or posi-
tioned sub-pleurally. A random, pre-determined set of 6 nodules was positioned in the 
artificial lungs, after which CT examination was performed. Each of the 15 nodules was 
examined in total 5 times, thus 13 different sets of nodules were positioned in the phantom 
(the last set consisted only of 3 nodules). The CT examination was, for each new phantom 
nodule set-up, repeated 5 times, with in between each examination a small translocation 
and rotation of the phantom to simulate participant movement. The thoracic phantom was 
a b 
c 
   Chapter 3 
 33 
also examined five times without pulmonary nodules to serve as a control. Thus, per CT 
technique 70 examinations were performed, including 65 test examinations and 5 control 
examinations. The thoracic phantom was examined with the same settings for the two CT 
techniques. Furthermore, all the nodules were examined in air, on the CT table, to confirm 
the visibility on low-dose CT.   
The reconstructed data were evaluated on a dedicated workstation (Leonardo, Sie-
mens, Forchheim, Germany) by two independent observers, both with experience in tho-
racic diagnostic imaging for more than 8 years, who were blinded to information about the 
presence, properties and location of the artificial pulmonary nodules. All the examinations 
were read by both observers. The observers were instructed to review the images for the 
presence of nodules within clinically relevant time duration (about 2 minutes per exami-
nation). The observers were asked to report whether there were one or more pulmonary 
nodules present or not. If a potential nodule was observed, the images were compared with 
the images of the control CT examination without nodules to confirm it was not a false-
positive finding caused by pulmonary background structures. Subsequently, the slice with 
maximal cross-sectional area of the nodule was selected. Then, the diameter and CT den-
sity were manually measured. The diameter was measured according to the Response 
Evaluation Criteria in Solid Tumors (RECIST) [10]. A region of interest was drawn as large 
as possible within the nodule border to measure the CT density. Because all nodules were 
spherical, the volume of the nodules could be easily calculated from the measured diame-
ter. Additionally, a dedicated semi-automated software tool (LungCARE, Siemens, 
Forchheim, Germany) was used to measure the volume of the detected solid nodules (CT 
density +100 HU). The diameter and volume of identified nodules were automatically cal-
culated by this three-dimensional volumetric assessment software. 
 
Statistics 
The sensitivity of detection of artificial pulmonary nodules was calculated for three densi-
ties (-800, -630 and +100 HU) and for 16- and 64-row multi-detector CT. The inter-observer 
reliability for both manual and semi-automated measurements was assessed using an in-
traclass correlation coefficient. The correlation of measurements between 16- and 64-row 
multi-detector CT was expressed as a Pearson’s correlation coefficient. The inter-observer 
and inter-machine agreement of nodule volumetry was analysed using Bland-Altman plots. 
If there was a difference in the measurements between 16- and 64-row multi-detector CT, 
or between the two observers, an independent sample t-test was used. If there was a differ-
ence in measuring diameter and volume using the manual and semi-automated methods, a 
paired-samples t-test was used. To find the difference between the observed value (diame-
ter, volume and density) and the actual value, a one-sample t-test was used. Results were 
given as mean ± standard deviation (SD). A p < 0.05 was considered to be statistically sig-
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nificant. All statistical analyses were performed with a software package (SPSS 18.0.3, IBM, 




Representative CT images of the anthropomorphic thoracic phantom are shown in Figure 
2. Nodules sized 5 mm in diameter and larger of all CT densities were detected by both 
observers on all examinations obtained with 16- and 64-MDCT. For nodules sized 3 mm in 
diameter, solid nodules (CT density +100 HU) were detected on 15 out of 25 examinations 
(60%) for both reviewers in 16-MDCT, and 15 (60%) and 20 (80%) examinations for the first 
and the second reviewer respectively in 64-MDCT. However, nonsolid nodules with CT 
density of -630 HU were only detected on 5 examinations out of 25 (20%) by the second 
reviewer on 16-MDCT. Nonsolid nodules with CT density of -800 HU were not detected on 
any examination (Figure 3). Each observed nodule was compared with the control exami-
nation to confirm the presence of the nodule; no false-positive nodules were found. All the 
nodules found were measured successfully using the manual or semi-automated method, 
except for one nodule with a diameter of 3 mm and a density of +100 HU for which seg-
mentation by the semi-automated method failed. Furthermore, on the CT examinations of 
the nodules in air (without the phantom), all 15 nodules were visualised on low-dose CT.  
The inter-observer reliability was very good with an intraclass correlation coefficient 
of 0.985 (p < 0.001) and 1.000 (p < 0.001) for manual and semi-automated measurement. 
The correlation of nodule measurements between 16-MDCT and 64-MDCT was high with a 
Pearson’s correlation coefficient of 0.983 (p < 0.001) and 0.999 (p < 0.001) for manual and 
semi-automated measurements, respectively. An increasing relative inter-observer and 
inter-machine volumetry difference at smaller nodule size was found (Figures 4 and 5). The 
mean absolute value of relative inter-observer difference was 11.7 ± 14.4% and 3.3 ± 6.6% for 
manual and semi-automated volumetry, respectively. The mean absolute value of relative 
inter-scanner difference was 12.9 ± 12.4% and 4.0 ± 5.6%, respectively. There was no signifi-
cant difference in the diameter measurements or CT density between the two techniques 





















Figure 2   Axial (a), coronal (b) and sagittal (c) 
images of the anthropomorphic thoracic phan-
tom with a nonsolid pulmonary nodule meas-
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Figure 3   Sensitivity of the detection of artificial pulmonary nodules for three densities (-800, -630 
and +100 HU) and two CT techniques (16-MDCT and 64-MDCT). 
 
In both the manual and the semi-automated method, nodule diameter and volume 
were significantly underestimated compared with the actual properties (p < 0.01) (Table 1). 
An increasing underestimation of nodule diameter and volume at smaller nodule size was 
found (Figures 6 and 7). In diameter evaluation, the overall underestimation for nodules of 
any density was 9.2 ± 6.0% using manual method. For solid nodules, the underestimation 
was 10.1 ± 6.9% using the manual method, compared with 3.7 ± 7.1% (p < 0.01) using the 
semi-automated method. In volumetry, the overall underestimation for nodules of any 
density was 24.1 ± 14.0% using the manual method. For solid nodules, the underestimation 
was 26.4 ± 15.5% using the manual method, compared with 7.6 ± 8.5% (p < 0.01) using the 
semi-automated method.  
The mean measured CT density was -813 ± 23 HU, -647 ± 9 HU and 123 ± 61 HU for 
nodule density of -800 HU, -630 HU and +100 HU respectively (Table 1), thus deviating 1.7 
± 2.3%, -2.7 ± 1.5% and 26 ± 57% from the expected density (p < 0.01).  
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Figure 4   Bland-Altman plots for inter-observer agreement of the measured volume. 
 
 
Figure 5   Bland-Altman plots for inter-scanner agreement of the measured volume. 
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Figure 6   Deviation of the measured diameter from the actual diameter by manual measurement for 
nodules of -800, -630 and +100 HU, and by semi-automated measurement for nodules of +100 HU. 
 
Figure 7   Deviation of the measured volume from the actual volume by manual volumetry for nod-
ules of -800, -630 and +100 HU, in addition to by semi-automated volumetry for nodules of +100 HU. 
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Table 1   Measurements of diameter and volume of artificial pulmonary nodules by the manual and 
semi-automated methods 



















3 14 n/d n/d n/d n/a n/a 
5 65 -811±15* 4.3±0.3* 41.4±8.2* n/a n/a 
8 268 -818±6* 7.4±0.3* 210±27* n/a n/a 
10 523 -819±18* 9.4±0.4* 431±54* n/a n/a 
-800 
12 904 -806±8* 11.4±0.3* 768±70* n/a n/a 
3 14 -639±25* 2.6±0.1* 9.3±1.3* n/a n/a 
5 65 -646±14* 4.3±0.3* 42.7±8.0* n/a n/a 
8 268 -646±5* 7.4±0.3* 213±29* n/a n/a 
10 523 -648±6* 9.4±0.3* 439±39* n/a n/a 
-630 
12 904 -650±6* 11.3±0.4* 763±69* n/a n/a 
3 14 -2±56* 2.4±0.3* 7.1±3.9* 2.6±0.4*† 10.9±2.4*† 
5 65 161±24* 4.2±0.2* 37.9±6.0* 4.8±0.2*† 59.7±2.6*† 
8 268 158±10* 5.9±1.2* 193±25* 7.6±0.2*† 245±4.5*† 
10 523 137±8* 9.5±0.3* 445±48* 9.8±0.3*† 513±12*† 
+100 
12 904 128±6* 11.3±0.3* 761±51* 11.7±0.3*† 856±8*† 
*: P<0.01 when compared with actual properties.  
†: P<0.01 when compared with manual measurement. 
The measured values were averaged over 16-slice and 64-slice CT for both observers. n/a = not 




In one of the first pulmonary nodule validation studies using an anthropomorphic thoracic 
phantom and current low-dose CT technology, we have shown that a clinically used lung 
cancer screening protocol with low-dose CT has 100% sensitivity of detection for spherical 
pulmonary nodules sized 5 mm in diameter
 
and larger. In addition, we have shown that 
low-dose CT yields more accurate nodule volume measurements when using a semi-
automated method than in the case of the manual method, with negligible underesti-
mation of actual size, especially for small nodules. 
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We found a sensitivity of 100% for nodules with a diameter equal to or larger than 5 
mm for all three nodule densities in this anthropomorphic thoracic phantom, and 60 to 
80% and 0 to 20% for solid and nonsolid nodules with a diameter of 3 mm, respectively. 
This anthropomorphic thoracic phantom was also used in another study in which sensitiv-
ity of 95% for solid nodules and 74 – 81% for nonsolid nodules were found for nodule di-
ameter equal to or larger than 5 mm [11]. Unlike the low-dose acquisition protocol for lung 
cancer screening in this study, the authors did not use a low-dose protocol, which limits 
comparability. In addition, the authors used 5-mm reconstructed slice thickness, compared 
with 1 mm in this study. It is well known that a larger slice width results in lower sensitivity 
of pulmonary nodules [6]. This anthropomorphic phantom was also used for an image da-
tabase of nodules of diameter larger than 5 mm of several shapes, but results for nodule 
detectability and comparing between manual and semi-automated measurements were not 
reported [12]. In some nodule detectability studies, solid nodules with a diameter of 2 to 3 
mm were detected in all cases [8,13,14]. In these studies, the nodules were placed in known 
order and examined in a thoracic phantom without lung vessels. On the other hand, in our 
study the artificial nodules were randomly positioned inside the lungs of an anthropomor-
phic thoracic phantom, thus limiting detection bias and strengthening the findings. As 
adjacent tissue can interfere with the nodule image reconstruction and reading, especially 
for nonsolid nodules, and because this interference increases with decreasing radiation 
dose, we expect that this interference explains why we could not detect some of the 3-mm 
nodules.  
No false-positive nodules were found compared with the control examinations. That 
is to say, all nodules detected on low-dose CT were actual nodular lesions. Nevertheless, in 
clinical practice, pulmonary parenchyma can be distorted and may contain scars and varia-
tions, which can erroneously be interpreted as a pulmonary nodule; thus the specificity in a 
clinical setting is usually decreased.  
We found an increasing underestimation of the nodule volume at smaller nodule di-
ameters, which was also found in some previous studies [15,16]. However, some other stud-
ies reported an increasing overestimation of the nodule volume at smaller nodule diame-
ters [17-22]. For small pulmonary nodules, the transit zone between nodule and pulmonary 
background caused by partial volume effect was found to be important for accurate volu-
metry [23]. Thus, measurement errors in small nodules when measured manually should be 
considered.  
In this study, we found that the measured nodule density was significantly different 
from the expected density. In lung cancer screening by unenhanced CT examination, accu-
rate CT density is important mainly to differentiate between solid and nonsolid nodules, 
and to evaluate increase in density over time in the case of nonsolid nodules. However, as 
we only had one type of solid nodule, and two types of nonsolid nodule with a relatively 
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large difference in CT density compared with the solid nodules, no reliable conclusion can 
be drawn about the potential impact of CT density variation on lung cancer screening re-
sults. Future studies with more variation in the density of solid nodules, with CT densities 
within the clinically relevant range, have been planned to investigate the impact of CT 
density on nodule volumetry in more detail.   
No difference was found between low-dose 16 and 64-row multi-detector CT from the 
same vendor regarding manual and semi-automated volumetry. However, a previous study 
found different nodule volumetry outcomes for four 16-row CT systems from different ven-
dors [17]. As the follow-up of screened participants or clinical patients can last for an ex-
tensive period, different CT systems from different vendors may be used. A direct compari-
son of nodule volumes obtained from different CT systems from the same vendor seems 
valid, at least for the vendor investigated in this study. However, whether similar nodule 
volumes would have been found for other vendors is unknown. 
 
Clinical implications 
Some lung cancer screening projects were mainly based on nodule diameter [3], whereas 
other lung cancer screening projects were mainly based on nodule volume measurements 
[9]. In the National Lung Screening Trial (NLST) study, a positive result indicating sus-
pected lung cancer on low-dose CT was defined as the presence of a nodule with a largest 
transverse axis of at least 4 mm [4]. In the Dutch-Belgian Randomized Lung Cancer 
Screening Trial (NELSON) study, a positive result was defined as either a fast-growing 
nodule with a volume of at least 50 mm
3
, i.e., nearly 5 mm in diameter, or a nodule with a 
volume of at least 500 mm
3
 [9]. The results of this study validate these screening protocols, 
as all solid nodules and nonsolid nodules with a diameter of 5 mm could be detected by 
observers on low-dose CT against an anthropomorphic pulmonary background.   
Pulmonary nodule volumetry is used to guide the diagnostic strategy in the follow-up 
of lung cancer screening [9] . Repeated CT-derived volumetry of pulmonary nodules can be 
used to determine the risk of lung cancer, and can be used to monitor tumour response in 
the case of nonsurgical therapy. The accuracy and precision of pulmonary nodule volu-
metry depend on a number of factors, including image acquisition and reconstruction pa-
rameters, nodule characteristics, and the performance of algorithms for nodule segmen-
tation and volume estimation [24]. Size measurement needs to be as accurate as possible in 
order to enable the assessment of nodule growth. A commonly used criterion for pulmo-
nary nodule growth is given by the Response Evaluation Criteria in Solid Tumors (RECIST), 
which states that nodules in the stable disease category should not be larger than 20% or 
smaller than 30% in diameter on subsequent CT examinations [10]. However, a 20% error 
in diameter measurement could result in an error in volume for a spherical nodule of up to 
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73%, which could result in inaccurate growth rate evaluation. To improve accuracy in 
growth rate evaluation, semi-automated volumetry is favoured over manual volumetry.   
 
Limitations 
There are limitations to this study. Firstly, only spherical nodules were used with five dis-
crete sizes. Additional data on the sensitivity of nodules with sizes between 3 and 5 mm in 
diameter is needed in order to determine the sensitivity of current low-dose CT and to op-
timise diagnostic screening strategies for small nodules. A further extension to our study is 
the assessment of the sensitivity of low-dose CT for nonspherical and irregular shaped 
(lobulated and/or spiculated) nodules. Secondly, we simulated healthy pulmonary tissues. 
The sensitivity of nodule detection is dependent on pulmonary structures and surrounding 
pathological lesions such as fibrosis, emphysema or consolidation could influence nodule 
detectability, which can make pulmonary nodules undetectable or be erroneously inter-
preted as pulmonary nodules. We therefore expect that the sensitivity in an in vivo setting 
may be lower, and that the false-positive rate may be higher, compared with the findings in 
this study. Thirdly, we used only one clinical low-dose CT screening protocol. Although the 
sensitivity of pulmonary nodules is also dependent on CT protocol, the protocol we used is 
the most common in current lung cancer screening projects using thin-slice, low-dose CT. 
Therefore, we expect that this protocol is the most relevant for the sensitivity of pulmonary 
nodule detection in lung cancer screening. Finally, semi-automated volumetry was not 
performed for nonsolid nodules, because the present commercially available volumetry 
software was only for solid nodules. In case of the considerable volumetry deviation from 
the actual volume in nonsolid nodules by manual measurements, a special software pack-





In conclusion, this anthropomorphic phantom study shows that a lung cancer screening 
protocol with low-dose CT is highly reliable for the detection of spherical pulmonary nod-
ules of 5 mm in diameter
 
and larger. Low-dose CT yields more accurate nodule volumetry 
when using a semi-automated software tool than manual measurements, with negligible 
underestimation of actual size, especially for small nodules. For early lung cancer detection, 
in which mostly small nodules are found, accurate measurement is especially necessary, to 
enable assessment of volume doubling time. Thus, a semi-automated volume measurement 
should be used in the setting of lung cancer screening. No difference in accuracy of volu-
metry was found between 16-row and 64-row multi-detector CT.     
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To evaluate observer detection and volume measurement of small irregular solid artificial 
pulmonary nodules on 64-row multi-detector computed tomography (CT) in an anthro-
pomorphic thoracic phantom. 
 
Materials and Methods 
Forty in-house made solid pulmonary nodules (lobulated and spiculated; actual volume 5.1 
to 88.4 mm
3
; actual CT densities -51 to +157 HU) were randomly placed inside an anthro-
pomorphic thoracic phantom with pulmonary vasculature. The phantom was examined on 
two 64-row multi-detector CT scanners, using a scan protocol as applied in lung cancer 
screening. Two independent blinded observers screened for pulmonary nodules. Nodule 
volume was evaluated semi-automatically using dedicated software, and compared to the 
actual volume using a t-test. The inter-scanner and inter-observer agreement of volumetry 
was assessed using Bland-Altman analysis. 
 
Results 
Observer detection sensitivity increased with raising size of irregular nodules.  Sensitivity 
was 100% when actual volume was at least 69 mm
3
, regardless of specific observer, scanner, 
nodule shape and density. Overall, nodule volume was underestimated by 18.9 ± 11.8 mm
3
 
(39 ± 21%, p < 0.001). Relative inter-scanner difference of volumetry was 3.3% (95% CI:  
-33.9% to 40.4%). Relative inter-observer difference was 0.6% (-33.3% to 34.5%). 
 
Conclusions 
Small irregular solid pulmonary nodules with an actual volume of at least 69 mm
3
 are re-
liably detected on 64-row multi-detector CT. However, CT-derived volume of those small 







Lung cancer is worldwide the most common cause for cancer death, and accounts for more 
than 18% of the total deaths from cancer [1]. Since lung cancer is predominantly found at a 
relatively late stage, its 5-year survival is only 15% or even less [2]. The National Lung 
Screening Trial (NLST) has demonstrated a promising result that early detection of lung 
cancer with computed tomography (CT) reduces mortality [3]. Therefore, CT allows the 
potential to be an effective screening tool for early detection and mortality reduction of 
lung cancer [4,5]. 
In the routine clinical population, there is inconsistency whether surveillance CT 
should be performed after encountering an overwhelming number of indeterminate small 
solid pulmonary nodules on CT examinations, as small as < 6 mm in diameter (approxi-
mately 90 mm
3
) [6]. In a high risk population, The Fleischner Society recommends follow-
up CT for those small nodules, because small nodules have a nonignorable opportunity to 
develop into malignancy [7]. The common participants in lung cancer screening trials are 
elderly and smokers, two major risk factors for lung cancer [3,5]. Optimal management 
protocol of small pulmonary nodules is important for early distinction of malignant lesions 
in screening.  
Assessment of small nodules starts with sensitive observer detection and accurate 
growth evaluation. Computed assisted diagnosis (CAD) or observer consensus has been 
used as a reference for pulmonary nodule detectability in human studies [8-10]. To reach 
more precise nodule evaluation, number and volume of the actually existing nodules need 
to be certain. Thus, an anthropomorphic phantom study is necessary, based on artificial 
nodules with a known number and volume. In-depth data from well-designed phantom 
studies is limited for nodules less than 6 mm in diameter, which are essential for optimiza-
tion of nodule management protocol for those small nodules in lung cancer screening [11-
13]. As an extension of our previous phantom study regarding focusing on spherical nod-
ules [11], the current study aims at irregular nodules. The purpose is to evaluate the detec-
tion and volumetry of small irregular solid pulmonary nodules, which were randomly 
placed in an anthropomorphic phantom with pulmonary vasculature.  
 
Materials and Methods 
 
Phantom  
An anthropomorphic chest phantom (Lungman, Kyoto Kagaku, Tokyo, Japan) was used, 
with an artificial thoracic wall, nonbeating heart, mediastinum, spine, ribs, diaphragm and 
lungs with pulmonary vessels (Figure 1). The phantom was an accurate life-size anatomical 
model of a healthy male thorax. Soft tissues were imitated with materials made of polyure-
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thane resin composites and bones were imitated with materials made of epoxy resin. X-ray 
absorption rates of these materials were very close to those of human tissues. The thoracic 




Figure 1   Photograph of the anthropomorphic chest phantom (a) and of the internal artificial heart 
and lungs (b).  
 
Preparation of artificial pulmonary nodules 
Forty artificial pulmonary nodules were made in-house, with two irregular shapes (spicu-
lated and lobulated) and five actual CT densities (-51, +2, +57, +125 and +157 Hounsfield 
Units (HU) at 120 kV). A three-dimensional printer (Objet Eden 250, Objet, Rheinmünster, 
Germany) was used to make the nodules of +157 HU, and the molds to prepare the nodules 
of the other four CT densities. The artificial nodules of +157 HU were made of plastic 
(Verowhite 830, Objet, Rheinmünster, Germany) with known physical density. The nodules 
of the other four CT densities were made of paraffin mixed with contrast media (Lipiodol 
480 mgI/ml, Guerbet, Villepinte, France).  
To make the artificial nodules, firstly, we prepared and scanned large pieces of paraf-
fin mixed with contrast media. The proportion between those two components was ad-
justed, until the pre-defined actual CT density was reached. Volume (v1) of these large 
pieces of paraffin was measured by submersion into a measuring cylinder filled with water. 
Mass (m1) was measured by an accurate balance. Density (ρ) was calculated by ρ = m1 / v1. 
Secondly, paraffin mixed with contrast media was melted and poured into molds to shape 
the nodules. Finally, 40 artificial small irregular nodules were made. Mass (m2) of each 




calculated by v2 = m2 / ρ. These measurements were repeated three times. Photographs and 
actual volumes of the 40 artificial nodules were shown in Table 1. The actual volume of the 
simulated nodules ranged from 5.1 ± 0.2 mm
3
 to 88.4 ± 3.4 mm
3






Two 64-row multi-detector CT scanners were utilized (CT-A: Sensation 64, Siemens 
Healthcare, Forchheim, Germany; CT-B: Brilliance 64, Philips Healthcare, Best, The Neth-
erlands), using a clinically applied CT acquisition protocol for lung cancer screening [13]. 
The image acquisition protocol for CT-A was: spiral acquisition at 120 kV, 20 mAs, rotation 
time 0.5 s, pitch 1.5, collimation 2 × 32 × 0.6 mm, field of view 300 mm, volume CT dose 
index (CTDIvol) 1.6 mGy and dose length product (DLP) 48 mGy∙cm, without using tube 
current modulation. The CT images were reconstructed at a 1.0 / 0.7 mm slice thickness / 
increment using a medium-smooth B30f kernel. The image acquisition protocol for CT-B 
was: spiral acquisition at 120 kV, 20 mAs, rotation time 0.5 s, pitch 1.39, collimation 64 × 
0.625 mm, field of view 300 mm, CTDIvol 1.3 mGy and DLP 39 mGy∙cm, without utilizing 
tube current modulation. The CT images were reconstructed at a 1.0 / 0.7 mm slice thick-
ness / increment using a medium-smooth B kernel.  
The thoracic phantom was examined once without any pulmonary nodules to serve 
as a control examination, in order to determine possible false positive nodules. Further-
more, all nodules were examined on the CT table without the phantom, so as to confirm 
the visibility on CT.  
Artificial nodules were randomly positioned in the anthropomorphic lungs. All nod-
ules were attached to pulmonary vessels. None of those nodules was connected to pleura or 
located sub-pleurally. A randomly defined set from 0 to 9 nodules was positioned inside 
the anthropomorphic phantom in an examination. Nodule location was randomly deter-
mined. Each nodule out of 40 artificial nodules was placed five times in different locations. 
Thus, per CT scanner 51 examinations with nodules were scheduled. Each examination was 
subsequently repeated three times. The position of human subjects is commonly not per-
fectly parallel to the central axis of the CT examination bed (z-axis). We simulated this by 
rotation of the phantom 5 - 10 degrees between each repeated examination. Also, the loca-
tion of individuals on the CT examination bed commonly changes between examinations. 
We simulated this by translation of the phantom 5 - 10 cm between each repeated exami-
nation. In total, per CT scanner 153 examinations were performed, in which 600 nodule 
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Table 1   Volume measurements of the 40 small artificial irregular pulmonary nodules 


































































































*: p < 0.01 when compared with the actual volume.  
†: Because of insufficient sample size, standard deviation and statistical significance were not calcu-





Two independent observers evaluated the examinations, including a radiologist (observer 
1) with 9 years of experiences in diagnostic thoracic imaging, and a resident (observer 2) 
with two years of radiological experiences. Each observer independently read all examina-
tions of two CT scanners, using a commercial workstation (Somaris/5 syngo, Siemens, 
Forchheim, Germany). Both observers were blinded to information about the presence, 
number and location of the artificial nodules.  
The observers reviewed the images on maximum intensity projection (MIP) and thin-
slice axial and coronal display, using a dedicated software tool (LungCARE, Siemens, 
Forchheim, Germany). The slab thickness of MIP display was 6 mm. The observers were 
instructed to review the images for the presence of nodules within clinically representative 
time duration of approximately two minutes per examination. When a nodule image was 
found in an examination, the observer documented the number and location of the ob-
served nodule image. Next, the nodule image was compared to the control examination 
(without a nodule), to verify whether the finding was true positive (TP) or false positive. If 




Results are presented as mean ± standard deviation (SD). Observer detection sensitivity 
was calculated per nodule, as a percentage of the TP findings. The relationship between 
sensitivity and actual nodule volume was explored using curve fitting based on a sigmoid 
function model [14]. The influential effects on nodule evaluation were assessed by univari-
ate analysis with a general linear model. In that univariate analysis, dependent variable was 
observer sensitivity or CT-derived volume. Independent factors were observer (observer 1 
and 2), CT scanner (CT-A and CT-B), nodule shape (spiculated and lobulated), actual vol-
ume (5.1 to 88.4 mm
3
) and density (-51, +2, +57, +125 and +157 HU).  
The inter-scanner and inter-observer reliability for CT-derived volume was expressed 
using intra-class correlation coefficients (ICC). ICC values larger than 0.90 were ranked as 
high agreement, in the range of 0.75 to 0.90 were rated as moderate, and smaller than 0.75 
were considered as low [15, 16]. The inter-scanner and inter-observer agreement of nodule 
volumetry was evaluated using Bland-Altman analysis. A 95% confidence interval (CI) was 
expressed as mean ± 1.96 SD. 
The difference in CT-derived and actual volume was evaluated by an independent-
samples t-test. The percentage deviation of CT-derived volume from the actual volume was 
calculated as (CT-derived volume - actual volume) / actual volume × 100%.  
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A p-value below 0.05 is considered statistically significant. Statistical analysis was 
performed using SPSS version 18.0 (IBM, New York, USA) and SigmaPlot version 12.1 (Sys-




Observer detection sensitivity 
When scanned outside the phantom on the CT table, all the 40 nodules could be visualized 
on CT regardless of nodule size. However, within the phantom, the first observer detected 
340 (56.7%) and 315 (52.5%) TP nodule images out of the maximum 600 nodule images in 
CT-A and CT-B, respectively. The second observer found 245 (40.8%) and 261 (43.5%), re-
spectively. In addition, the first observer identified 3 (0.5%) false positive nodule images in 
CT-A. The second observer identified 2 (0.3%) in CT-A and 2 (0.3%) in CT-B. Representa-
tive CT images of the anthropomorphic thoracic phantom and nodules are shown in Figure 
2.  
 
Table 2   Influential effects on nodule evaluation, assessed by univariate analysis  
Observer sensitivity   CT-derived volume 
Influential factor 
Beta p value  Beta p value  
Observer -0.17 <0.05  0.06 0.17 
Scanner -0.01 0.90  -0.08 <0.01 
Shape 0.11 0.16  0.43 <0.001 
Actual volume 0.10 <0.001  0.84 <0.001 
Actual density 0.16 0.31  0.01 0.73 
Dependent variable was observer sensitivity or CT-derived volume. Independent factors were ob-
server (observer 1 and 2), CT scanner (CT-A and CT-B), nodule shape (spiculated and lobulated), 
actual volume (5.1 to 88.4 mm3) and density (-51, +2, +57, +125 and +157 HU). 
 
Observer sensitivity was positively associated with the first observer and larger actual 
volume (p < 0.05). But scanner, nodule shape and density were not significant factors (p > 








Figure 2   Axial (a) and coronal (b) computed tomographic image of the anthropomorphic chest 
phantom. Maximal intensity projection (c, MIP) and three-dimensional (d, 3D) reconstruction  









Figure 3   Observer detection sensitivity of artificial small irregular pulmonary nodules by observer 1 
(a) and observer 2 (b). The sensitivity fitted a sigmoid curve (p < 0.001) for both observers (solid 
lines), with 95% confidence bands indicated (dashed lines). The R values of the curve fitting were 





Observer detection sensitivity fitted a sigmoid curve, versus actual nodule volume (p 
< 0.001) for both observers (Figure 3). Those curves demonstrated that sensitivity increased 
with larger nodule volume. In case of nodules with an actual volume < 15 mm
3
, sensitivity 
was 6% to 28% of the first observer, and 5% to 11% of the second. For nodules <50 mm
3
, 
sensitivity of the first observer was slightly higher than of the second. When actual volume 
increased to ≥ 69 ± 2 mm
3
 (CT-derived volume 39 ± 6 mm
3
, 95% CI: 27 to 51 mm
3
), the sen-




Figure 4   Bland-Altman plots for inter-scanner (a) and inter-observer agreement (b) of CT-derived 
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Nodule volumetry  
Majority of the observed nodules were successfully segmented and measured. The first 
observer evaluated 297 (87.4%) out of 340 TP nodule images and 226 (71.7%) out of 315, in 
CT-A and CT-B, respectively. The second observer evaluated 227 (92.7%) out of 245 and 
207 (79.3%) out of 261, in CT-A and CT-B, respectively. The nonsegmentable nodules were 
not measured. Actual nodule volume, CT scanner and nodule shape significantly influ-
enced CT-derived volume (p < 0.01). Yet observer and actual density were not significant 
factors (p > 0.05) (Table 2).  
Inter-scanner and inter-observer reliability of CT-derived volume was high, with an 
ICC of 0.90 (p < 0.001) and 0.95 (p < 0.001), respectively. In Bland-Altman analysis, the 
relative difference of volumetry between two CT scanners was 3.3% (95% CI: -33.9% to 
40.4%). The relative difference between two observers was 0.6 % (-33.3% to 34.5%) (Figure 
4).  
CT-derived volume of the segmentable nodules was significantly lower than actual 
volume (p < 0.01) (Table 1). The mean underestimation was 18.9 ± 11.8 mm
3
 (percentage 
underestimation: 39 ± 21%). CT-derived volume in CT-A and CT-B was underestimated by 
18.5 ± 12.0 mm
3
 (38 ± 21%) and 19.3 ± 10.8 mm
3
 (40 ± 15%), respectively. CT-derived volume 
of the spiculated and lobulated nodules was underestimated by 21.0 ± 11.2 mm
3
 (48 ± 21%) 
and 17.2 ± 12.2 mm
3




In this anthropomorphic phantom study for small irregular solid pulmonary nodules, ob-
server detection sensitivity increased with raising nodule volume. When actual volume was 
at least 69 mm
3
 (CT-derived volume 39 ± 6 mm
3
), sensitivity was always 100%. The 95% CI 
of relative inter-scanner and inter-observer volumetry difference is within 40%. CT-derived 
volume was considerably underestimated by 39%, compared to the actual volume.  
In some previous phantom studies on nodule detectability, spherical nodules with an 
actual volume of 4 to 15 mm
3
 were all detected [17,18]. Yet the nodules were placed in a 
known order and examined inside a phantom without pulmonary vasculature. Using an 
anthropomorphic phantom with pulmonary vessels, detection sensitivity fell to 60% to 
80% for randomly positioned spherical nodules of 14 mm
3
 [11]. In our current study, as an 
extension to the aforementioned study using the same anthropomorphic phantom, sensi-
tivity diminished to ≤ 28% for randomly positioned irregular nodules of less than 15 mm
3
. 
In this well-controlled in-vitro setting, other influential factors were excluded. Pulmonary 
vasculature and irregular nodule shape contribute to explain the decreased observer sensi-
tivity in case of small irregular nodules. 
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We found that larger nodule volume resulted in higher observer sensitivity. When 
nodules were larger than 69 mm
3
 in actual volume, all the nodules were detected. This 
finding was similar to the previous study on spherical nodules, in which nodules larger 
than 65 mm
3
 were all detected [11]. Thus, the current study strengthened the finding of 
nodule detection sensitivity. Pulmonary nodules larger than 69 mm
3
 can be detected with 
high reliability, regardless of specific observer, CT scanner and nodule characteristics. 
However, nodules smaller than 65 mm
3
 cannot be reliably detected by observers.  
Only a few false-positive nodules were found (0% to 0.5%), due to erroneous inter-
pretation of overlapping vessels as nodules. In-vivo pulmonary structures contain scars and 
variations, which could lead to false-positive interpretations. Thus, one would expect 
higher false-positive rates in a clinical setting, compared to 0% to 0.5% in the present study. 
Variability has been found in semi-automatically CT-derived nodule volumetry [19, 
20]. An in-vivo study showed that the 95% CI of inter-scan variability of nodule volumetry 
for solid nodules from 15 to 500 mm
3
 was within 25%, based on two CT examinations per-
formed on the same day [21]. In our study, the 95% CI of relative inter-scanner and inter-
observer difference was within 40%, for irregular nodules smaller than 90 mm
3
. Variability 
of volumetry seems larger in small irregular nodules.  
CT-derived volume of small irregular solid nodules was largely underestimated by 
39% in this study. In the previous study on spherical nodules of similar size, CT-derived 
volume was underestimated by ≤ 25% [11,22]. In contrast, CT-derived volume was overesti-
mated in some publications based on larger spherical and irregular nodules [23-25]. It is 
well known that volumetry accuracy of pulmonary nodules depends on a number of factors, 
e.g., image processing and nodule characteristics [26,27]. In CT, there is transition in 
Hounsfield values between high and low density objects, caused by the partial volume ef-
fects [28]. In our study, this transition is between a nodule and the surrounding pul-
momary parenchyma, which degrades the exactness of nodule segmentation, especially for 
small nodules [29, 30]. The transition around an irregular nodule was expected to be larger 
than around a spherical nodule with a smooth contour. Consequently, small irregular nod-
ules showed a larger underestimation of CT-derived volume than spherical nodules.  
Several nodule characteristics were fabricated in this study. Firstly, irregular nodules 
were frequent findings in lung cancer screening [19,31]. Secondly, solid nodules were the 
majority of observed nodules, rather than nonsolid nodules [5]. Thirdly, CT density range 
from -57 to 157 HU was usual in solid nodules [31]. Finally, nodule number range from 0 to 
9 per participant was also common [32]. Therefore, we expected that these characteristics 
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Clinical implications 
Different lower limits of CT-derived nodule volume were utilized in lung cancer screening 
trials to define a nodule in which malignancy cannot be excluded, leading to follow-up 
examination or further work-up, for example, 50 mm
3
 in the Dutch-Belgian Ran-
domized Lung Cancer Screening Trial, 60 mm
3
 in the Multi-centric Italian Lung Detection 
trial and 4 mm in diameter (approximately 35 mm
3
 in volume) in the NLST [5, 33]. Of 
course, before nodule management can be determined, the nodule first has to be detected. 
Our results show that nodules with CT-derived volume of 39 ± 6 mm
3
 (95%CI: 27 to 51 mm
3
) 
can be reliably detected by observers, at least in a phantom setting, independent of CT 
scanner and nodule characteristics. This finding supports the use of a nodule CT volume 
cut-off of about 50 mm
3
 to determine presence of a nodule, as nodules of this CT size are 
not likely to be missed.  
The 95% CI of variability in nodule volumetry is used to exclude systematic errors, 
and to define a stable nodule. A volume increase of at least 25% has been defined as the 
minimum to distinguish growth from measurement variability, for small and indetermi-
nate nodules with CT volume < 500 mm
3
 [5,21,33]. Because it is unsure whether a CT-
derived nodule growth < 25% is caused by true growth or by measurement variability, lung 
cancer screening subjects with CT-derived nodule growth < 25% will be examined in an-
other follow-up examination to confirm nodule stability or reliably detect nodule growth, 
instead of immediate action [4,5].  In our study, the 95% CI of variability was within 40% 
for nodules < 90 mm
3
 (95% CI of CT derived volume, 44 to 60 mm
3
). This means that, be-
cause of higher variability, we cannot distinguish true growth from measurement variabil-
ity when a nodule <90 mm
3
 increases in volume less than 40%. Here, using the 25% cut-off 
criterion would lead to a higher number of false-positive results, potentially resulting in 
avoidable patient anxiety and morbidity. Another follow-up examination seems appropri-
ate when a nodule < 90 mm
3
 increases in volume less than 40%, to confirm stability or re-
liably detect growth. 
If the measured volume of a nodule is underestimated in two repeated examinations 
but to a similar extent (percentage wise), the calculated nodule growth rate is still accurate. 
Thus, nodule management of intermediate size nodules based on repeated CT examina-
tions and assessment of volume doubling time, such as in the NELSON study [34], is not 
affected.  
Small irregular nodules yield a larger underestimation in CT-derived volumetry than 
small spherical nodules (underestimation by 39% versus 20% compared to actual volume) 
[11]. This may affect the assessment of nodule management. E.g., a nodule with actual size 
of 60 mm
3
 could be measured in CT as 50 mm
3
 in case of spherical shape, but 40 mm
3
 in 
case of irregular shape. Thus, in the latter case, the nodule would fall in the small size cate-
gory (< 50 mm
3
), which receives standard follow-up examination, instead of short-term 
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repeat CT scanning [34]. Although this could have resulted in misclassification of indeter-
minate size, irregular nodules at the baseline round of the NELSON study, in view of the 
very low interval cancers [5], it is unlikely that this potential misclassification has had 
clinical impact. Change in nodule shape between CT examinations could affect volumetry 
and thus, assessment of growth rate. The implication of this finding could be explained by 
assuming the following scenario. If there is an indeterminate spherical nodule of an actual 
volume of 63 mm
3
, the volume is generally underestimated in CT by 20%, resulting in a CT-
derived volume of 50 mm
3
. When that nodule is followed up and examined again after 90 
days, it might have developed into an irregular nodule of 81 mm
3
 in actual volume. This 
corresponds to a volume doubling time of 315 days, and thus, the nodule should be as-
sessed as fast growing [34], and suspected for malignancy. As, in case of irregular nodules, 
underestimation of actual volume is generally larger and can go up to 39% it is possible 
that the CT-derived volume remains around 50 mm
3
.  Thus, in this particular scenario, 
misdiagnosis of that nodule would have occurred. This scenario indicates that when nod-
ule shape is not considered in case of small nodules, there is a chance to misjudge growth 
rate. Therefore, since a pulmonary nodule has an opportunity to develop into another ap-
pearance during growth [6, 35], volumetry errors as a function to nodule shape have to be 
considered during follow-up, at least as demonstrated in our phantom studies for nodules 





Firstly, only 40 solid nodules were simulated in this study, which is inconsistent with gen-
erally varying shapes in real patients. We expected that those artificial nodules were repre-
sentative for small irregular pulmonary nodules. Secondly, healthy pulmonary tissues were 
simulated in this study. Nodule detection depends on successful distinction of a pulmonary 
nodule from normal pulmonary structures and surrounding pathological lesions, such as 
fibrosis and consolidation, which make pulmonary nodules undetectable or lead to errone-
ous interpretation. Hence, sensitivity might be lower in real patients, and false positive 
rates might be higher. Thirdly, we only tested one CT acquisition protocol and dedicated 
volumetry software. That protocol has been widely applied in lung cancer screening [4]. 
That software has also been frequently utilized in screening [5,36,37]. However, accuracy of 
nodule volumetry depends on acquisition and algorithm in individual settings [27,38]. 
When discussing the results, we linked to the studies based on similar CT acquisition pro-
tocol and the same software [11,19,21,31,35]. Thus, our results might be comparable to those 








This study adds understandings for evaluation of irregular solid pulmonary nodules, 
smaller than 6 mm in diameter (approximately 90 mm
3
) in lung cancer CT screening. Ob-
servers reliably detect irregular nodules with an actual volume of at least 69 mm
3
 (CT-
derived volume 39 ± 6 mm
3
), regardless of specific CT scanner, observer and nodule char-
acteristics. Relative inter-scanner and inter-observer difference of volumetry is within 40%. 
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To assess inter- and intra-scanner variability in volumetry of solid pulmonary nodules in an 
anthropomorphic thoracic phantom, using low-dose computed tomography (CT). 
 
Materials and Methods 
Five spherical solid artificial nodules (diameters 3, 5, 8, 10 and 12 mm; CT density +100 HU) 
were randomly placed inside an anthropomorphic thoracic phantom, in different combina-
tions. The phantom was examined on two 64-row multi-detector CT (64-MDCT) systems 
from different vendors with a low-dose protocol. Each CT examination was performed 
three times. The CT examinations were evaluated twice by independent blinded observers. 
Nodule volume was semi-automatically measured by dedicated software. Inter-scanner 
variability was evaluated by Bland-Altman analysis, and expressed as 95% confidence inter-
val (CI) of relative differences. Intra-scanner variability was expressed as 95% CI of relative 
variation from the mean.  
 
Results 
No significant difference in CT-derived volume was found between CT-A and CT-B, except 
for the 3 mm nodules (p < 0.05). The 95% CI of inter-scanner variability was within ±41.6%, 
±18.2% and ±4.9%, for 3, 5 and ≥ 8 mm nodules, respectively. The 95% CI of intra-scanner 
variability was within ±28.6%, ±13.4% and ±2.6%, for 3, 5 and ≥ 8 mm nodules, respectively.  
 
Conclusions 
Different 64-MDCT scanners in low-dose setting yield good agreement in volumetry of 
artificial pulmonary nodules between 5 and 12 mm diameter. Inter- and intra-scanner vari-
















Lung cancer is worldwide the primary cancer in men and the second most common cancer 
in women, causing 18% of the total number of deaths [1]. Many lung cancers are found at a 
relatively late stage, resulting in a 5-year survival of only 15% or less [2]. Low-dose com-
puted tomography (CT) is a promising screening method for early detection of lung cancer 
[3-7]. First results indicate that CT lung cancer screening can reduce lung cancer-specific 
mortality [8]. 
In lung cancer screening, treatment decisions usually depend on pulmonary nodule 
size for the nodules at first detection, and on growth rate at follow-up [4]. Therefore, it is 
essential to assess nodule size and growth rate accurately and reproducibly [9,10]. Variabil-
ity has been found in CT-derived nodule size assessment [11, 12]. In view of the current 
practice that patients frequently undergo follow-up examinations, sometimes not on the 
same scanner, reliable inter- and intra-scanner reproducibility of nodule volumetry is im-
portant.  
However, previous studies reported inconsistent results regarding the reproducibility 
of nodule volumetry. Some in-vitro studies have been performed in which artificial nodules 
were placed at known locations in a thoracic phantom without pulmonary vessels [13-15]. 
Some of these studies were based on older generation CT scanners [13,16]. These studies 
generally showed a small margin of variability in nodule volumetry for software from dif-
ferent vendors. On the other hand, in-vivo studies have shown that variability can be con-
siderable, with variability up to 25% for 15 to 500 mm
3
 nodules [11,17-19]. A study to investi-
gate inter- and intra-scanner variability under optimally controlled conditions yet resem-
bling human lungs, using a more realistic phantom, has not been performed. Nowadays, 
most commonly 64-row multi-detector CT (64-MDCT) scanners are utilized, also in lung 
cancer screening. The variability of nodule volumetry of these scanners impacts nodule 
management, for example the interval of repeated CT scanning. As an extension to our 
recent study on observer detection and accuracy of manual and semi-automated volumetry 
[10], the focus of this study is on reproducibility between and within 64-MDCT systems. 
We assessed the inter- and intra-scanner variability of pulmonary nodule volumetry on 
low-dose 64-MDCT, using randomly placed solid nodules in an anthropomorphic thoracic 
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Materials and Methods 
 
Phantom 
This study was performed using an anthropomorphic thoracic phantom (Lungman, Kyoto 
Kagaku, Tokyo, Japan) with an artificial thoracic wall, heart, mediastinum, diaphragm and 
lungs with pulmonary vasculature (Figure 1). This phantom simulates an accurate life-size 
anatomical model of a male thorax. Soft tissue substitute materials were made of polyure-
thane resin composites. Synthetic bones were made of epoxy resin, with x-ray absorption 
rates close to those of human tissue. The space between the pulmonary vessels in the tho-
racic cavity contained air.  
 
 
Figure 1   External view (a) and internal artificial heart and lungs (b) of the anthropomorphic thoracic 
phantom. 
 
Moreover, we used five commercially available artificial spherical pulmonary nodules 
(Kyoto Kagaku, Tokyo, Japan) with a smooth surface in five diameters (3, 5, 8, 10 and 12 mm, 
corresponding to a volume of 14, 65, 268, 524 and 905 mm
3
), made of polyurethane resin 









Figure 2   Artificial spherical pulmonary nod-
ules with five different diameters (from left to 
right, 12, 10, 8, 5 and 3 mm, corresponding to 





Two 64-MDCT systems (CT-A: Sensation 64, Siemens, Forchheim, Germany; CT-B: Bril-
liance 64, Philips, Best, The Netherland) were utilized. The low-dose CT acquisition proto-
col in the Dutch-Belgian Randomized Lung Cancer Screening Trial (NELSON) was applied 
[4]. The protocol for CT-A was: spiral acquisition at 120 kV, 20 mAs, rotation time 0.5 s, 
pitch 1.5 and slice collimation 2 × 32 × 0.6 mm, field of view 300 mm; images were recon-
structed at a slice thickness of 1 mm, a slice increment of 0.7 mm, using a medium-smooth 
B30f image reconstruction kernel. The protocol for CT-B was: spiral acquisition at 120 kV, 
20 mAs, rotation time 0.5 s, pitch 1.39 and slice collimation 64 × 0.625 mm, field of view 
300 mm; images were reconstructed at a slice thickness of 1 mm, a slice increment of 0.7 
mm, with a medium-smooth B kernel. Both scanners were routinely calibrated.  
Artificial nodules were randomly positioned in the pulmonary vessels of the phantom. 
All nodules were firmly held in the vessels without using glue. To avoid the influence from 
thoracic walls on nodule segmentation, all nodules were attached to pulmonary vessels, 
none of the nodules were attached to pleura or positioned subpleurally. After randomly 
positioning a predetermined set of one to three nodules in the artificial lungs, CT image 
acquisition was performed. Thirteen different combinations of nodules were set up so that 
each nodule was examined in total five times. The CT examination was repeated three 
times for each nodule configuration, with a small translocation (approximately 5 to 10 mm) 
and rotation (approximately 5 to 10 degrees) of the phantom in between each examination 
to simulate participant movement. The thoracic phantom was also examined once without 
pulmonary nodules, serving as a control examination to exclude false positive findings. 
Thus, per CT system 40 examinations were performed, including 39 test examinations and 
one control examination.  
Therefore, each nodule was examined 30 times (five different locations, three repeat-
ing examinations and two CT systems). Furthermore, all nodules were examined in air, on 
the CT table, to confirm the visibility of the artificial pulmonary nodules on low-dose CT 
without the artificial thoracic background.   
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Quantitative image analysis 
The reconstructed data were evaluated on a workstation (Leonardo, Siemens, Forchheim, 
Germany). Three observers participated in image analysis, including two radiologists spe-
cialized in thoracic diagnostic imaging with eight years experiences (observer-A and ob-
server-B), and one resident with two years experiences (observer-C). All the examinations 
were assessed twice separated by at least one month by all three observers. The data were 
presented in the same order for the double reading. Observer-A evaluated the examina-
tions of CT-A and CT-B. Observer-B evaluated the examinations of CT-A. Observer-C 
evaluated the examinations of CT-B. The three observers were blinded to information 
about the presence, properties and location of the artificial pulmonary nodules. Since each 
nodule was scanned 15 times on each CT system and measured twice, in total at most 30 
paired evaluations for each nodule could be included for inter-scanner analysis. Also 30 
evaluations for each nodule could be included for intra-scanner analysis.   
The observers were asked to report whether there were pulmonary nodules present 
or not. If a potential nodule was observed, the images were compared to the images of the 
control CT examination without a nodule to confirm that it was not a false positive finding 
caused by pulmonary background structures. If comparison with the control CT confirmed 
the presence of the pulmonary nodule, a dedicated commercial software tool (LungCARE, 
Siemens, Forchheim, Germany) was utilized to semi-automatically measure the volume of 
the detected nodules. The accuracy of nodule volumetry of this software was shown to be 
very high [20]. 
In addition, image noise was assessed by measuring the standard deviation of mean 
HU in a circular region of interest (ROI) with a radius of 10 mm. The ROIs were placed in 
artificial left ventricle, avoiding image artifact [21]. Ten examinations per CT scanner were 
randomly selected. Three ROIs were measured in each examination.   
 
Statistics 
The normality of data was assessed by the Kolmogorov-Smirnov test. Influential effects on 
nodule volumetry were investigated using univariate analysis of a general linear model. The 
dependent variable was CT-derived volume. The fixed factors were CT system (CT-A and 
CT-B) and observer (Observer-A, Observer-B and Observer-C). Differences in CT-derived 
volumes between the two CT systems were evaluated by a paired-samples t-test.  
Inter-scanner reliability of CT-derived volume was expressed as an intraclass correla-
tion coefficient (ICC). An ICC value larger than 0.90 was considered as high agreement, in 
the range of 0.75 to 0.90 as moderate, and smaller than 0.75 as low [22]. Inter-scanner vari-
ability of CT-derived volume was explored using Bland-Altman plots. Relative difference 
was calculated as (a - b) / m1 × 100%, in which, a and b were CT-derived volumes on CT-A 
and CT-B, respectively. m1 was the mean of a and b. The 95% confidence interval (CI) of 
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relative difference was calculated as a mean relative difference ± 1.96 standard deviation 
(SD).  
Since multiple image acquisitions and measurements were performed for an individ-
ual nodule, intra-scanner variability was expressed as a variation coefficient, by calculating 
SD/m2, where m2 was the mean of 30 evaluations of each nodule [16]. Relative variation 
from the mean was calculated. The 95% CI of relative variation was calculated as (± 1.96 SD) 
/ m2 × 100% [23]. A 95% CI smaller than 25% was considered as good agreement for inter- 
and intra-scanner variability [17].  
Results were given as mean ± SD. A p < 0.05 was considered as statistically significant. 

































All the nodules were detected and measured by the two observers. No false positive nod-
ules were found. Representative CT images of the anthropomorphic thoracic phantom are 
shown in Figure 3. CT-derived volume for each artificial nodule conformed to a normal 




Figure 3   Axial (a), coronal (b) and sagital image (c) of the anthropomorphic thoracic phantom with 









Table 1   Inter-scanner variability of CT-derived volume for artificial spherical solid pulmonary nod-
ules 
Nodule characteristics  Relative difference 
Diameter, mm Volume, mm3  Mean, % 95% CI, % 
3 14  16.7 -19.3, 41.6 
5 65  7.2 -5.6, 18.2 
8 268  0.9 -2.3, 4.0 
10 524  2.2 -0.5, 4.9 
12 905  1.3 -1.1, 3.7 
Relative difference was calculated as (volume on CT-A – volume on CT-B) / (mean volume of CT-A 
and CT-B) × 100%. 95% CI was calculated as mean ± 1.96 SD. 
 
 
Figure 4   Bland-Altman plots of the relative inter-scanner difference in semi-automated volumetry, 
for solid (+100 HU) nodules in five sizes (3, 5, 8, 10 and 12 mm in diameter, corresponding to vol-
umes of 14, 65, 268, 524 and 905 mm3) as measured on two CT systems of two different vendors, 
CT-A and CT-B. The dotted lines indicate the 95% confidence interval. The grey zone indicates a 
relative difference of ±25%, which is commonly used to exclude systematic errors, thus to exclude a 
growing nodule on subsequent CT scans. 
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Volumetry 
Univariate analysis showed that neither CT system nor observer was a significant factor 
influencing volumetry (p > 0.05). No significant difference in CT-derived volume was found 
between CT-A and CT-B (p > 0.05), except for the smallest 3 mm nodules (p < 0.05). Semi-
automated volumetry demonstrated underestimation from the actual volume. Overall, CT-
derived volume was underestimated by 9.1 ± 7.9% (p < 0.001). The noise level in CT-A was 
21.8 ± 1.3, significantly lower than 24.0 ± 1.3 in CT-B (p < 0.01).  
 
Inter- and intra-scanner variability 
Inter-scanner reliability of CT-derived volume was high (ICC = 1.000, p < 0.001). Inter-
scanner variability of CT-derived volume decreased at larger nodule size (Table 1, Figure 4). 
Inter-scanner variability was low for nodules ≥ 8 mm in diameter, in which the maxima of 
the 95% CI was 4.9%.  
 
Table 2   Intra-scanner variability of CT-derived volume for artificial spherical solid pulmonary nod-
ules 











95% CI of relative 
variation, % 
3 14 14.6 -28.6, 28.6 14.6 -28.6, 28.6 
5 65 3.9 -7.6, 7.6 6.8 -13.4, 13.4 
8 268 1.1 -2.2, 2.2 1.1 -2.2, 2.2 
10 524 1.3 -2.6, 2.6 0.7 -1.4, 1.4 
12 905 0.6 -1.3, 1.3 1.1 -2.2, 2.2 
Variation coefficient was calculated as SD / mean × 100%. 95% CI of relative variations was calcu-
lated as (±1.96 SD) / mean × 100%. 
 
Intra-scanner variability also decreased at larger nodule size (Table 2, Figure 5). In-
tra-scanner variability of CT-derived volume was also low for nodules ≥ 8 mm in diameter, 









Figure 5   Grouped plots of the relative intra-scanner variation in semi-automated volumetry, for 
solid (+100 HU) nodules in five sizes (3, 5, 8, 10 and 12 mm in diameter, corresponding to volumes 
of 14, 65, 268, 524 and 905 mm3) on CT-A (a) and CT-B (b). The grey zone indicates a relative dif-
ference of ±25%, which is commonly used to exclude systematic errors, thus to exclude a growing 










In this anthropomorphic phantom study investigating inter- and intra-scanner variability, 
and inter-measurement variability of CT-derived nodule volume, variability of CT-derived 
volume decreased at increasing nodule size, to a maximum of 4.9% for ≥ 8 mm nodules. 
Good inter- and intra-scanner agreement was found for nodules ≥ 5 mm in diameter, but 
not for 3 mm nodules.  
One-dimensional measurement (diameter) of a target lesion is commonly utilized 
[24]. Yet accuracy and reproducibility of diameter measurement to assess pulmonary nod-
ule size are low [10]. Also, discrepancies in manual assessment of lesion size can signifi-
cantly influence therapeutic decisions [25]. On the other side, semi-automated volumetry 
using dedicated software shows better reproducibility than manual assessment of nodule 
size [26, 27]. However, even semi-automated volumetry suffers from some variability [11, 12]. 
It is well known that reproducibility of CT-derived volume of pulmonary nodules is influ-
enced by a number of factors, such as CT equipment, nodule characteristics and pulmonary 
surroundings [9, 11]. In view of current practice of lung cancer screening that uses multiple 
CT systems, management of systematic errors is essential to reach a reliable result.  
Variability of CT-derived volume by semi-automated method decreased at larger 
nodule size. In previous in-vivo studies, pulmonary nodules were commonly analyzed as a 
whole, without assessing variability by nodule size categories [17, 18]. Also, inconsistent 
results were reported about dependency of volumetry variability on nodule size. Rampinelli 
et al. found that volumetry for larger nodules was more reproducible, based on 83 nodules 
with a mean volume of 220 ± 241 mm
3
 [19], yet Marchiano et al. observed that variability 
was not affected by nodule volume based on 233 nodules of 99 ± 127 mm
3
 [28]. In those in-
vivo studies, different volume ranges of included nodules have likely caused these inconsis-
tent results. We performed the current study based on five discrete and well-defined sizes 
of nodules from 14 to 905 mm
3
, which is the common nodule volume range in lung cancer 
screening [4], and found that variability does depend on nodule size. 
Currently, a threshold of 25% is commonly utilized as the minimal volume change for 
growing solid nodules [3]. That in-vivo result was based on inter-scan variability observed 
in one CT system for nodules 15 to 500 mm
3
 [17]. Our results were based on two CT systems, 
which is closer to the practice of lung cancer screening with multiple CT systems involved. 
In our study, the maxima of 95% CI of variability was less than 18% for ≥ 5 mm (65 mm
3
) 
solid nodules, and less than 5% for ≥ 8 mm (268 mm
3
) nodules. This suggests that the 
threshold of 25% can be used for solid nodules of ≥ 5 mm and is a conservative threshold. 
The threshold of 25% could potentially be decreased for larger pulmonary nodules of ≥ 8 
mm. Because large variability was found for 3 mm nodules, the threshold of 25% is not 
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likely to be usable for 3 mm nodules. However, the likelihood of < 5 mm nodules to be ma-
lignant is very low [29]. 
In lung cancer screening, images are often read twice, commonly by different paired 
observers. E.g., in the NELSON trial, the CT examination of participants was assessed first 
at the local site, and then at the central site. Two radiologists with more than 6 years ex-
perience performed the evaluation at the central site, and 13 radiologists or residents with 
variable experience at the local sites [30]. To adhere to this screening practice of double 
reading, we chose two observers (local readers) for the first evaluation and one observer 
(central reader) for the second evaluation. 
A significant volumetry difference was observed between CT-A and CT-B in 3 mm 
nodule, but not in the larger nodules. This was caused by different properties between the 
scanners from both vendors, i.e., image acquisition and reconstruction parameters. Be-
cause volumetry analysis of smaller nodules is more affected by noise, we quantified the 
image noise in the images from both CT scanners. Higher image noise degrades nodule 
segmentation, thus leading to underestimated CT-derived volume [31]. As we observed, 
CT-B has higher noise level than CT-A, this could very well explain the observed lower CT-
derived volume in CT-B than in CT-A for the 3 mm nodule. 
Semi-automated volumetry systematically underestimated the nodule volume when 
using a low-dose CT acquisition protocol. This finding is in concordance with previous 
studies based on the same phantom, in three different CT scanners [10, 32]. It is well know 
that accuracy of nodule volumetry depends on many factors, such as CT acquisition and 
reconstruction algorithm. De Jong et al. reported that low-dose CT yielded lower volumes 
than normal-dose CT [33]. It is likely that our low-dose setting contributes to the system-
atic volume underestimation. However, given the systematic nature of this error, this is 
less important to evaluate growth rate in lung cancer screening.  
 
Clinical implications 
Changes in nodule size that exceed measurement variability are important to determine 
actual growth, which can impact treatment decision and estimation of therapy outcome 
[34, 35]. In lung cancer screening trials, volumetry and diameter methods to assess pulmo-
nary nodule size and growth have been applied. Semi-automated volumetry was utilized in 
the NELSON trial [36]. Manual diameter measurement was utilized in some earlier 
launched trials, such as the National Lung Screening Trial [8]. Since determination of nod-
ule growth depends on nodule size, a volumetry method with less variability can poten-
tially provide more accurate and more timely treatment decisions and a better outcome 
estimation. We found that semi-automated volumetry showed good inter- and intra-
scanner variability. Thus, the semi-automated method is reliable for pulmonary nodule 
assessment in lung cancer screening. Moreover, no difference was found between two CT 
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systems from different vendors for ≥ 5 mm nodules. As the follow-up of screened partici-
pants can last for an extensive period, different CT systems from different vendors may be 
used. A direct comparison of nodule volumes obtained from different CT systems seems 
valid, at least for the CT systems investigated in this study.  
To determine a growing nodule, inter- and intra-scanner variability should be opti-
mized to minimize systematic errors. This allows for the determination of a cut-off value to 
assess with confidence whether nodule volumes have actually increased. For an indetermi-
nate nodule, lung cancer screening trials commonly use a follow-up CT of three to fourth 
months to evaluate nodule growth, based on a minimum increase of 25% [6]. The thresh-
old of 25% can likely be lowered for nodules of ≥8 mm in diameter, when using semi-
automated volumetry and 64-MDCT scanning, since the variability was only 4.9% in this 
study. If based on a minimum increase of 5% to determine growth, the follow-up interval 
can potentially be reduced to three to four weeks. This can also limit the time of partici-
pant anxiety.  
 
Limitations 
Firstly, although the anthropomorphic phantom more closely resembles the human thorax 
than previously published phantoms, degenerative changes in lung tissue were not present 
in the phantom. Fibrosis, emphysema and consolidations can influence the nodule volu-
metry. Additional patient factors were not present either, such as breathing variability, 
variable habitus and patient size. A phantom with these variable characteristics is difficult 
to make. Our phantom study represents the variability of nodule volumetry in a relatively 
optimal environment, although the variability might be higher in vivo. Also, only spherical 
nodules of five discrete sizes were used. Although pulmonary nodules of these sizes are 
common findings in lung cancer screening [4], nodule shape is more often irregular and 
nonspherical in-vivo, with a continuous size range. A study extension would therefore be 
variability assessment for irregular nodules.  
Secondly, we only evaluated one CT acquisition protocol. That protocol has been 
widely applied in lung cancer screening [3].However, variability of nodule volumetry de-
pends on acquisition and algorithm in individual settings [7, 35]. When discussing the re-
sults, we linked to the studies based on the same CT acquisition protocol [5, 10, 11, 17]. Thus, 
our results are comparable to those previous data. A further extension would be the evalua-










Different 64-MDCT scanners in low-dose setting yield similar volumetry of artificial pul-
monary nodules between 5 and 12 mm diameter. Inter- and intra-scanner variability, and 
inter-measurement variability of CT-derived volumes of spherical solid pulmonary nodules 
decreases at increasing nodule size. In lung cancer screening, the commonly accepted cut-
off of 25% to determine nodule growth has the potential to be reduced for nodules of ≥ 8 
mm in diameter. This phantom study offers potential to reduce the interval for repeated 
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Coronary calcium score (CS), traditionally based on electrocardiography (ECG)-triggered 
computed tomography (CT), predicts cardiovascular risk. Nowadays, nontriggered thoracic 
CT is extensively utilized, such as in lung cancer screening. The study-purpose was to de-
termine the correlation in CS between nontriggered and ECG-triggered CT, and to evaluate 
the prognostic performance of the CS derived from nontriggered CT. 
 
Methods and Results 
PubMed, Embase and Web of Knowledge were searched until November, 2012. Two re-
viewers independently screened 2,120 records to identify studies reporting the CS in non-
triggered CT, and extracted information. Study quality was evaluated by standardized as-
sessment tools. Cohen’s κ was extracted for agreement of CS categories between nontrig-
gered and ECG-triggered CT (validation). Hazard ratio was extracted for prognostic per-
formance. Five studies comprising 1,316 individuals were included regarding validation. 
Five studies comprising 34,028 cardiac asymptomatic individuals, mainly from lung cancer 
screening trials, were included regarding prognosis. All studies were of high quality. Meta-
analysis could only be performed for validation studies, as studies on prognostic perform-
ance were highly heterogeneous. Pooled Cohen’s κ for agreement between the two tech-
niques was 0.89 (95%CI: 0.83 to 0.95) for increasing CS categories. Increasing CS categories 
were associated with increasing risk of cardiovascular death or events.  Nontriggered CT 
yielded false-negative CS in 8.8% of individuals, and underestimated high CS in 19.1%. 
 
Conclusions 
Our analysis shows the prognostic value and potential role of nontriggered assessment of 
















The amount of coronary artery calcium, based on computed tomography (CT) and tradi-
tionally expressed as calcium score (CS) according to Agatston [1], is a strong predictor of 
cardiovascular events [2-5].  Calcium scoring has been found to improve cardiovascular risk 
stratification beyond cardiovascular risk factors [4,6]. Due to the irregular and periodic 
movements of coronary arteries, electrocardiography (ECG)-triggered cardiac acquisition 
techniques are applied in CT to minimize motion artifacts and optimize calcium scoring [3].  
 Compared to ECG-triggered CT, nontriggered CT is extensively utilized. In 2007, 13.6 
million nontriggered thoracic CT examinations were performed in the United States, in 
contrast to 0.7 million ECG-triggered CT examinations for calcium scoring [7]. Recent trial 
results have increased the interest in lung cancer screening by thoracic CT [8]. Thus, the 
number of nontriggered examinations will likely further increase. Age and smoking, the 
current selection criteria for lung cancer screening, are also correlated with coronary calci-
fication and coronary heart disease [9]. In lung cancer screening, coronary calcification is a 
frequent finding [10]. If nontriggered CT can be used for calcium scoring, to stratify indi-
viduals in categories of cardiovascular risk and to identify those at high cardiovascular risk, 
there may be a substantial unused primary prevention potential [11]. Also, deriving the CS 
from the same examination as used in lung cancer screening may positively impact the 
cost-effectiveness of screening. 
Because motion of coronary arteries influences calcium scoring [12], the utilization of 
coronary calcium scoring in nontriggered CT is still being debated [13]. With the increasing 
interest in lung cancer screening, this is an optimal moment to investigate the potential 
utilization of nontriggered CT for calcium scoring. However, compared with the extensive 
publications in ECG-triggered cardiac CT, the literature on calcium scoring in nontriggered 
thoracic CT is relatively limited. Therefore, we conducted a systematic review and meta-
analysis to investigate the validity and prognostic value of calcium scoring derived from 
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Figure 1   Flowchart of literature review and selection. 
 
Information sources and search 
We searched PubMed, Embase, and Web of Knowledge until November, 2012, using terms 
related to computed tomography and nontriggered thoracic examination (ungated, untrig-
gered, nongated, nontriggered, thorax, chest, thoracic, pulmonary, etc.) and coronary and 
calcium (calcium or calcification, etc.) without language restrictions (Supplemental Table 
A). Unpublished studies were not included.  
 
Study selection  
Two reviewers (XQ.X. and YR.Z.) with at least eight years of experience in thoracic and 
cardiovascular radiology participated in literature selection. Each record was evaluated 
independently. Disagreement in literature selection was resolved by consensus. Studies 
were included in the systematic review when they: 1) evaluated cardiac asymptomatic adult 
humans, or phantoms; 2) analyzed one of the following topics regarding calcium scoring in 
nontriggered CT: agreement between nontriggered and ECG-triggered CT, or prognostic 
performance to predict death or events; 3) used at least 16-row MDCT as ECG-triggered 
examination when ECG-triggered CT was used as reference examination. Sixteen-row 
MDCT was used as minimum CT generation because previous research showed higher ac-
Records identified through  
database searching (n=3059) 
Records screened by title and abstract  
after duplicates removed (n=2120) 
Records excluded (n=2043) 
Full-text articles assessed  
for eligibility (n=77) 
Full-text articles excluded:  
Not in humans, or phantom (n=1) 
ECG-triggered examination (n=43) 
Not preferred topics (n=19) 
<16-MDCT as reference (n=2) 
Possible duplicate (n=2) 
Studies included in systematic review:  
Studies on agreement (n=5) 
Studies on prognosis (n=5) 
Studies included in meta-analysis:  
Studies on agreement (n=3) 
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curacy and reproducibility in calcium scoring for 16-row MDCT compared to earlier gen-
eration CT systems [15].  
Articles were excluded when they: 1) were reviews, abstracts, case reports or letters; 2) 
investigated participants with confounding factors, e.g., pacemaker or defibrillator implant, 
and cardiac surgery. When multiple similar publications based on the same trial were iden-
tified, only the study with the largest sample size was included to avoid possible duplicate 
reporting.  
Subsequently, meta-analysis was performed in studies on agreement between non-
triggered and ECG-triggered CT, when the studies used the same calcium scoring method, 
i.e., continuous CS and/or four CS categories (0, 1 - 99, 100 - 399, ≥ 400). No meta-analysis 
could be performed of the studies on prognostic value, because of large heterogeneity in 
calcium quantification methods, CS categorization and outcomes.   
 
Data collection process  
A standardized data extraction form was used to collect study and participant characteris-
tics, methodology, and main results. Two reviewers (XQ.X. and YR.Z.) collected data inde-
pendently. Disagreement in data collection was resolved by consensus.  
For results of studies on agreement of calcium scoring between nontriggered and 
ECG-triggered CT, a correlation coefficient (CC) was extracted for continuous data, and 
Cohen’s κ and concordance percentage were extracted for categorical data. When available, 
the subject number with CS of > 0, < 400 and ≥ 400 was extracted for the two techniques. A 
CS of ≥ 400 is commonly considered as indicating high cardiovascular risk [3,5]. Thereafter, 
the diagnostic performance of nontriggered CT was calculated using ECG-triggered CT as 
reference. The percentage of false negative CS was calculated as the percentage of subjects 
with zero CS in nontriggered CT among subjects with CS > 0 in ECG-triggered CT. The 
percentage of underestimated high-risk CS was considered as the percentage of subjects 
with CS < 400 in nontriggered CT among subjects with CS ≥ 400 in ECG-triggered CT. The 
percentage of overestimated high-risk CS was calculated as the percentage of subjects with 
CS ≥ 400 in nontriggered CT among subjects with CS < 400 in ECG-triggered CT.  
For prognostic performance of calcium scoring in nontriggered CT, hazard ratio (HR) 
for increasing CS categories derived from nontriggered CT to predict cardiovascular death 
or cardiovascular events (coronary heart disease, cerebrovascular disease, heart failure, 
peripheral arterial disease, aortic aneurysm, etc.) was extracted. When possible, unadjusted 
and adjusted HR with 95% confidence interval (CI) was extracted. Furthermore, the num-
ber of subjects with zero CS was extracted, as well as the number of subsequent cardiovas-
cular deaths or events among these subjects.    
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Study quality assessment 
Two reviewers (XQ.X. and YR.Z.) evaluated study quality independently on the studies 
included in the systematic review. Disagreement in quality assessment was resolved by 
consensus. Two quality assessment tools for different type of study were utilized to evalu-
ate methodological quality and potential sources of bias, as described below.  
For validation studies on agreement between nontriggered and ECG-triggered CT, 
the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) with 14 standard items 
was utilized [16]. For each study, a quality score was derived by assigning 1 point to each 
fulfilled item, 0.5 to an unclear item, and 0 to an unmet item, with a total possible score of 
14 (Supplemental Table B).  
For prognostic studies, the quality assessment criteria to evaluate reports on progno-
sis of CAC in American College of Cardiology Foundation / American Heart Association 
(ACCF / AHA) guideline with 8 standard criteria was utilized [5]. For each study, a quality 
score was derived by assigning 0 to 3 points to each criterion, with a total possible score of 
16 (Supplemental Table C).  
 
Synthesis of results and risk of bias 
The pooling calculations of agreement between the two techniques were performed using 
the Hedges-Vevea random effects model and Z-test for overall effect. The pooling calcula-
tion was performed if there were at least two studies reporting the same measurement. 
Heterogeneity was tested using Q statistic and I
2
 index. A two-sided p value for Q statistic 
< 0.10 or I
2
 > 50% was considered to indicate heterogeneity. The random effects model was 
used regardless of the heterogeneity test, although results in Q statistics and I
2
 index were 
still stated. Publication bias was evaluated with the Begg and Mazumdar rank correlation 
and Egger’s regression test if the number of effect size in the included studies was at least 
three. For other statistical analysis, a two-sided p value < 0.05 was considered as significant. 
Statistical analysis was performed using R 2.14.2 (R Foundation, Vienna, Austria) and Stata 





The search of the three databases elicited 2,120 records after removal of duplicate records. 
Ten studies were included in systematic review, including five on agreement between non-
triggered and ECG-triggered CT [17-21] and five on prognostic performance [10,22-25]. Sub-
sequently, meta-analysis was performed in three studies [20, 22, 24] with consistent meth-






















































































64-MDCT Low 2.5 2.5 
Einstein 
2010 [18] 








Low n/a n/a 
Kim 2008 
[19] 






40-MDCT Low 2.5 2.5 
Kirsch 
2011 [20] 






Normal 5.0 3.0 
Wu 2008 
[21] 





16MDCT Low 3.0 3.0 
SD = standard deviation; CT = computed tomography; n/a = not available; COPD = chronic obstruc-
tive pulmonary disease; ECG = electrocardiographic; MDCT = multi-detector computed tomography; 
SPECT = single-photon emission computed tomography; PET = positron emission tomography. 
 
Study characteristics  
The systematic review included 35,344 participants (range of mean age, 51 to 65 years), 
comprising 21,558 (61%) men, 13,736 (39%) women and 50 (0.1%) individuals without indi-
cated gender (Tables 1 and 2). Six (60%) studies were prospective, four (40%) retrospective. 
Four studies (40%) were from North America, three (30%) from Europe, and three (30%) 
from Asia. All studies were published in English.  
Different CT modalities were utilized, ranging from single-slice to 64-row MDCT. 
Also CT systems as part of single-photon emission computed tomography (SPECT) / CT 
and positron emission tomography (PET) / CT were utilized [18]. Low-dose acquisition was 
applied in eight studies (80%), normal dose in one study (10%). In one (10%) study the ra-
diation dose was not reported. Scan data derived from nontriggered CT were reconstructed 
with different slice thicknesses, ranging from 1.25 to 10 mm (Tables 1 and 2). The most 
commonly used slice thicknesses were 2.5 / 3 mm and 5 mm. Four studies used a (medium-) 
smooth kernel [10,20,21,25], the other studies did not indicate the applied kernel. Six stud-
ies utilized Agatston scoring [10,17-19,21,25], while four others utilized visual grading of the 
presence and extent of coronary calcification. No study utilized contrast media. No phan-
tom study was included. 
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Table 2   Characteristics of studies on prognostic performance of calcium scoring for cardiovascular 








































































Low 10 Nagano 
Jacobs 
2011 [23]  







4-, 8-, 16-, 
40- and 64-
MDCT 
n/a 3.0-10 PROVIDI 
Jacobs 
2012 [10]  





16-MDCT Low 3.1 NELSON 
Shemesh 
2010 [24] 








Low 1.25-5 I-ELCAP 
Sverzellati 
2012 [25]  





16-MDCT Low 5 MILD 
SD = standard deviation; CT = computed tomography; n/a = not available; MDCT = multi-detector 
computed tomography; PROVIDI = the prognostic value of unrequested information in diagnostic 
imaging; NELSON = the Dutch-Belgian randomized lung cancer screening trial; I-ELCAP = interna-
tional early lung cancer action program; MILD = multi-centric Italian lung detection. 
 
Study quality  
All five studies on agreement between the nontriggered and ECG-triggered CT were of high 
quality (score ≥ 10 according to the QUADAS tool). Suboptimal scores were present in two 
QUADAS items: none of the five studies mentioned uninterpretable results (item 13); three 
studies did not mention whether there were withdrawals (item 14) (Supplemental Table B).  
All five studies on prognostic performance were of high quality (a score ≥ 12 accord-
ing the quality assessment criteria to evaluate prognosis of coronary calcification). Subop-
timal scores were present for criterion 4: none of the five studies reported results by eth-
nicity (Supplemental Table C). 
 
Validation of calcium scoring in nontriggered CT  
Five studies were included in the systematic review, comprising 1,316 cardiac asymptomatic 
participants (Table 1) [17-21]. Diagnostic performance of nontriggered CT was calculated in 
four studies with 1,153 subjects (Table 3) [17-19,21], in which 137 (11.9%) had CS of 100 - 400 
in nontriggered CT. Fifty-five subjects (8.8%) showed no coronary calcification in nontrig-
gered CT examination among 625 subjects with CS > 0 in ECG-triggered CT. In those fifty-
five subjects, fifty-two (8.3%) had CS 1-100 in ECG-triggered CT, and three (0.5%) had CS 
100-400. Among 162 subjects with CS ≥ 400 in ECG-triggered CT, nontriggered CT underes-
timated the CS in 31 subjects (19.1%). In these thirty-one subjects, two (1.2%) had CS   1 - 100 
in nontriggered CT, and twenty-nine (17.9%) had CS 100-400. On the other hand, among 
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991 subjects with CS < 400 in ECG-triggered CT, nontriggered CT showed a CS ≥ 400 in 
twenty-six subjects (2.6%) and thus overestimated the CS. In those twenty-six subjects, one 
(0.1%) had CS 1-100 in ECG-triggered CT, and twenty-five (2.5%) had CS 100 - 400.   
Figure 2   Forest plots for agreement of coronary calcium scoring between nontriggered and elec-
trocardiography-triggered computed tomography 
Study, year Effect size (95% CI) Size,n Forest plots 
Calcium score 
 Correlation coefficient   
Budoff 2011[17]  0.96 (0.93, 0.98) 50  
Kim 2008[19]  0.89 (0.85, 0.92) 128  
Wu 2008[21]  0.95 (0.94, 0.96) 483  
    
    Pooled 0.94 (0.89, 0.97) 661  
 
    Heterogeneity p(Q) < 0.001, I2 = 89.1%            0.0                0.5                 1.0 
    Overall effect  p(Z) < 0.001  Correlation coefficient 
    Publication bias p(B) = 0.60, p(E) = 0.80   
4 categories of calcium score* 
 Concordance Cohen’s κ    
    Budoff 2011[17] 94% 0.90 (0.79, 1.00) 50  
    Wu 2008[21] 93% 0.89 (0.82, 0.96) 483  
    
    Pooled 0.89 (0.83, 0.95) 533  
 
    Heterogeneity p(Q) = 0.88, I2 = 0%             0.0                  0.5                 1.0 
    Overall effect p(Z) < 0.001  Cohen’s κ 
*The four categories of calcium score were defined as 0, 1-99, 100-399, and ≥ 400. p(Q) = p value 
for Q statistic; p(Z) = p value for Z test; p(B) = p value for Begg and Mazumdar rank correlation test; 
p(E) = p value for Egger’s regression test.  
 
Meta-analysis was performed in three studies comprising 661 participants (Figure 2) 
[17,19,21].  The study by Kirsch could not be included because it evaluated the amount of 
coronary calcification using visual grading score [20]. The pooled CC for CS was 0.94 
(95%CI: 0.89 to 0. 97). The pooled Cohen’s κ was 0.89 (95%CI: 0.83 to 0.95) for four cate-
gories of the calcium score. Heterogeneity was found in the pooling calculation of the cal-
cium score (P for Q statistic < 0.001 and I
2
 >50%). No publication bias was found in the 
pooling calculation of the calcium score (P > 0.05). Publication bias testing was not per-
formed in the pooling calculation of four CS categories, due to insufficient number of stud-
ies. 
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Prognosis of calcium scoring in nontriggered CT 
Five studies were included, comprising 34,028 cardiac asymptomatic participants (Table 2) 
[10,22-25]. In the five studies, mean follow-up duration was 45 months (range, 10 to 72 
months). None of the participants in the included studies had a history or symptoms of 
cardiovascular diseases before CT examination. During follow-up, 207 cardiovascular 
deaths and 675 cardiovascular events were observed. Overall, with increasing CS categories, 
increasing unadjusted and adjusted hazard ratio for cardiovascular death or events was 
observed. Risks in CS categories were not consistently reported, however in one study, un-
adjusted and adjusted hazard ratio increased up to 7.5 and 5.3 for CS > 1000, respectively 
(Table 4) [10].  
A small percentage of subjects with zero CS in nontriggered CT suffered cardiovascu-
lar death or events. During a mean follow-up of 45 months, 47 cardiovascular deaths 
(0.55%) were found in 8,487 subjects with zero CS [22,24], whereas 72 cardiovascular 
events (1.3%) occurred in 5,249 subjects with zero CS [10,23]. However, the event rate for 
subjects with positive CS was higher. During follow-up, 160 cardiovascular deaths (2.5%) 
were found in 6,415 subjects with positive CS [22,24], whereas 570 cardiovascular events 




In this systematic review and meta-analysis, we aimed to investigate whether coronary 
calcium scoring can be performed in nontriggered thoracic CT, for instance utilized in lung 
cancer screening. A strong correlation in calcium score categories between nontriggered 
and ECG-triggered CT was found. In cardiac asymptomatic elderly and smokers, mainly 
from lung cancer screening trials, increasing coronary calcium burden translated into a 
higher risk of cardiovascular death or events.  
Calcium score for individual atherosclerotic lesions is greatly influenced by motion 
[12]. Regardless, we found that the correlation in CS between nontriggered and ECG-
triggered CT was excellent (r = 0.94) on a group level. In broad CS categories, we found a 
high agreement between nontriggered and ECG-triggered CT (Cohen’s κ = 0.89). Thus, for 
an individual patient, although variability in CS between nontriggered and ECG-triggered 
CT is likely considerable, broad CS categories can potentially be utilized for cardiovascular 








Table 3   Agreement of coronary calcium scoring between nontriggered thoracic and ECG-triggered 












































































































































































































































































































































































































































































































































*False negative calcium score is indicated as the percentage of CS = 0 subjects on nontriggered CT 
among CS > 0 subjects on triggered CT. Underestimated high-risk calcium score is indicated as the 
percentage of CS < 400 subjects on nontriggered CT among CS ≥ 400 subjects on triggered CT. 
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Overestimated high-risk calcium score is indicated as the percentage of CS ≥ 400 subjects on non-
triggered CT among CS < 400 subjects on triggered CT.  
†Four categories of CS were defined as 0, 1-99, 100-399, and ≥400.  
‡Six categories of CS were defined as 0, 1-9, 10-99, 100-399, 400-999 and ≥1000.  
§A score was assigned for each major coronary artery. 0: No calcification; 1: single pixel calcification; 
3: dense calcification with blooming artifact; 2: calcification between 1 and 3. The visual grading 
score (range 0 to 12) was calculated by the sum of the score for each artery. CT = computed tomo-
graphy; CS = calcium score; n/c = not calculated because different scoring systems were used in 
nontriggered and ECG-triggered CT.  
 
Absence of coronary calcification in ECG-triggered CT is associated with a very low 
cardiovascular risk, and thus is commonly utilized to rule out coronary artery disease [3,26]. 
We found that nontriggered CT can yield a false-negative CS in about 9% of individuals 
compared to ECG-triggered CT. Furthermore, we found that a zero CS in nontriggered CT 
indicates a low cardiovascular risk, although nontriggered CT cannot reliably exclude 
coronary calcification. When a high CS (≥ 400) is found in asymptomatic individuals, the 
risk of cardiovascular events is elevated. The ACCF / AHA consensus document suggests to 
regard these individuals as candidates for intensive preventive therapies [5]. The probabil-
ity of overestimating the CS is low, and thus, it is reasonable to assume an elevated cardio-
vascular risk in case of a CS ≥ 400 in nontriggered CT. On the other hand, nontriggered CT 
underestimated the CS in a nonnegligible percentage of individuals with CS ≥ 400 in ECG-
triggered CT, thus underestimating cardiovascular risk. In the validation study, 11.9% had a 
CS of 100-400 in the nontriggered CT examination. In this relatively small proportion of the 
included study populations, dedicated ECG-triggered CT could be considered, to assess 
whether the CS is actually ≥ 400. This proportion is much lower than the population per-
centage in which calcium scoring could be considered according to current consensus 
documents (40%) [27].   
In this study, hazard ratios of CS categories for cardiovascular events were generally 
lower than in a previous systematic review on calcium scoring derived from ECG-triggered 
CT [5]. For example, adjusted HR for cardiovascular events was up to 5.3 for CS > 1000 in 
our study, lower than 10.8 in a previous report in ECG-triggered CT in an elderly popula-
tion [28]. The relative risk is usually based on the risk of subjects without coronary calcium 
at baseline as reference category. During a mean follow-up of 45 months, we found that 
1.3% subjects without coronary calcium had a cardiovascular event. In contrast, a meta-
analysis by Sarwar et al. on ECG-triggered CT reported only 0.47% of subjects without 
coronary calcium suffered a cardiovascular event during a mean follow-up of 50 months 
[26]. In that meta-analysis, studies mainly consisted of middle-aged individuals at low-to-
intermediate cardiovascular risk, referred for cardiovascular risk evaluation. In contrast, 
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the majority of the populations in the prognostic studies on calcium scoring using nontrig-
gered CT comprised participants of lung cancer screening trials. The generally higher age 
and heavier smoking history in the prognostic studies included in our study likely at least 
partly explain the higher event rate in individuals with zero CS. Besides, this higher event 
rate in case of zero CS for nontriggered CT may also be explained by the fact that a propor-
tion of the individuals without coronary calcification on the nontriggered CT, actually have 
a positive CS in ECG-triggered CT. As this reference risk is higher, the relative risk for in-
creasing CS categories also yield lower values. Our finding does suggest that presence of 
coronary calcification in nontriggered CT is an independent predictor of cardiovascular 
events. Also, we found that higher calcium burden translated into a higher cardiovascular 
risk in a large aggregated sample.  
Reproducibility of calcium scoring in repeated nontriggered CT has been investigated. 
Jacobs et al investigated 584 subjects who underwent two nontriggered examinations of the 
thorax, and calculated the CS for both exams [29]. The calcium scores were divided into 
the commonly used categories of 0, 1 - 100, 101 - 400, > 400. In 440 cases (75%), the calcium 
scores of the two CT examinations fell in the same category. In 138 subjects (24%), calcium 
scores differed by one category, and in 6 subjects (1%) by more than one category. The in-
tra-class correlation coefficient was 0.94. On the other hand, reproducibility of calcium 
scoring in ECG-triggered CT is also not perfect. Using ECG-triggered CT, Rutten reported 
that 76% to 85% of individuals ended up in the same CS category, and in 15% to 24%, the 
results differed by one category [30].  
The agreement of repeated calcium scoring in nontriggered CT within and between 
observers is high, although slightly lower than in ECG-triggered CT. Nearly all studies in 
this systematic review investigated either intra- or inter-observer variability of calcium 
scoring in nontriggered CT. For example, in 483 subjects, Wu reported an inter-observer 
variability of 3.6% for ECG-triggered CT, and of 9.6% for nontriggered CT [21]. However, all 
studies found a very strong concordance in score categorization within and between ob-
servers (kappa values 0.77 to 0.91, intraclass correlation coefficient 0.93 to 0.99) 
[10,18,20,21,23-25]. 
The majority of included studies (80%) were based on low-dose thoracic CT [10,17-
19,21,22,24,25], which has a lower radiation dose than a dedicated cardiac CT for calcium 
scoring. A typical effective radiation dose for low-dose CT utilized in lung cancer screening 
is 0.8 - 0.9 mSv for normal sized body [8,21]. However, the mean dose for a cardiac CT for 
calcium scoring is approximately 1.0 - 2.9 mSv, depending on scanner type and scanning 
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*A grading score was assigned for each major coronary artery. 0: No calcification. 1: One or two 
calcifications. 2: >2 calcifications or one calcification extending ≥2 slices. 3: Calcification covering a 
large coronary segment. Four visual grades were stratified by the sum of the score (0, 1-2, 3-5 and 
6-12). 
†A grading score was assigned for each major coronary artery. 0: No calcification. 1: ≤⅓ of the artery 
length showed calcification. 2: ⅓ to ⅔. 3:≥⅔. Three visual grades were stratified by the sum of the 
score (0, 1-3 and 4-12). CI = confidence interval; n/a = not available. 
 
Clinical implication 
A large number of nontriggered CT examinations are annually performed world-wide. In 
the aging and smoking population, coronary calcification is a common finding. A lung can-
cer screening trial reported that over 70% of the participants had coronary calcification [10]. 
The group at risk for lung cancer overlaps with the group at highest risk of cardiovascular 
diseases, because at least aging and smoking are two major risk factors for both diseases. 
There may be a substantial primary prevention potential if the calcium score can be de-
rived from the same examination, at least in participants of lung cancer screening trials. 
While results from the one study in a clinical population suggest that the extent of coro-
nary calcification is also predictive outside lung cancer screening setting, more studies are 
needed to confirm the value of calcium scoring in routine clinical thoracic CT 
We observed that CS categorization between nontriggered and ECG-triggered CT 
correlated very well, and increasing CS categories based on nontriggered CT are predictive 
of increasing cardiovascular risk. Thus, for subjects who were examined by nontriggered 
thoracic CT, the cardiovascular risk could potentially be stratified by performing calcium 
scoring. Subjects identified in nontriggered CT as having high CS could be considered as 
candidates of intensive risk factor modification, especially in an aging and smoking popula-
tion such as the participants in lung cancer screening. However, a zero calcium score in 
nontriggered CT does not exclude coronary calcification.    
Furthermore, cardiovascular event rate of subjects without CS in nontriggered CT is 
higher than in ECG-triggered CT. Absent coronary calcification in nontriggered CT may 
not reliably exclude the risk of cardiovascular events. Future studies on this topic are 
needed to provide stronger support for coronary calcium scoring in nontriggered CT.  
 
Limitations 
Firstly, despite our favorable results it remains to be clarified whether differences in the 
accuracy between nontriggered and ECG-triggered CS measures translate into differences 
in prognostic value. For example, a zero CS in nontriggered CT may render a positive CS in 
ECG-triggered exams. Secondly, for agreement in calcium scoring between nontriggered 
and ECG-triggered CT, the number of studies and participants in the meta-analysis was 
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relatively low. To compare calcium scoring between nontriggered and ECG-triggered CT, 
the patients have to be scanned twice in a short time-interval, and at doubled radiation 
dose. This could contribute to the relatively small number of studies in this field. Our con-
clusions are not only based on the pooling calculations but also on the systematic review. 
Besides, for the second part of our study, regarding the prognostic value, the aggregated 
sample size was over 30,000 individuals. Thirdly, different calcium scoring methods were 
utilized in studies on prognostic performance. Meta-analysis could therefore not be per-
formed to assess predictive value of the calcium score derived from nontriggered CT. How-
ever, heavier calcium burden was in the systematic review associated with increasing car-
diovascular risk. Finally, included studies were fairly heterogeneous in terms of participant 
population, imaging equipment and acquisition protocol. Those factors weakened the 
strength of meta-analysis. We used a random effects model to compensate for at least some 
of the heterogeneity in the pooling calculation. On the other hand, the differences in imag-
ing procedures also reflect the heterogeneity of procedures in clinical practice. Despite 
different CT equipment and calcium scoring methods, at least the presence or absence of 
coronary calcium is clear. Results on the presence and absence of coronary calcification 
should not differ significantly based on important CS categories. Thus, our conclusions 




In this systematic review and meta-analysis, strong agreement in CS categorization was 
found between nontriggered CT and ECG-triggered CT. Compared to ECG-triggered CT, a 
high calcium score category in nontriggered CT is a fairly reliable finding. However, non-
triggered CT yielded false-negative CS in 8.8% of individuals, and underestimated high CS 
in 19.1%. In cardiac asymptomatic participants mainly from lung cancer screening trials, 
increasing CS categories in nontriggered CT were associated with increasing risk of cardio-
vascular events. Our analysis presents preliminary evidence for the prognostic value and 
potential role of calcium scoring in nontriggered CT.  However, it does not suggest that 
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Supplemental Table A   Literature search strategy 
Search terms used to identify relevant citations 
 
PubMed 
("Tomography, X-Ray Computed"[MeSH] OR "computed tomography"[tiab] OR CT[tiab] OR 
“MDCT”) AND ("untriggered” OR “ungated” OR “nongated” OR “nontriggered” OR “nonelectrocar-
diogram” OR “thorax”[MeSH] OR “chest” OR “thoracic” OR “lung” OR “pulmonary” OR “torso”) 
AND (“coronary vessels”[MeSH] OR "Coronary") AND (“Calcium” OR “calcification” OR “calcific” 
OR “calcified”) AND 1900/01:2012/11[dp] 
 
EmBase 
#1: ((Computed  tomography) OR CT:ab,ti OR MDCT) AND (untriggered OR ungated OR non-
gated OR nontriggered OR nonelectrocardiogram OR thorax OR chest OR thoracic OR lung:ab,ti 
OR pulmonary:ab,ti OR torso) AND Coronary AND (Calcium OR calcification OR calcific OR cal-
cified) 
Grammar in advanced search: #1 AND [1-1-1900]/sd NOT (#1 AND [30-11-2012]/sd) 
 
Web of Knowledge 
#1 topic: ((Computed tomography) OR CT OR MDCT) 
#2 topic: (untriggered OR ungated OR nongated OR nontriggered OR nonelectrocardiogram OR 
thorax OR chest OR thoracic OR lung OR pulmonary OR torso) 
#3 topic: Coronary  
#4 topic: (Calcium OR calcification OR calcific OR calcified) 






















Supplemental Table B   Quality assessment for validation studies on agreement and diagnostic 
































































































































































































































































































































































































































2011[17]               12.0 
Einstein 
2010[18]               12.0 
Kim 
2008[19]               12.5 
Kirsch 
2011[20]               13.0 
Wu 
2008[21]               13.5 
*Maximum delay of 2 months between nontriggered and reference examination was considered as 
acceptable.  
†For each study, a quality score was accumulated by assigning 1 point to “yes” item, 0.5 point to 
“unclear” item, and 0 to “no” item. The total possible score was 14. A score of ≥ 10 points was con-
sidered as high quality, and a score between 6 and 9 points as moderate quality, a score of ≤ 5 as 
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Supplemental Table C   Quality assessment for studies on prognosis, by the quality assessment 
criteria of prognostic studies on coronary artery calcium in American College of Cardiology Founda-


















































































































































































































































































Itani 2004[22] 2 1 2 1 1 1 3 0 11 
Jacobs 2011[23] 1 2 2 0 1 2 2 1 11 
Jacobs 2012[10] 2 2 2 0 1 2 3 1 13 
Shemesh 2010[24] 2 2 2 1 1 2 3 1 14 
Sverzellati 2012[25] 2 2 2 1 1 2 3 1 14 
*For each study, a quality score was accumulated by assigning a score for each criterion as the 
following: Criterion1: Retrospective vs. prospective study (1 = retrospective, 2 = prospective). Criterion2: 
Potential for referral bias (0 = clinically referred patients, 1 = unselected cohort, 2 = population sam-
ple). Criterion3: Reporting coronary calcification by CHD death or myocardial infarction (1 = no, 2 = yes). 
Criterion4: Reporting of results by gender or ethnicity (0 = no, 1 = gender only, 2 = ethnicity only, 3 = 
both). Criterion5: Sample size ≥ 1000 (0 = no, 1 = yes). Criterion6: Potential for limited challenge (1 = no 
reporting of calcium outcomes in low- to high-risk global risk scores, 2 = reporting of calcium out-
comes in low- to high-risk global risk scores). Criterion7: Risk factor reporting (1 = historical only, 2 = 
measured in subset, 3 = measured in all subjects). Criterion8: Covariate or risk-adjusted outcomes (0 = 
no, 1 = yes). 
Total possible score was 16. A score of ≥ 11 points was considered as high quality, and a 
score between 7 and 10 points as moderate quality, a score of ≤ 6 as low quality. CHD = coronary 
heart disease. 
  
Can Nontriggered Thoracic CT be Used for Coronary 
Artery Calcium Scoring? A Phantom Study 
 




















/ Marcel J.W. Greuter
1 
/ Jaap M. Groen
3 










University of Groningen, University Medical Center Groningen,
 1
Department of Radiology, 
 
2
Center for Medical Imaging – North East Netherlands, 
4
Department of Epidemiology; 
 
3
Department of Radiology, Zaans Medical Center; 
 
5
Department of Radiology, University Medical Center Utrecht 
105 





Coronary artery calcium score, traditionally based on electrocardiography (ECG)-triggered 
computed tomography (CT), predicts cardiovascular risk. However, nontriggered CT is 
extensively utilized. The study-purpose is to evaluate the in-vitro agreement in coronary 
calcium score between nontriggered thoracic CT and ECG-triggered cardiac CT.   
 
Materials and Methods 
Three artificial coronary arteries containing calcifications of different densities (high, me-
dium and low), and sizes (large, medium and small), were studied in a moving cardiac 
phantom. Two 64-detector CT systems were used. The phantom moved at 0 to 90 mm/s in 
nontriggered low-dose CT as index test, and at 0 to 30 mm/s in ECG-triggered CT as refer-
ence. Differences in calcium scores between nontriggered and ECG-triggered CT were 
analyzed by t-test and 95% confidence interval. The sensitivity to detect calcification was 
calculated as the percentage of positive calcium scores. 
 
Results 
Overall, calcium scores in nontriggered CT were not significantly different to those in 
ECG-triggered CT (p > 0.05). Calcium scores in nontriggered CT were within the 95% con-
fidence interval of calcium scores in ECG-triggered CT, except predominantly at higher 
velocities (≥ 50 mm/s) for the high-density and large-size calcifications. The sensitivity for 
a nonzero calcium score was 100% for large calcifications, but 46 ± 11% for small calcifica-
tions in nontriggered CT. 
 
Conclusions 
When performing multiple measurements, good agreement in positive calcium scores is 
found between nontriggered thoracic and ECG-triggered cardiac CT. Agreement decreases 
with increasing coronary velocity. From this phantom study, it can be concluded that a 
high calcium score can be detected by nontriggered CT, and thus, that nontriggered CT 
likely can identify individuals at high risk of cardiovascular disease. On the other hand, a 











Coronary artery calcium score, derived from computed tomography (CT) and tradition-
ally expressed as Agatston score, reflects the extent of coronary atherosclerosis. Calcium 
score is an independent predictor of cardiovascular morbidity and mortality [1,2]. Recent 
guidelines from cardiological and radiological scientific societies support the utilization of 
calcium score to assess cardiovascular risk in asymptomatic individuals at intermediate 
risk [3,4]. CT is a well-accepted imaging modality to assess calcium score [4]. Due to peri-
odic and rapid movement of coronary arteries, prospective or retrospective electrocardio-
graphic (ECG)-triggering or gating has been employed in CT to allow least-motion imag-
ing of coronary arteries with calcified lesions. Because of the relatively lower radiation 
dose, prospective ECG-triggering is the current standard practice [5].  
So far, ECG-triggering has been part of the standard CT protocol for coronary cal-
cium scoring. There may be substantial unused potential if calcium score could also be 
determined in nontriggered thoracic CT. The latter procedure is extensively utilized 
worldwide. For example, 13.6 million nontriggered thoracic CT examinations were per-
formed in the United States in 2007, in contrast to 0.7 million ECG-triggered CT examina-
tions for calcium scoring [6]. Interests in coronary calcium quantification based on tho-
racic CT examinations have further increased in view of the recent evidence on reduced 
mortality with lung cancer CT screening [7]. If the same screening examination could be 
performed to assess early-stage lung cancer as well as coronary calcium score, the benefits 
and cost-efficiency of low-dose thoracic CT might considerably increase. However, vari-
ability in coronary calcium quantification between those two techniques was substantial. 
To determine the influence of variability on the correlation between those two techniques, 
an in-depth validation study for the impact of motion artifacts on calcium score in non-
triggered CT using a phantom model has to be performed.   
The purpose of this study was therefore to evaluate the agreement in coronary cal-
cium scoring between low-dose thoracic computed tomography (CT) and dedicated car-
diac CT examinations with ECG-triggering using a moving cardiac phantom. 
 
Materials and Methods 
 
Phantom 
The moving cardiac phantom (Sim2D, QRM, Möhrendorf, Germany) consisted of a com-
puter-controlled motion unit and a water container. The cardiac phantom was placed in-
side a thoracic phantom (Thorax, QRM, Möhrendorf, Germany) to simulate thoracic envi-
ronment (Figure 1). A lever on the motion unit moved at a linear velocity programmed at 0 
Part 3   Coronary artery calcification 
 108 
to 90 mm/s (Figure 2), which is within the velocity range of in-vivo coronary arteries [8]. 
ECG signal was simulated, and synchronized with the lever movement cycle.  
 
Figure 1 The moving cardiac 
phantom, comprising of a 
computer controlled motion unit 
(a), a water container (b), a 
thoracic phantom (c), a lever (d), 










Figure 2 Position of the artificial 
coronary artery as a function of 
time, for velocities of 10, 30, 50, 
70 and 90 mm/s. The image 
acquisition windows of CT-A 
and CT-B in ECG-triggered 
acquisition mode are indicated, 
starting at 370 ms and with a 






Three artificial coronary arteries with calcified lesions made of hydroxyapatite were 
investigated (Figure 3). The density of the calcified lesions differed per artificial artery 
(high density, 800 Hounsfield units (HU), medium density, 400 HU and low density, 200 
HU, all at 120 kV). Each artificial artery contained three calcifications of different size 
(large, 62.8 mm
3
, medium, 24.6 mm
3
, and small, 9.1 mm
3
) (Table 1). The density and size 
of the calcified lesions resembled the density and size of in-vivo coronary calcifications 
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[9,10]. The background density of the artificial arteries was 50 HU at 120 kV, made of poly-
urethane resin, resembling in-vivo CT attenuation of blood. The artificial arteries were 
attached to the lever and imaged one by one to avoid overlap artifacts. The lever with one 
attached artificial artery was placed inside the water container which was subsequently 
inserted in the thoracic phantom. The artificial artery was positioned parallel to the cen-





Figure 3   Artificial arteries with calcified lesions of high (800 HU), medium (400 HU) and low den-
sity (200 HU) in large, medium and small size. Schematic drawing (a) of an artificial artery, the 
black shadows indicated the artificial calcified lesions in the artificial artery, the length, radius and 




Nontriggered thoracic and ECG-triggered cardiac CT examinations were performed in two 
medical centers using 64-slice CT systems from two different vendors (CT-A: Soma-tom 
Sensation 64, Siemens, Forchheim, Germany; CT-B: Brilliance 64, Philips, Best, The Neth-
erlands). The acquisition protocol for the nontriggered examination was derived from the 
Dutch-Belgian randomized lung cancer screening trial (NELSON) [11]. The ECG-triggered 
CT examination was performed according to the daily utilized protocol for car-diac CT in 
the individual centers. For ECG-triggered examination, prospective ECG-triggering at 37% 
of the cardiac cycle was used to allow data acquisition at the lowest velocity (Figure 2). 
Details about image acquisition and reconstruction parameters are shown in Table 2. Each 
examination was repeated three times on both CT systems with a small random transloca-
tion (approximately 5 mm) and rotation (approximately 5 degrees) of the phantom be-
tween each examination. The two CT systems were routinely calibrated. 
a b 
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Table 1   Physical property of artificial calcified lesions of high, medium and low density in large, 
medium and small size 






High 796 62.8 50.0 
Medium 401 62.8 25.2 Large 
Low 197 62.8 12.4 
High 796 24.6 19.6 
Medium 401 24.6 9.9 Medium 
Low 197 24.6 4.8 
High 796 9.1 7.2 
Medium 401 9.1 3.6 Small 
Low 197 9.1 1.8 
 
Quantitative image analysis 
The amount of calcium, expressed as Agatston score [12], was quantified by a software 
package (Aquarius iNtuition, TeraRecon, Foster City, US), for each calcified lesion, using 
the widely-utilized threshold of 130 HU in nontriggered and ECG-triggered scan [13]. 
Thresholds from 90 to 160 HU, with steps of 10 HU, were also used in nontriggered scan to 
analyze the influence of threshold on the agreement of calcium scores between these two 
techniques. Calcium scores derived from nontriggered thoracic CT examinations with 
velocities of 0-90 mm/s were considered as index test results, because these veloci-ties 
were in the common coronary velocity range in a cardiac cycle [8]. Calcium scores for cal-
cified lesions with velocities of 0-30 mm/s derived from ECG-triggered CT examina-tions 
were considered as reference standard, because these velocities were in the common 
coronary velocity range of mid-systolic and mid-diastolic coronary motion, in which a 












Table 2   CT acquisition protocol and image reconstruction parameters  
 CT-A (Siemens Sensation 64)  CT-B (Philips Brilliance 64) 
 Nontriggered ECG-triggered  Nontriggered ECG-triggered 
Acquisition 
mode 
Spiral Sequential  Spiral Sequential 
Tube voltage 120 kV 120 kV  120 kV 120 kV 
Tube charge 20 mAs 120 mAs  20 mAs 120 mAs 
Collimation 32×2×0.6 mm 20×1.2 mm  64×0.625 mm 40×0.625 mm 
Pitch 1.5 n/a  1.39 n/a 
Rotation time 500 ms 330 ms  500 ms 400 ms 
Reconstruction 
mode 
Single sector Single sector  Single sector Single sector 
Reconstruction 
Kernel 
B30f B30f  B B 
Field of view 250 mm 250 mm  250 mm 250 mm 
Slice thickness 3 mm 3 mm  3 mm 2.5 mm 
Slick interval 3 mm 3 mm  3 mm 2.5 mm 
ECG = electrocardiographically; n/a = not applicable. 
 
Theoretical assessment of blurring 
A quantitative method was used to analyze the calcium scores caused by motion blurring. 
The cardiac motion susceptibility (CMS) index was calculated, which quantifies the sus-



















in which x0 is the calcium score at rest, xi is the calcium score at a velocity (v). In nontrig-
gered scan, v = 10, 30, 50, 70 and 90 mm/s, respectively. In ECG-triggered scan, v = 10 and 
30 mm/s, respectively. And N is the total number of velocities used (N = 6 for nontrig-
gered scan, N = 3 for ECG-triggered scan). The mean CMS was calculated over three re-
peating scans and two CT scanners. A smaller CMS index represents lower susceptibil-ity 
of calcium scores to motion. 
 
Statistical analysis 
Results were provided as mean ± standard deviation (SD). Sensitivity to detect calcifica-
tion was calculated as percentage of nonzero calcium score among all the scores of an 
artificial calcified lesion in the respective velocity range (0-90 mm/s for nontriggered and 
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0-30 mm/s for ECG-triggered CT). The agreement in detection of calcification between the 
nontriggered and ECG-triggered CT examination was expressed by kappa value.  
Normality of distribution of calcium scores for each calcified lesion at different ve-
locities (0-90 mm/s for nontriggered CT, 0-30 mm/s for ECG-triggered CT) was assessed 
by one-sample Kolmogorov-Smirnov test. The reliability of calcium scores between non-
triggered and ECG-triggered CT examinations, and between CT-A and CT-B was ex-
pressed as intra-class correlation coefficient (ICC). Differences in calcium scores between 
the nontriggered and ECG-triggered CT examination were evaluated by paired-samples t-
test. Then, 95% confidence interval (CI) of calcium scores based on ECG-triggered CT was 
calculated by mean ± 1.96 SD. Outliers of calcium scores on the nontriggered CT examina-
tions beyond the 95% CI of ECG-triggered CT were descriptively analyzed.  
A p < 0.05 was considered as statistically signiﬁcant. Statistical analyses were per-




Detection of calcified lesions 
Images of the nine calcified lesions in nontriggered and, to a lesser extent, in ECG-
triggered CT were blurred by motion. Increasing blurring was observed when velocity in-
creased (Figure 4). Nontriggered examinations showed overall higher susceptibility of 
calcium scores to motion, than ECG-triggered mode. The susceptibility difference be-
tween nontriggered and ECG-triggered scans was smaller in medium density and me-dium 












   
Figure 4   Computed tomography (CT) images of the artificial high-density calcifications in (a) the 
nontriggered thoracic examination (large, medium and small size of the lesion from top to bottom, 
and velocity of 0, 10, 30, 50, 70 and 90 mm/s from left to right), and (b) ECG-triggered cardiac ex-
amination (large, medium and small size from top to bottom, and 0, 10 and 30 mm/s from left to 
right). Window center: 75 HU, window width: 350 HU. 
 
Table 3   Sensitivity to detect coronary calcifications in nontriggered and ECG-triggered CT 
Nontriggered  ECG-triggered  
Velocity, mm/s Velocity, mm/s Size  Density 
Sensitivity 
0 10 30 50 70 90 
Sensitivity 
0 10 30 
Kappa* 
High 100% ● ● ● ● ● ● 100% ● ● ● 1.00 
Medium 100% ● ● ● ● ● ● 100% ● ● ● 1.00 Large 
Low 58% ● ● ● ○   100% ● ● ● 0.58 
High 100% ● ● ● ● ● ● 100% ● ● ● 1.00 
Medium 100% ● ● ● ● ● ● 100% ● ● ● 1.00 Medium 
Low 42% ● ● ○    67% ● ●  0.47 
High 50% ● ● ○ ○   67% ● ●  0.50 
Medium 33% ● ●     67% ● ●  0.44 Small 
Low 0%       0%    1.00 
*kappa value is for the agreement to detect coronary calcification between nontriggered and ECG-
triggered CT.  
Sensitivity to detect coronary calcification was calculated by the percentage of nonzero scores 
among all the scores of an artificial calcified lesion in the velocity range. Black dot = calcification 
was detected in CT-A and CT-B; white dot = calcification was detected either in CT-A or CT-B; 
empty = calcification was not detected.  
a b 
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Figure 5   Cardiac motion susceptibility (CMS) index of eight measurable artificial calcified lesions 
in nontriggered and ECG-triggered CT examinations.  
 
Using CT density threshold of 130 HU in both nontriggered and ECG-triggered ex-
aminations, calcium scores of four large calcifications (calcium score > 25 in ECG-
triggered mode) could be determined successfully at all velocities with a sensitivity of 
100% (Table 3). The agreement to detect large calcifications was excellent (kappa = 1.00) 
between the nontriggered and ECG-triggered CT. However, as the velocity increased, cal-
cium score assessment failed in four small calcifications (calcium score < 25 in ECG-
triggered mode), because the CT attenuation of these lesions dropped under the thresh-
old of 130 HU. For these small calcifications, mean sensitivity of detection was 46 ± 11% in 
nontriggered CT, and 75 ± 17% in ECG-triggered CT (p value for difference < 0.05). The 
agreement to detect small calcification was moderate (kappa = 0.44 to 0.58) between the 
nontriggered and ECG-triggered CT. For the low-density small-size lesion, the calcium 
score could not be assessed because the CT value was always < 90 HU at all velocities. 





Figure 6   Comparison of calcium scores between nontriggered and ECG-triggered CT examina-
tions in eight measurable calcified lesions. The CT density thresholds were from 90 to 160 HU in 
nontriggered CT. The threshold was 130 HU in ECG-triggered CT as reference. A significant dif-
ference was indicated by “*”. 
 
Agreement between nontriggered and ECG-triggered CT 
Increasing CT density threshold resulted in decreasing calcium score (Figure 6). The 
agreement of calcium scores between nontriggered and ECG-triggered scans depended on 
threshold. E.g., applying thresholds from 90 to 150 HU, significant difference was found 
for the large-size high-density lesion (p < 0.05). When the threshold increased to 160 HU, 
no significant difference was found (p > 0.05). Considering the thresholds, 120 HU and 130 
HU showed the highest rate of agreement (7 out of 8 measurable lesions, p > 0.05) be-
tween nontriggered and ECG-triggered scans, except for the high-density large-size lesion 
(p < 0.001).  
Calcium scores in nontriggered and in ECG-triggered CT conformed to a normal dis-
tribution (test for normality p > 0.05). High reliability of calcium scoring was found be-
tween nontriggered and ECG-triggered CT (ICC = 0.960, p < 0.001), and between the two 
CT modalities (ICC = 0.982, p < 0.001).  
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Figure 7   Grouped plots of the calcium scores of the eight measurable artificial calcified lesions 
in the nontriggered and ECG-triggered CT examinations. The dotted boxes indicate 95% confi-
dence interval (95% CI) of the calcium scores in ECG-triggered CT examinations. 
 
Calcium scores for individual calcifications varied with velocity. Compared to the 
calcium score at rest, calcium score for high-density and large-size lesions generally 
showed overestimation at increasing velocity, while calcium score for the other calcifica-
tions generally showed underestimation. Most of the calcium scores in nontriggered CT 
were within the 95%CI of those in ECG-triggered CT. Exceptions to that were the high-
density large-size lesion (calcium score 165 - 325 in ECG-triggered mode), mostly when 
velocity was at least 50 mm/s, the high-density medium-size lesion, and the medium-













This is the first phantom validation study on the impact of motion artifacts, regarding 
coronary calcium scoring in nontriggered CT. When performing multiple measurements, 
good agreement in calcium scores was found between nontriggered low-dose thoracic and 
ECG-triggered cardiac CT, but not for large-size and high-density calcifications at higher 
coronary velocity. Nontriggered CT showed lower sensitivity to detect small calcification 
(calcium score < 25) than ECG-triggered CT.   
Good agreement in calcium scores between the nontriggered and ECG-triggered CT 
was established by distribution analysis, which implies that calcium score derived from 
low-dose, nontriggered CT can estimate coronary calcium. Coronary calcium reflects the 
extent of atherosclerotic coronary disease, which is a strong risk marker for cardiac mor-
tality. The relative risk of coronary events increases with increasing coronary calcium bur-
den [4]. In several lung cancer screening trials based on nontriggered thoracic CT, the 
group of individuals with coronary calcium had higher mortality rate, compared to the 
group without coronary calcium [17-19]. Compared to mere assessment of presence of 
coronary calcification, calcium scoring in nontriggered CT may yield information regard-
ing the amount of coronary calcium.  
Four in-vivo studies investigated the agreement of calcium scores between nontrig-
gered and ECG-triggered CT [20-23], which included 1,153 subjects in total. In these four 
studies, 55 subjects (8.8%) showed CS = 0 in nontriggered CT among 625 subjects with CS 
> 0 in ECG-triggered CT. In concordance with these in-vivo studies, our phantom study 
validated that a zero calcium score in nontriggered CT does not reliably exclude coronary 
calcification, thus can not exclude low cardiovascular risk of an individual with a zero CS. 
On the other hand, nontriggered CT underestimated high-risk CS in 31 (19.1%) subjects, 
who showed CS < 400 in nontriggered CT, among 162 subjects with CS ≥ 400 in ECG-
triggered CT. However, nontriggered CT only overestimated 26 subjects (2.6%), who 
showed CS≥400 in nontriggered CT, among 991 subjects with CS < 400 in ECG-triggered 
CT. These results suggest that a high CS detected in nontriggered CT is fairly reliable. In 
accordance with in-vivo results, our phantom study found that nontriggered CT often 
underestimated CS, except for the high-density large-size calcified lesion, which is un-
common in clinical practice [24]. From phantom results, we can deduce that a zero CS in 
nontriggered CT cannot exclude the presence of coronary calcium, and thus can underes-
timate cardiovascular risk. On the other hand, nontriggered CT can reliably detect a high 
CS, and thus can likely identify individual at high risk of cardiovascular disease.  
Disagreement in calcium scores between nontriggered and ECG-triggered CT ex-
aminations was found for the high-density large-size lesion (calcium score 165 to 325). In-
vivo, this lesion has not been commonly found, whereas calcified lesions with medium- 
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and low-density with medium- and small-size are more common [24]. Disagreement was 
also found for some calcifications at high velocity (≥ 50 mm/s). The velocity of left main 
artery and left anterior descending artery has been observed to be lower than that of right 
coronary artery and left circumflex artery [8]. The contribution of left anterior descending 
artery to calcium score is, on the other hand, higher than that of the other three coronary 
branches [25]. Deviations in calcium score between nontriggered and ECG-triggered CT 
were found mainly at high velocities, which do not usually occur in left main and left an-
terior descending artery [26]. For those reasons, we expect the disagreement in calcium 
scores between nontriggered and ECG-triggered CT to be less in clinical situations. 
In our study, using the calcium scores in ECG-triggered scan as reference, the 
agreement of calcium scores depended on CT density threshold applied for the nontrig-
gered examination. Using physical lesion properties as reference, Groen et al reported that 
threshold-adjusted calcium scoring is less susceptible to cardiac motion and more accu-
rate [16]. Thus, a new software based lesion size- and density-dependent threshold might 
yield better results. In contrast, current software packages commonly utilize a universal 
threshold. In our results, there was the highest rate of agreement between nontriggered 
and ECG-triggered results, when using 120 or 130 HU as the threshold, except for the high-
density large-size lesion. Also, 130 HU was extensively validated for calcium scoring in 
coronary risk assessment [4]. Thus, our results confirm the application of 130 HU as a 
threshold for calcium scoring in current software.  
Previous phantom studies have observed less accurate calcium scoring in ECG-
triggered 64-MDCT, the CT system used in this study, compared to the reference, elec-
tron-beam tomography, as well as dual-source CT [27,28]. Compared to the reference 
standard, especially underestimated calcium score was found [27]. In the current study, 
under-estimation by nontriggered 64-MDCT for small calcifications (calcium score < 25 in 
ECG-triggered mode) appeared even stronger. The sensitivity of nontriggered CT for less 
dense and smaller calcifications was significantly lower than for ECG-triggered CT (differ-
ence in sensitivity up to 42% for individual calcified lesions). The ability to discriminate 
between a zero and nonzero calcium score is of great importance, as absence of coronary 
calcification has been found to be associated with an extremely low risk of coronary 
events in the next years, and is thus a very reassuring finding if accurate [29].  
The velocities investigated in this study were in the common motion range of in-
vivo coronary arteries. For nontriggered CT examinations, calcium scores at velocities 
from 0-90 mm/s were applied as index test results because the peak velocity for all seg-
ments in coronary artery has been reported to be 88 mm/s [8]. Also, when performing a 
thoracic low-dose CT, it is unknown at what coronary velocity the individual calcifications 
are scanned, as data are acquired over entire heart beats. In contrast, ECG-triggered ac-
quisition is performed in the interval of the cardiac cycle with the least motion to reduce 
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motion artifacts. Velocities have been reported up to 13.0 ± 2.3 mm/s when triggered in 
mid-systole (for heart rates below 83 bpm), and up to 26.1 ± 2.3 mm/s in mid-diastole (for 
heart rates above 83 bpm) [8]. This was the basis for our decision to consider calcium 
scores at velocities of 0-30 mm/s in ECG-triggered CT as reference.  
The influence of motion on calcium score in the nontriggered CT examinations 
strongly depended on velocity. Similar results have been found in ECG-triggered CT for 
coronary calcium quantification [30-32]. This finding can be explained by blurring in im-
ages and partial volume effects [28]. Motion artifacts generally cause overestimation of 
calcium volume and underestimation of CT density (except in case of smaller calcifica-
tions - these are potentially missed), thus leading to inaccurate calcium scores. Individual 
calcifications in nontriggered CT are likely imaged at different intervals of the cardiac 
cycle, with different deviations from the optimal calcium score, derived if ECG-triggering 
would be used. For the individual patient, differences in calcium scores between nontrig-
gered and ECG-triggered acquisition can be positive or negative.  
Calcium score according to Agatston was calculated in this study. In a multi-
manufacturer standard for cardiac CT, mass score was promoted for coronary calcium 
quantification, as this scoring method showed the lowest variance [33]. However, in clini-
cal practice, so far Agatston score has been mostly utilized to quantify coronary calcium, 
and to stratify cardiovascular risk. Moreover, in a large screening study, only small differ-
ences in cardiovascular risk categorization were found in case of Agatston score versus 
mass score [34].  
In traditional ECG-triggered cardiac CT, often small FOV size is used, in order to 
improve the detection of coronary calcifications [13]. The standard reconstructed slice 
thickness is 3 mm. Conversely, in nontriggered thoracic CT often a large FOV (≈ 350 mm) 
is applied, combined with thin-slices (≈ 1 mm). When evaluating calcium scores in non-
triggered mode, an additional dataset should be reconstructed, using a small FOV (≈ 250 
mm) and somewhat thicker slices (≈ 3 mm) [22,23,35]. 
 The primary aim of this study was to assess in a controlled environment, whether 
nontriggered CT, i.e., thoracic CT, can be used to determine the coronary calcium score. 
The background of this question is the increasing application of thoracic CT, for example 
in lung cancer screening. In a lung cancer screening trial, over 70% of the participants 
showed coronary calcifications [19]. The group at risk for lung cancer overlaps with the 
group at risk for cardiovascular disease, because aging and smoking are two major risk 
factors for both diseases [36]. There may be substantial primary prevention potential if the 
calcium score can be derived from the same CT examination. Based on these phantom 
results, nontriggered CT cannot be promoted as a primary tool to evaluate the calcium 
score, instead of a dedicated, ECG-triggered cardiac CT. However, the current study does 
suggest that a nontriggered, thoracic CT examination can additionally yield information 
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on cardiovascular risk as estimated by the calcium score. From this phantom study, it can 
already be concluded that a high calcium score can be detected by nontriggered CT, and 
thus, that nontriggered CT likely can identify individuals at high risk of cardiovascular 
disease. On the other hand, the calcium score derived from nontriggered CT cannot ex-
clude low risk, as the absence of coronary calcification cannot reliably be determined. 
 There are limitations to our study. Firstly, the movement of the artificial calcified 
lesions was linear. The in-vivo coronary arteries exhibit, however, diverse and complex 
motion patterns in different planes. Because the right coronary artery exhibits the largest 
motion, and shows the largest artifacts in ECG-triggered scans [26,37], we simulated the 
motion in the direction of the primary movement of the right coronary artery, in the x-y 
plane. It is very difficult to accurately simulate the complex motion of coronary arteries. 
Further study is needed to confirm our findings in a phantom with multilinear movement, 
more resembling the actual motion of coronary arteries in three-dimensional space. Sec-
ondly, the calcium score could not be assessed for the low-density small-size lesion, be-
cause the CT value was always < 90 HU at all velocities. In a previous study using the same 
phantom with same calcium inserts, this low-density small-size lesion was not detectable 
or measurable either, even in a stationary setting [38]. Thirdly, calcium score depends on 
modality, acquisition protocol and scoring parameter setting [15,27]. Our acquisition pro-
tocol for nontriggered examinations was derived from the NELSON trial [39], which is a 
common protocol for low-dose CT lung cancer screening. Finally, because of the setting 
for CT imaging from different vendors, several parameters were different between CT-A 
and CT-B, i.e., pitch, rotation time and slice thickness, which could have potentially in-




















In this phantom study, when performing multiple measurements, overall good agreement 
in positive calcium scores was found between nontriggered thoracic and ECG-triggered 
cardiac CT examinations. However, agreement decreased with increasing coronary veloc-
ity. Variability existed among different measurements of a calcified lesion. Nontriggered 
CT was less sensitive to detect small calcifications than ECG-triggered CT. Our phantom 
study supports the potential to evaluate coronary calcium score in nontriggered CT. From 
our results, it can already be concluded that calcium scoring based on nontriggered CT 
likely can identify individuals at high risk of cardiovascular disease. However, a zero cal-
cium score in nontriggered CT does not reliably exclude the presence of coronary calcifi-
cation. Further study is needed with calcifications that represent the entire spectrum of 
coronary calcifications, using a moving phantom with multilinear motion, to confirm and 
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To determine the correlation between CT measurements of emphysema or peripheral air-
ways and airflow obstruction in chronic obstructive pulmonary disease (COPD).  
 
Materials and Methods 
PubMed, Embase and Web of Knowledge were searched from 1976 to 2011. Two reviewers 
independently screened 1,763 citations to identify articles that correlated CT measurements 
to airflow obstruction parameters of pulmonary function test in COPD patients, rated 
study quality and extracted information. Three CT measurements were accessed: lung at-
tenuation area percentage < -950 Hounsfield units, mean lung density and airway wall area 
percentage. Two airflow obstruction parameters were accessed: forced expiratory volume 
in the first second as percentage from predicted (FEV1 %pred) and FEV1 divided by the 
forced volume vital capacity. 
 
Results 
79 articles (9,559 participants) were included in systematic review, demonstrating different 
methodologies, measurements and CT-airflow obstruction correlations, 15 high-quality 
articles (2,095 participants) in the meta-analysis. The absolute pooled correlation coeffi-
cients ranged from 0.48 (95% CI, 0.40 to 0.54) to 0.65 (0.58 to 0.71) for inspiratory CT and 
0.64 (0.53 to 0.72) to 0.73 (0.63 to 0.80) for expiratory CT.  
 
Conclusions 
CT measurements of emphysema or peripheral airways are significantly related to airflow 
obstruction in COPD patients. CT provides a morphological method to investigate airway 
















Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation that 
is not fully reversible [1]. The pathogenesis of airflow limitation in COPD is mainly related 
to emphysema and small airway remodelling [2]. Although airflow obstruction parameters 
in pulmonary function test (PFT) by spirometry are essential in COPD diagnosis, these 
parameters fail to quantify the proportionate impact of emphysema and small airways dis-
ease individually. Morphologic changes can be characterized and quantified by computed 
tomography (CT), especially by multi-detector CT [3]. For COPD patients, quantitative 
chest CT are important to understand pathogenesis and the effect of therapeutic interven-
tions [4], and can help to identify those most at risk for acute exacerbations [5]. A long 
history of CT emphysema quantification exists since the introduction of the ‘density-mask’ 
in 1988 [6-8]. Multi-detector CT can accurately evaluate emphysema [9]. However, quanti-
fication of air-way remodelling by CT is challenging because of its spatial resolution. Air-
way wall quantification started over a decade ago, mainly for large airways [3], but investi-
gators have measured peripheral airways down to 0.5 mm lumen diameter [10] and 2.8 mm 
outer diameter [11]. Measurement of narrowing of CT-detectable airways may estimate the 
degree of small airway disease [10].  





are correlated to airflow obstruction in COPD patients. Study results have been 
variable and sometimes conflicting. However, some individual studies have been small and 
underpowered [2, 12-15]. Therefore, we conducted a systemic review and meta-analysis to 
determine the correlation between emphysema or peripheral airway measurements on 
inspiratory and expiratory CT, and airflow obstruction in COPD. 
 
Materials and Methods 
 
This study was conducted according to Preferred Reporting Items for Systematic Reviews 
and Meta-analyses (PRISMA) [16].  
 
Data sources and searches 
We searched PubMed, Embase, and Web of Knowledge from January, 1976 to December, 
2011, from the start of whole-body CT, using terms related to computed tomography and 
PFT (i.e., lung function*, respiratory function*, pulmonary function*, etc) and COPD (i.e., 
chronic obstructive pulmonary disease*, chronic obstructive lung disease*, etc) without 
language restrictions (Supplemental Table A). Unpublished studies were not included. 
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Study selection 
Four reviewers with at least six years experience in thoracic radiology participated in study 
selection. Each study was evaluated independently by two reviewers out of three, with dis-
agreements resolved by the fourth reviewer. Articles were included in the systematic re-
view if they: 1) analyzed the association between CT quantitative emphysema or airway 
measurements and PFT; 2) investigated human beings; 3) included participants diagnosed 
with stable adult COPD, according to the Global initiative for chronic Obstructive Lung 
Disease (GOLD) [1] or the American Thoracic Society (ATS) or the European Respiratory 
Society (ERS) or clearly defined similar criteria; 4) included participants who had clearly 
described PFT, according to the guideline of ATS or ERS or similar methods. Articles were 
excluded if they: 1) were reviews or abstracts or case reports or letters; 2) were laboratory or 
phantom studies; 3) covered participants with confounding disease, such as interstitial 

















Figure 1   Flowchart of literature review and selection. COPD = chronic obstruction pulmonary dis-
ease; PFT = pulmonary function test; MDCT = multi-detector computed tomography. 
 
Articles were subsequently included in the meta-analysis if they: 1) had no selection 
bias (e.g., only mild or only severe COPD); 2) had a sample size of ≥ 20 (20 subjects would 
provide a power of 0.90 when detecting a typical effect correlation coefficient of 0.60); 3) 
were performed using volumetric multi-detector CT; 4) reported correlation coefficients; 5) 
reported percentage of lung attenuation area under -950 HU (%LAA-950) or mean lung 
density (MLD) or wall area percentage (WA%) in airways ≥ 5
th
 airway generation (sub-sub-
1763 citations identified from  
database searching 
1646 citations excluded by title or abstract 
117 full-texts reviewed 
38 articles excluded based on full-text: 
20 not suitable COPD sample 
18 no association between CT and PFT 
79 articles included in  
systematic review 
15 articles included in  
meta-analysis 
64 articles excluded from meta-analysis: 
3   selection bias 
14 small sample size 
33 not MDCT volumetric scan 
8   no preferred CT quantitative parameters 
6   no preferred PFT parameters 
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segment level) as CT measurements; 6) reported the predicted forced expiratory volume in 
the first second as percentage (FEV1 %pred) and FEV1 divided by the forced volume vital 
capacity (FEV1/FVC) as spirometry parameters. Studies were excluded if the CT exami-
nation only included selected pulmonary levels or if slice increment was larger than slice 
thickness. In possible duplicate reports, the report with largest sample size was included.  
 
Data extraction and quality assessment 
Two reviewers evaluated independently, with disagreements resolved by another reviewer. 
A standardized extraction form was used to collect study characteristics, participant char-
acteristics, methodology and correlation coefficients. The systematic review included 10 CT 
measurements: %LAA-960, %LAA-950, %LAA-910, %LAA-900, MLD, 15 percentile point of 
lung density (Perc 15), lung volume (LV), WA%, airway wall thickness (WT) and airway 
lumen area (Ai). Three CT measurements, %LAA-950, MLD and WA% were pooled in the 
meta-analysis. Two PFT parameters for airflow obstruction were collected, including FEV1 
%pred and FEV1/FVC. 
Methodological quality and potential sources of bias of the included meta-analysis 
articles were assessed with 14 standard items of the Quality Assessment of Diagnostic Ac-
curacy Studies (QUADAS) tool [17]. For each article, a quality score was accumulated by 
assigning 1 point to each fulfilled QUADAS item, 0.5 to unclear items, and 0 to unmet 
items. A score of ≥ 11 points was considered high quality and a score < 11 points as low qual-
ity. Cohen’s k was calculated to indicate inter-observer agreement. Publication bias was 
evaluated with Begg and Mazumdar rank correlation, Egger’s regression test and Rosenthal 
fail-safe N test.  
 
Data synthesis and analysis  
Summary measure was the correlation coefficient (CC). Pooled CCs with 95% confidence 
intervals (CIs) were calculated using Hedges-Vevea random effects model and Z-test for 
normality. Pooled CCs were calculated for the correlations between %LAA-950 and FEV1 
%pred, %LAA-950 and FEV1/FVC, MLD and FEV1 %pred, MLD and FEV1/FVC, WA% and 
FEV1 %pred in inspiratory and expiratory CT. If multi-level bronchi were evaluated, we 
chose the smallest bronchi. Heterogeneity was tested using Q statistic and I
2
 index. The 
random effects model was used regardless of the heterogeneity test, although results in Q 
statistic were still stated. To investigate the impact of individual variables on the meta-
analysis results, subgroup analysis was performed if a subgroup consisted of at least two 
studies. Subgroups were based on radiation dose (low or normal dose), and breath-hold 
procedure (inspiratory or expiratory). Meta-regression was performed to investigate the 
influence from gender, if male percentage was reported by at least three studies. Statistical 
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analysis was performed using SPSS 18.0 (IBM, New York, USA) and R 2.12.0 (R Foundation, 





The database searches elicited 1,763 citations (Figure 1). 79 articles were included in the 
systematic review and fifteen articles [13, 18-31] in the meta-analysis, including ten [18-23, 
25-26, 28-29] from trial cohorts.  
 
Figure 2   Sample size of the articles included in the systematic review, by year of publication and 
CT generation. MDCT = multi-detector computed tomography. 
 
Systematic review 
The systematic review included 9,559 COPD participants (range of mean age, 48 to 73 
years), including 6,101 (63.8%) men, 2,000 (20.9%) women and 1,458 (15.3%) without indi-
cated gender (Supplemental Table B). 6,935 (72.5%) were (ex-) smokers, 133 (1.4%) non-
smokers, and in 2,491 (26.1%) no smoking status was reported. Fifty-four (68.4%) studies 
were prospective, 23 (29.1%) retrospective, and in 2 (2.5%) articles the study design was not 
reported. Forty-one (51.9%) articles were from Europe, 23 (29.1%) from Asia and 15 (19.0%) 
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from North America. Of the articles, 69 (87.3%) were written in English, 5 (6.3%) in Italian, 
3 (3.8%) in Chinese, 1 (1.3%) in French and 1 (1.3%) in Polish.  
Tendency was towards larger sample size and more advanced CT equipment in recent 
publications (Figure 2). Before 2007, only articles with sample size < 100 were found. After 
2007, larger sample size articles were published. Although single-slice CT (32 articles, 
40.5%) was continuously used from 1993 to 2009, multi-detector CT was popular in recent 
years. From 2002, 4- and 8-slice multi-detector CT (16 articles, 20.2%) was used. From 2005, 
16- and 64-slice multi-detector CT (29 articles, 36.7%) was used.  
Included articles varied in methodology. Volume acquisition was used in 36 articles 
(45.6%), nonvolume acquisition in 43 (54.4%). Selected slices were scanned in 21 studies 
(26.6%), whole lung in 58 (73.4%). Median slice thickness was 1.0 mm (range, 0.625 to 10 
mm). Median slice increment was 2.0 mm (range, 0.625 to 20 mm). Low radiation dose was 
used in 12 articles (15.2%), normal dose in 67 (84.7%). Both inspiratory and expiratory CT 
findings were evaluated in 24 articles (30.4%), only inspiratory in 54 articles (68.3%) and 
expiratory in one article (1.3%).  
Sixty-four different CT measurements and 27 different PFT parameters were reported 
(Supplemental Figures A and B). Common CT measurements were %LAA-950 in 36 (45.6%) 
studies, MLD in 22 (27.8%), WA% in 17 (21.5%) and visual score in 17 (21.5%). Common PFT 
parameters were FEV1 %pred in 72 articles (91.1%) and FEV1/FVC in 64 articles (81.0%). 
Common lung parenchyma thresholds defining emphysema ranged from -900 HU to -960 
HU, the most commonly used threshold being -950 HU. In some studies, different correla-
tions to airflow obstruction parameters in PFT were found with these differing thresholds 
in the same sample [12, 14, 27, 32]. The CC between %LAA-950 and FEV1 %pred ranged 
from -0.67 to -0.09 [12-13], between MLD and FEV1 %pred from 0.18 to 0.85 [12, 33], be-
tween WA% and FEV1 %pred from -0.713 to -0.044 [22, 34], between %LAA-950 and 
FEV1/FVC -0.75 to -0.09 [12, 35], and between MLD and FEV1/FVC from 0.21 to 0.89 [12, 33]. 
In four articles, the CC between Perc 15 and FEV1 %pred in inspiration ranged from 0.09 to 
0.62, and the CC between Perc 15 and FEV1/FVC in inspiration from 0.12 to 0.62 [12-13, 36-37] 



















Inspiratory     
  Akira 2009 [13] -0.66 (-0.77, -0.51) 76 10.9 
  Bon 2009 [18] -0.43 (-0.53, -0.32) 234 20.6 
  Dransfield 2007 [19] -0.44 (-0.52, -0.36) 396 24.8 
  Iwasawa 2011 [31] -0.43 (-0.67, -0.12) 35 5.8 
  Park 2008 [23] -0.46 (-0.68, -0.17) 39 6.4 
  Pauls 2010 [24] -0.36 (-0.49, -0.21) 145 16.4 
  Yamashiro 2010 [26] -0.63 (-0.78, -0.41) 46 7.3 
  Zhang 2008 [27] -0.52 (-0.70, -0.28) 50 7.9 
  Overall, p(Z) < 0.001 -0.48 (-0.54, -0.40) 1021  100.0 
Expiratory     
  Akira  2009 [13] -0.67 (-0.78, -0.52) 76 50.0 
  Lee  2008 [22] -0.55 (-0.75, -0.26) 34 21.0 
  Yamashiro  2010 [26] -0.64 (-0.78, -0.43) 46 29.0 




















Subgroup, p < 0.05*   -1.00       - 0.50           0.00          0.50         1.00  
Inspiratory     
  Akira 2009 [13] -0.71 (-0.81, -0.58) 76 14.7 
  Dransfield 2007 [19] -0.58 (-0.64,  0.51) 396 29.2 
  Hesselbacher 2011 [29] -0.73 (-0.81, -0.63) 224 17.5 
  Iwasawa 2011 [31]  -0.49 (-0.71, -0.19) 35 8.3 
  Park 2008 [23] -0.67 (-0.81, -0.45) 39 9.0 
  Yamashiro 2010 [26] -0.71 (-0.83, -0.53) 46 10.3 
  Zhang 2008 [27] -0.63 (-0.77, -0.42) 50 11.0 
  Overall, p(Z) < 0.001 -0.65 (-0.71, -0.58) 866  100.0 
Expiratory     
  Akira 2009 [13] -0.67 (-0.78, -0.52) 76 62.9 
  Yamashiro 2010 [26] -0.73 (-0.84, -0.56) 46 37.1 



















Subgroup, p > 0.05*   -1.00       - 0.50           0.00          0.50         1.00  
Inspiratory     
  Akira 2009 [13] 0.69 (0.56, 0.80) 76 37.6 
  Lee 2008 [22] 0.44 (0.12, 0.68) 34 16.0 
  Yamashiro 2010 [26] 0.50 (0.24, 0.69) 46 22.2 
  Zhang 2008 [27] 0.42 (0.16, 0.62) 50 24.2 
  Overall, p(Z) < 0.001 0.51 (0.38, 0.63) 308  100.0 
Expiratory     
  Akira 2009 [13] 0.79 (0.69, 0.86) 76 41.6 
  Lee 2008 [22] 0.62 (0.36, 0.79) 34 26.3 
  Yamashiro 2010 [26] 0.66 (0.46, 0.80) 46 32.1 
















Subgroup, p < 0.05*   -1.00       - 0.50           0.00          0.50         1.00  
Inspiratory     
  Akira 2009 [13] 0.76 (0.65, 0.84) 76 32.4 
  Washko 2009 [25] 0.56 (0.47, 0.65) 224 39.4 
  Zhang 2009 [27] 0.51 (0.27, 0.69) 50 28.2 
  Overall, p(Z) < 0.001 0.64 (0.52, 0.74) 452  100.0 
Expiratory     
  Akira 2009 [13] 0.72 (0.59, 0.81) 76 62.9 
  Yamashiro 2010 [26] 0.74 (0.58, 0.85) 46 37.1 
















Subgroup, p > 0.05*   -1.00       - 0.50           0.00          0.50         1.00  
Inspiratory     
  Hasegawa 2006 [20] -0.55 (-0.72,-0.33) 52 16.2 
  Leader 2008 [21] -0.58 (-0.66, -0.49) 240 30.8 
  Ohno 2011 [30] -0.69 (-0.76, -0.61) 186 28.8 
  Yamashiro 2010 [28] -0.47 (-0.60, -0.31) 114 24.2 
















   -1.00       - 0.50           0.00          0.50         1.00  
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Risk of bias in the meta-analysis 
All articles included in the meta-analysis were high quality (Supplemental Table D and 
Supplemental Figure C). The quality score ranged from 12.5 to 13.5. Suboptimal scores were 
present for three QUADAS items: seven articles without interval between CT and PFT 
(item 4), nine articles without indication whether CT quantification was blinded to PFT 
(item 10), and thirteen articles without indication whether PFT was blinded to CT quantifi-
cation (item 11). Cohen’s k was 0.925, expressing very good inter-observer agree-ment. No 
publication bias was found (Supplemental Table E). The median of Rosenthal fail-safe N 
was 122 (range, 84 to 614), indicating a solid empirical result.  
Three of the nine meta-analysis calculations showed mild heterogeneity. I
2
 index was 
> 50% for the correlation between MLD and FEV1 %pred in inspiration (p = 0.11, I
2
 index = 
50.6%), between MLD and FEV1/FVC in inspiration (p = 0.02, I
2
 index = 75.9%) and be-
tween WA% and FEV1 %pred (p = 0.04, I
2
 index = 64.7%).   
 
Synthesis of results in the meta-analysis 
The meta-analysis included 2,095 participants out of 9,559 in the systematic review (Figure 
3).  
 Nine articles [13, 18-19, 22-24, 26-28, 31] reported CC between %LAA-950 and FEV1 
%pred in inspiration. Two [19, 25] were from the National Lung Screening Trial (NLST) 
cohort and two [22-23] from the Korean Obstructive Lung Disease (KOLD) cohort. Due to 
possible duplicate reporting, articles [22, 25] with smaller sample size were excluded from 
each cohort. The pooled CC between %LAA-950 and FEV1 %pred was -0.48 (95%CI: -0.54,  
-0.40) in inspiration and -0.64 (-0.72, -0.53) in expiration. The pooled CC between %LAA    
-950 and FEV1/FVC was -0.65 (-0.71, -0.58) in inspiration and -0.69 (-0.78, -0.59) in expira-
tion.   
 No potential duplicate report was found for MLD. The pooled CC between MLD and 
FEV1 %pred was 0.51 (95%CI: 0.38, 0.63) in inspiration and 0.71 (0.58, 0.81) in expiration. 
The pooled CC between MLD and FEV1/FVC was 0.64 (0.52, 0.74) in inspiration and 0.73 





◄ Figure 3   Forest plots for correlations between CT measurements and airflow obstruction. CI = 
confidence interval; p(Z) = p value of Z test; FEV1 %pred = percentage of the predicted forced expi-
ratory volume in the first second; FEV1/FVC = FEV1 divided by forced vital capacity; %LAA-950 = 
percentage lower attenuation area than -950 HU; MLD = mean lung density; Perc 15 = 15 percentile 
point of lung density; WA% = wall area percentage. 
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Seven articles [18, 20-22, 25, 28, 30] reported CC between WA% and FEV1 %pred in in-
spiration. Two articles [18, 22] were excluded because airway measurements concerned 
only airways above the 5
th
 airway generation. Another article [25] was excluded because it 
did not report which airways were measured. Four articles [20-21, 28, 30] were finally in-
cluded. The lumen diameter of peripheral airways was about 2 to 3 mm in the included 
articles. The pooled CC between WA% and FEV1 %pred was -0.59 (95%CI: -0.68, -0.48) in 
inspiration. Expiratory CT was not used for airway measurements.  
 
Subgroup analysis and meta-regression 
Subgroup analysis for radiation dose was performed for the association between %LAA-950 
and FEV1 %pred in inspiration, indicating no significant difference (p > 0.05). In low dose 
[18-19], the pooled CC was -0.44 (95%CI: -0.50, -0.37). In normal dose [13, 23-24, 26-27, 31], 
the pooled CC was -0.50 (-0.57, -0.42). Subgroup analysis was also performed for inspira-
tory and expiratory CT examination. A significantly stronger negative correlation was 
found between %LAA-950 and FEV1 %pred in expiratory CT (p < 0.05), and a stronger posi-
tive correlation between MLD and FEV1 %pred (p < 0.001), but no difference was found in 
the association between %LAA-950 and FEV1/FVC (p > 0.05), or MLD and FEV1/FVC (p > 
0.05). In meta-regression for gender contribution, no statistically significant effect modifi-




In this meta-analysis, significant correlations were found between CT measurements of 
emphysema or peripheral airway and airflow obstruction parameters in PFT in COPD pa-
tients, both in inspiratory and expiratory CT examination. The range of absolute correla-
tion coefficients between included CT measurements and airflow obstruction was 0.48 to 
0.65 for inspiratory CT and 0.64 to 0.73 for expiratory CT. These results confirm correla-
tions between morphology and function in COPD patients. The confidence in these find-
ings is strong, as results were based on high methodological quality studies without publi-
cation bias. Thus, CT provides a quantitative morphological method to investigate the 
principle components of airway obstruction in COPD, with similar strength of associations 
with airflow obstruction for CT measurements of emphysema and peripheral airways. The 
strongest association was found between CT emphysema measurements and FEV1/FVC, 
especially in expiratory CT. Our systematic review demonstrated differing methodologies 
for CT quantification, and contrasting correlations with airflow obstruction in COPD pa-
tients. 
CT quantification reflects pathophysiological changes in COPD to some degree. The 
pathological findings of airway limitation are in airways < 2 mm in internal diameter [38]. 
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Such small airways can hardly be measured directly by CT due to spatial resolution limit. 
However, peripheral airway (≥ 5
th
 generation) wall thickness can be measured as WA%. 
Destruction of the lung parenchyma (emphysema) can be measured as %LAA-950 or MLD. 
The morphological contribution from these two pathologic processes is difficult to distin-
guish by spirometry, but is important for COPD research. The morphological information 
in CT quantification of the relative predominance of peripheral airway wall disease or em-
physema may in the future allow more focused treatment of the predominating COPD 
phenotype.  
This systematic review incorporated ten different CT measurements. Although visual 
score was common in earlier publications, we did not discuss it, because of its subjective 
nature. Perc 15 seems an effective measurement for emphysema, but Perc 15 results could 
not be pooled because of insufficient study number. Only three (%LAA-950, MLD and 
WA%) of the ten measurements were eventually pooled because study number was suffi-
cient to perform meta-analysis. We investigated two PFT parameters (FEV1 %pred and 
FEV1/FVC) as they are the two most commonly used functional parameters regarding air-
way limitation.  
In subgroup analysis, associations for inspiratory and expiratory CT findings were 
compared. Some authors have reported that CT measurements in expiration are more 
closely correlated with airflow obstruction than in inspiration [14, 39-41]. Our results indi-
cate that CT measurements in expiration rather than in inspiration were more correlated 
with FEV1 %pred, not with FEV1/FVC. Whether an additional expiratory CT data acquisi-
tion should be performed for COPD evaluation, is debatable. Expiratory CT exposes pa-
tients to additional radiation, however with developments in CT technique, the additional 
dose will likely decrease. Also, we found low radiation dose did not change correlations 
between CT emphysema quantification and airflow obstruction compared to normal dose. 
Low dose CT can decrease the overall radiation dose for CT quantitative emphysema 
evaluation without loss in diagnostic value.    
Multiple airway generations were included in the systematic review but only periph-
eral airways (≥ 5
th







 generation, and found that the association between airway wall 
measurements and PFT was stronger for higher generations than lower generations [20, 28]. 
Therefore, we only pooled results for airways ≥ 5
th
 generation. Some authors reported 
moderate associations with larger airways, ranging from -0.39 to -0.54 [18, 42]. In our meta-
analysis, the association between wall area percentage of peripheral airways and FEV1 
%pred was -0.59. One factor to keep in mind is the overestimation of airway wall thickness, 
showing a relative increase with each airway generation [3]. Despite that factor, based on 
our pooled results, the association between disease of the more peripheral airways (≥ 5
th
 
generation) and lung function appears stronger than for lower generation airways (< 5
th
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generation), suggesting that airway wall thickness measurements on CT should be per-
formed on the smallest airways visible. 
This study confirms significant correlations between CT measurements and airflow 
obstruction in COPD. The correlations were in agreement with some expert narrative re-
views [9-10] and individual studies [14-15, 39, 42-43]. Nevertheless, other studies reported 
weaker associations, like the National Emphysema Treatment Trial (NETT) study [12] and 
the International COPD Genetics Network (ICGN) study [2]. In NETT and ICGN, predo-
minantly single-slice CT was used. Since single-slice CT decreases reproducibility and ac-
curacy [44], that has likely caused the reduced strength of the correlations.  
This study has some limitations. First, no prospective large cohort with up-to-date 
CT technology was found as primary study. The largest study [45] included over 2,000 par-
ticipants, but most of the participants had normal lung function. In inspiratory CT, the 
number of included articles was relatively small but sufficient to perform a reliable meta-
analysis. However, in expiratory CT, some indicators of bias could not be determined due 
to the limited number of studies. Second, we found 64 different quantitative CT measure-
ments in the literature. We chose ten for systematic review and three for meta-analysis. 
Although included parameters are representative, the other 54 measurements could be 
valuable to evaluate COPD. In another way, FEV1 %pred and FEV1/FVC were selected as 
airflow obstruction parameters in PFT, but other parameters in PFT were valuable to 
evaluate COPD. Third, mild heterogeneity was found in three correlations in the meta-
analysis. A random effects model was used to compensate for the heterogeneity.  
In conclusion, measurements of emphysema and peripheral airways on inspiratory 
and expiratory CT have significant correlations with airflow obstruction as accessed by 
FEV1 %pred and FEV1/FVC in COPD patients. Thus, CT provides a quantitative morpho-
logical method to investigate airflow obstruction by emphysema and peripheral airway 
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◄ Supplemental Figure A   Counting of CT measurements in the systematic review. %LAA = per-
centage low attenuation area; MLD = mean lung density; WA = airway wall area; Ai = airway lumen 
area; LV = lung volume; WT = wall thickness; Perc = percentile point of lung density; Ao = total air-
way area; T/D radio = radio of airway wall thickness to total diameter; EV = emphysema volume; HU 
= Hounsfield unit; BSA = body surface area; Vex = expiration volume; Vin = inspiration volume; EA = 
expiration airway lumen area; IA = inspiration airway lumen area; SRWA = square root of wall area; 
FWHM = full width at half maximum; SD = standard deviation. 
 
 


























































Supplemental Figure B   Counting of pulmonary function test parameters in the systematic review. 
%pred = predicted percentage; FEV1 = forced expiratory volume in the first second; FEF = forced 
expiratory flow; VA = alveolar volume; TLC = total lung capacity; RV = residual volume; DLCO = 
diffusing capacity of the lung for carbon monoxide; VC = vital capacity; TGV = thoracic gas volume; 
FVC = forced vital capacity; PEFR = peak expiratory flow rate; KCO = carbon monoxide transfer 
coefficient; MEF = maximal expiratory flow; IC = inspiratory capacity; FRC = functional residual ca-




Supplemental Figure C   Study quality summaries of articles included in the meta-analysis, as-
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Supplemental Table A   Literature search strategy. Last search on January 5, 2012 
Search terms used to identify relevant citations 
 
A: Computed tomography 
    CT 
B: Lung function* 
 Respiratory function* 
 Pulmonary function* 
 Spirometr* 
 Diffusing capacity 
 Diffusion capacity 
 Airway obstruction parameter* 
C: Chronic obstructive pulmonary disease*  
 COPD 
 Chronic obstructive lung disease* 
 Chronic airflow obstruction* 
To search: A and B and C 
The term ‘CT’ is restrained to the title and abstract 
Publication date: From January 1976 to December 2011 
 
Search query for PubMed 
#1: ("Tomography, X-Ray Computed"[MeSH] OR "computed tomography"[TIAB] OR CT[TIAB]) 
#2: ("Pulmonary Disease, Chronic Obstructive"[MeSH]  OR COPD OR "chronic obstructive pul-
monary disease*" OR "chronic obstructive lung disease*" OR "Chronic airflow obstruction*")  
#3: ("Pulmonary Function Test" OR Spirometr* OR "pulmonary function*" OR "Lung function*" OR 
"Respiratory function*" OR "Diffusing capacity" OR "Diffusion capacity" OR "Airway obstruction 
parameter*") 
Grammar in advanced search: 1976/01:2011/12 [dp] and #1 and #2 and #3 
 
Search query for Embase 
#1: ((Computed tomography):ab,ti OR CT:ab,ti) 
#2: ((Chronic Obstructive Pulmonary Disease*) OR COPD OR (Chronic Obstructive Lung Dis-
ease*) OR (Chronic obstructive airway disease*) OR (Chronic airflow obstruction*)) 
#3: ('lung function test'/exp OR (Spirometr*) OR ('Lung function') OR ('Pulmonary function') OR 
('Respiratory function') OR ('Lung functions') OR ('Pulmonary functions') OR ('Respiratory func-
tions') OR ('Diffusing capacity') OR ('Diffusion capacity') OR ('Airway obstruction')) 
Grammar in advanced search: #1 AND #2 AND #3 AND [1-1-1976]/sd NOT 
(#1 AND #2 AND #3 AND [31-12-2011]/sd) 
 
Search query for Web of Knowledge 
#1 topic: ((Computed tomography) OR CT) 
#2 topic: ((Chronic Obstructive Pulmonary Disease*) OR COPD OR (Chronic Obstructive Lung 
Disease*) OR (Chronic obstructive airway disease*) OR (Chronic airflow obstruction*)) 
#3 topic: (Spirometr* OR (Lung function*) OR (Pulmonary function*) OR (Respiratory function*) 
OR (Diffusing capacity) OR (Diffusion capacity) OR (Airway obstruction parameter*)) 


















































































Achenbach 2008 [42] 16 75 65(50-75) Stage II-III 4 Insp Vol Nor 
Akira 2009 [13]* 76 88 67(37-85) Stage 0-IV 16 Both Vol Nor 
Bae 1997 [46] 10 NA 57(41-77) NA 1 Both N-vol Nor 
Bafadhel 2011 [47] 75 77 67(43-88) 47±2%
†
 16 Insp N-vol Nor 
Baldi 2001 [48] 24 75 61±11 35%(17-72%) 1 Insp N-vol Nor 
Beinert 1995 [49] 11 82 48(34-56) 41±0.04%† 1 Both N-vol Nor 
Bon 2009 [18]* 234 50 61(50-78) Stage 0-IV 4&8 Insp Vol Low 





1 Insp N-vol Nor 
Camiciottoli 2006[39] 51 90 64(43-78) 52%(15-106%) 1 Both N-vol Nor 
Cavigli 2009 [50] 30 77 68(52-81) Stage I-IV 16 Insp Vol Nor 
Cerveri 2004 [51] 39 90 64(48-80) 47%(21-72%) 1 Exp N-vol Nor 
Crausman 1995 [52] 9 22 67±2† 40%(20-89%) 1 Insp N-vol Nor 
Daghfous 1993 [53] 51 90 55(25-80) 
40±21%(n=31) 
39±17%(n=20) 
1 Insp N-vol NA 
D’Anna 2011 [54] 59 68 68±7 52±18 16 Insp N-vol Nor 
Demir 2005 [55] 16 100 65±6 41±15% 1 Insp N-vol NA 
Deveci 2004 [34] 22 100 
57±5(n=17) 
61±7(n=5) 
Stage II-III 1 Insp N-vol Nor 
Dransfield 2007 [19]* 396 62 
63±5(n=246) 
61±5(n=150) 
Stage 0-IV Multi Insp Vol Low 
Falaschi 1995 [33] 46 83 63(46-78) NA 1 Both N-vol Nor 
Gelb 1993 [56] 56 48 68(53-76) 46%(18-79%) 1 Insp N-vol Nor 
Grydeland 2010 [57] 463 65 
65±9(n=299) 
63±9(n=164) 
Stage II-IV 8 Insp N-vol Nor 
Grydeland 2011 [58] 288 70 
64±10(n=202) 
60±8(n=86) 
Stage II-IV 8 Insp N-vol Nor 
Hasegawa 2006 [20]* 52 96 72(41-84) Stage I-IV 4 Insp Vol Nor 
Hesselbacher2011[29]* 224 65 >40 Stage I-IV 64 Insp Vol Nor 
Heussel 2009 [36] 102 NA 64(20-87) Stage III-IV 4 Insp Vol Nor 
Iwasawa 2007 [35] 19 100 71±7 Stage II-IV 16 Insp Vol Nor 
Iwasawa 2011 [31]* 35 100 70±6 Stage I-IV  16 Insp Vol Nor 
Jin 2007 [32] 43 51 65(45-85) NA 16 Both Vol Nor 
Jogi 2011 [59] 30 65 65(53-76) 51%(25-81%) Multi Insp Vol NA 
Kim 2009 [60] 338 64 68±6 <45% 1 Insp N-vol Nor 
Kosciuch 2009 [11] 12 58 57±9 72±19% 16 Insp N-vol Nor 





1 Both N-vol Nor 
Leader 2008 [21]* 240 NA NA Stage 0-IV 
4(n=112) 
8(n=128) 
Insp Vol Low 
Leader 2009 [61] 200 NA NA Stage 0-IV 64 Insp Vol Nor 
Lee 2008 [22]* 34 97 65(50-78) 45%(17-82%) 16 Both Vol Nor 





16 Both Vol Nor 
Lee 2011 [63]  115 NA 65 Stage I-IV 16 Both Vol Nor 
Li 2009 [64] 24 75 56(32-70) 56±16% 64 Both N-vol Nor 
Madani 2010 [65] 16 63 62(48-83) Stage I-IV 4 Both N-vol Nor 
Marquez-Martin2011[66] 64 NA 64±7 Stage I-IV NA Insp N-vol Nor 
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Matsuoda 2007 [14] 32 88 73(57-89) Stage 0-IV 1 Both N-vol Nor 
Matsuoda 2008 [67] 50 80 70(57-89) Stage I-IV 64 Both Vol Nor 
Matsuoda 2008 [68] 36 86 71(57-89) Stage I-IV 64 Both Vol Nor 
Mets 2011 [69] 198 NA about 60 Stage I-IV 16 Both Vol Low 
Mishima 1999 [70] 72 NA NA NA 1 Insp N-vol Both 
Mohamed Hoesein 2011 
[45] 
2085 2085 60±5 Stage 0-III 16 Insp Vol Low 
Moron 2004 [71] 16 63 62±9 40±18% 1 Insp N-vol NA 
Moroni 2001 [72] 20 95 63(42-73) NA 1 Both N-vol Nor 
Nakano 1999 [73] 73 NA 69±6 46±20% 1 Insp N-vol Nor 
Nakano 2000 [3] 94 NA NA 48%(8-124%) 1 Insp N-vol Nor 




Stage 0-IV 1 Both N-vol Nor 
Ohara 2006 [74] 30 100 69±8 41±16% 1 Insp N-vol Nor 
Ohno 2011 [30]* 186 65 (23-87) Stage 0-IV 16&64 Insp Vol Nor 
Orlandi 2004 [15] 11 82 68(60-75) NA 1 Insp N-vol Both 
Orlandi 2005 [75] 42 88 63(42-73) 49%(15-83%) 1 Insp N-vol Nor 
Park 2008 [23]* 39 92 66(51-79) 44±15% 16 Insp Vol Nor 
Patel 2008 [2] 519 51 58±5 <60% 1 Insp N-vol Nor 
Pauls 2010 [24]* 145 NA NA Stage I-IV 16 Insp Vol Nor 
Pescarolo 2008 [76] 43 58 62(44-81) Stage 0-IV 16&64 Insp Vol Nor 
Petersen 2010 [77] 152 NA NA ≥Stage II 16 Insp Vol Low 
Sandek 2002 [78] 20 40 60±8 38±16% 1 Both N-vol Nor 
Scichilone 2008 [79] 15 NA 69(53-90) Stage I-IV 40 Insp Vol Nor 
Shaker 2005 [37] 42 38 63±8 48±13% 4 Insp Vol Low 
Sorensen 2010 [80] 20 NA 64(49-80) 57%(37-76%) 4 Insp Vol Nor 
Spiropoulos 2003 [81] 20 90 59±9 57±26% 1 Both N-vol NA 
Torres 2011 [82] 115 84 63±10 75±15% 64 Insp Vol Low 
Tsushima 2010 [83] 48 83 61±9 Stage I-III 4 Insp N-vol Low 
Van Der Lee 2006[84] 50 58 60(29-83) 46±24% 1 Insp N-vol Nor 
Washko 2008 [12] 1094 61 67±6 <45% 1 Insp N-vol Nor 
Washko 2009 [25]* 224 42 62±5 Stage I-IV 4 Insp Vol Low 
Watanuki 1994 [85] 21 NA 65(38-77) <70% 1 Insp N-vol NA 
Yamashiro 2010 [26]* 46 57 68(46-81) Stage 0-IV 16 Both Vol Nor 
Yamashiro 2010 [28]* 114 57 62(56-74) Stage I-IV 4 Insp Vol Low 
Yamashiro 2011 [86] 46 57 68(46-81) Stage 0-IV 16 Both Vol Nor 
Zampatori 1997 [87] 20 80 69(61-86) 33%(21-57%) 1 Both N-vol Nor 
Zampatori 2001 [88] 15 80 63 32%(22-63%) 1 Insp N-vol Nor 
Zampatori 2001 [89] 17 77 66(47-78) 47±25% 1 Insp N-vol Nor 
Zampatori 2002 [90] 18 67 61(27-81) <71% 4 Insp N-vol Nor 
Zaporozhan 2005 [41] 31 71 60(41-76) Stage II-IV 16 Both Vol Nor 
Zhang 2008 [27]* 50 66 67±10 Stage 0-IV 16 Insp Vol Nor 
SD = standard deviation; SE = standard error; Insp = inspiratory; exp = expiratory; Vol = volumetric 
scan; N-vol = non-volumetric scan; Nor = normal dose; GOLD = the Global Initiative for Chronic 
Obstructive Lung Disease; FEV1 %pred = predicted forced expiratory volume in the first second; 




Supplemental Table C Correlation coefficients between CT measurements and airflow obstruction 
parameters of pulmonary function test in the systematic review 
Correlation coefficients between  
CT measurements and airflow obstruction, r 
Study, Year CT  
Measurements Inspiratory scan Expiratory scan 
Achenbach 2008 [42] WA%, WA  WA% & FEV1 %pred : -0.537 
WA & FEV1 %pred : -0.423 
NA 
Akira 2009 [13]* %LAA-950, -910, 
MLD, Perc15 
Visual score, etc. 
%LAA-950 & FEV1 %pred: -0.659 
%LAA-950 & FEV1/FVC: -0.712 
%LAA-910 & FEV1 %pred:  -0.601 
%LAA-910 & FEV1/FVC: -0.661 
MLD & FEV1 %pred: 0.694 
MLD & FEV1/FVC: 0.764 
Perc15 & FEV1 %pred: 0.292 
Perc15 & FEV1/FVC: 0.600 
%LAA-950 & FEV1 %pred: -0.668 
%LAA-950 & FEV1/FVC: -0.666 
%LAA-910 & FEV1 %pred:  -0.632 
%LAA-910 & FEV1/FVC: -0.642 
MLD & FEV1 %pred: 0.792 
MLD & FEV1/FVC: 0.721 
Perc15 & FEV1 %pred: 0.352 
Perc15 & FEV1/FVC: 0.544 
Bae 1997 [46] %LAA-900 %LAA-900 & FEV1 %pred: -0.52 
%LAA-900 & FEV1/FVC: -0.33 
%LAA-900 & FEV1 %pred: -0.87 
%LAA-900 & FEV1/FVC: -0.45 
Bafadhel 2011 [47] Emphysema  
pattern, WT 
No CT quantitative measurements NA 
Baldi 2001 [48] %LAA-950, MLD %LAA-950 & FEV1 %pred: -0.50 
MLD & FEV1 %pred: 0.62 
NA 
Beinert 1995 [49] MLD No reports on the correlation between 
MLD & FEV1 %pred or FEV1/FVC 
NA 
Bon 2009 [18]* %LAA-950, WA% %LAA-950 & FEV1 %pred: -0.43 
WA% & FEV1 %pred : -0.39 
NA 
Boschetto 2006 [43] %LAA-950, MLD %LAA-950 & FEV1 %pred: -0.480 
MLD & FEV1 %pred: 0.659 
NA 
Camiciottoli 2006 [39] %LAA-950, %LAA-
910, MLD 
%LAA-910 & FEV1/FVC: -0.57 
MLD & FEV1/FVC: 0.60 
%LAA-910 & FEV1/FVC: -0.72 
MLD & FEV1/FVC: 0.80 
Cavigli 2009 [50] %LAA-950, MLD, 
Perc15, etc. 
No reports on the correlation to  
FEV1 %pred or FEV1/FVC 
NA 
Cerveri 2004 [51] %LAA-900 NA %LAA-900 & FEV1 %pred: -0.52 
Crausman 1995 [52] %LAA-900 %LAA-900 & FEV1 %pred: 0.34
† 




Daghfous 1993 [53] Visual Score No CT quantitative measurements NA 
D’Anna 2011 [54] Visual Score No CT quantitative measurements NA 
Demir 2005 [55] Visual Score No CT quantitative measurements NA 
Deveci 2004 [34] WA%, T/D ratio WA% & FEV1 %pred: -0.713 
WA% & FEV1/FVC: -0.573 
T/D ratio & FEV1 %pred: -0.735 
T/D ratio & FEV1/FVC: -0.579 
NA 
Dransfield 2007 [19]* %LAA-950 %LAA-950 & FEV1 %pred: -0.44 (total) 
%LAA-950 & FEV1/FVC: -0.58 (total) 
%LAA-950 & FEV1 %pred: -0.42 (men) 
%LAA-950 & FEV1/FVC: -0.62 (men) 
%LAA-950 & FEV1 %pred:-0.49(women) 
%LAA-950 & FEV1/FVC: -0.55 (women) 
NA 
Falaschi 1995 [33] %LAA-900, MLD, 
Visual Score 
%LAA-900 & FEV1 %pred: -0.80 
%LAA-900 & FEV1/FVC: -0.86 
MLD & FEV1 %pred: 0.76 
MLD & FEV1/FVC: 0.81 
%LAA-900 & FEV1 %pred: -0.82 
%LAA-900 & FEV1/FVC: -0.86 
MLD & FEV1 %pred: 0.85 
MLD & FEV1/FVC: 0.89 
Gelb 1993 [56] Visual Score No CT quantitative measurements NA 
Grydeland 2010 [57] %LAA-950, -910, 
etc. 
No reports on the correlation to  
FEV1 %pred or FEV1/FVC 
NA 
Grydeland 2011 [58] %LAA-950, WT No reports on the correlation to  
FEV1 %pred or FEV1/FVC 
NA 
Hasegawa 2006 [20]* 
 
 
WA%, Ai, WA WA% & FEV1 %pred: -0.547 






%LAA-950, etc. %LAA-950 & FEV1/FVC: -0.71 (current 
smoker) 
%LAA-950 & FEV1/FVC: -0.78 (former 
smoker) 
NA 
Heussel 2009 [36] %LAA-950, MLD, 
Perc15, LV, etc. 
%LAA-950 & FEV1 %pred : -0.35 
%LAA-950 & FEV1/FVC: -0.63 
MLD & FEV1 %pred : 0.43 
MLD & FEV1/FVC: 0.69 
Perc15 & FEV1 %pred : 0.34 
Perc15 & FEV1/FVC: 0.62 
LV & FEV1 %pred : -0.02 
LV & FEV1/FVC: -0.58 
NA 
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Iwasawa 2007 [35] %LAA-950, MLD 
 
%LAA-950 & FEV1: -0.661 
%LAA-950 & FEV1/FVC: -0.745 
MLD & FEV1: 0.636 
MLD & FEV1/FVC: 0.782 
NA 
Iwasawa 2011 [31]* %LAA-950 %LAA-950 & FEV1 %pred: -0.43 
%LAA-950 & FEV1/FVC: -0.49 
NA 




%LAA-960 & FEV1 %pred: -0.501 
%LAA-960 & FEV1/FVC: -0.465 
%LAA-950 & FEV1 %pred: -0.534 
%LAA-950 & FEV1/FVC: -0.513 
%LAA-910 & FEV1 %pred: -0.516 
%LAA-910 & FEV1/FVC: -0.584 
%LAA-900 & FEV1 %pred: -0.470 
%LAA-900 & FEV1/FVC: -0.563 
%LAA-910 & FEV1 %pred: -0.562 
%LAA-910 & FEV1/FVC: -0.506 
%LAA-900 & FEV1 %pred: -0.571 
%LAA-900 & FEV1/FVC: -0.523 
Jogi 2011 [59] Emphysema  
percentage 
No CT quantitative measurements NA 
Kim 2009 [60] %LAA-950, WT %LAA-950 & FEV1 %pred: -0.07 
WT & FEV1 %pred: -0.12 
NA 
Kosciuch 2009 [11] WA%, Ai, WA  No reports on the correlation with FEV1 
%pred or FEV1/FVC in COPD subgroup 
NA 
Lamers 1994 [8] Visual score No CT quantitative measurements No CT measurements 
Leader 2008 [21]* WA%, Ai, Ao, WA WA% & FEV1 %pred: -0.584 
Ai & FEV1 %pred: 0.540 
Ao & FEV1 %pred: 0.410 
WA & FEV1 %pred: 0.172 
NA 
Leader 2009 [61] WA%, Ai, Ao, WA, 
etc. 
WA% & FEV1 %pred: -0.238 
WA% & FEV1/FVC: -0.180 
Ai & FEV1 %pred: 0.286 
Ai & FEV1/FVC: 0.237 
Ao & FEV1 %pred: 0.149 
Ao & FEV1/FVC: 0.128 
WA & FEV1 %pred: -0.007 
WA & FEV1 %pred: -0.001 
NA 
Lee 2008 [22]* %LAA-950, MLD, 
Ai, WA, WA% 
%LAA-950 & FEV1 %pred: -0.547 
MLD & FEV1 %pred: 0.439 
WA% & FEV1 %pred: -0.044 
%LAA-950 & FEV1 %pred: -0.553 
MLD & FEV1 %pred: 0.619  
 
Lee 2011 [62] %LAA-950 No reports on the correlation  
with FEV1 %pred or FEV1/FVC 
No reports on the correlation with 
FEV1 %pred or FEV1/FVC 
Lee 2011 [63] %LAA-950, MLD, 
LV, etc. 
No reports on the correlation  
with FEV1 %pred or FEV1/FVC  
No reports on the correlation with 
FEV1 %pred or FEV1/FVC  
Li 2009 [64] LV, etc. LV & FEV1 %pred: 0.315 
LV & FEV1/FVC: 0.191 
LV & FEV1 %pred: -0.616 
LV & FEV1/FVC: -0.543 
Madani 2010 [65] %LAA-980 to -900 
Perc 1 to 18  
No reports on the correlation with FEV1 




Visual score No CT quantitative measurements NA 
Matsuoda 2007 [14] %LAA-950,  
%LAA-900 
%LAA-950 & FEV1 %pred: -0.471 
%LAA-950 & FEV1/FVC: -0.428 
%LAA-900 & FEV1 %pred: -0.404 
%LAA-900 & FEV1/FVC: -0.320 
%LAA-950 & FEV1 %pred: -0.602 
%LAA-950 & FEV1/FVC: -0.554 
%LAA-900 & FEV1 %pred: -0.618 
%LAA-900 & FEV1/FVC: -0.525 
Matsuoda 2008 [67] Ai, etc. Ai & FEV1 %pred: 0.26 
Ai & FEV1/FVC: 0.28 
Ai & FEV1 %pred: 0.63 
Ai & FEV1/FVC: 0.64 
Matsuoda 2008 [68] Percentage  
between two 
thresholds  
No CT quantitative measurements No CT quantitative measurements 
Mets 2011 [69] log%LAA-950, 
Perc15,etc. 
log%LAA-950 & logFEV1: 0.53
† 
log%LAA-950 & FEV1/FVC: 0.61
† 
Perc15 & logFEV1: 0.44
† 
Perc15 & FEV1/FVC: 0.53
† 
NA 
Mishima 1999 [70] %LAA-960 %LAA-960 & FEV1 %pred: -0.320 




%LAA-950, Perc15 %LAA-950 & FEV1 %pred: -0.16 
%LAA-950 & FEV1/FVC: -0.42 
Perc15 & FEV1 %pred: 0.12 
Perc15 & FEV1/FVC: 0.39 
NA 
Moron 2004 [71] Visual score No CT quantitative measurements NA 
Moroni 2001 [72] %LAA-910, MLD No reports on the correlation with FEV1 
%pred or FEV1/FVC 
%LAA-910 & FEV1/FVC: -0.78 
MLD & FEV1/FVC: 0.85 
Nakano 1999 [73] %LAA-960 %LAA-960 & FEV1: -0.492 
%LAA-960 & FEV1/FVC: -0.622 
NA 
Nakano 2000 [3] %LAA-960 
WA%, Ai, Ao, T/D 
ratio, etc. 
%LAA-960 & FEV1 %pred: -0.529 
%LAA-960 & FEV1/FVC: -0.650 
WA% & FEV1 %pred: -0.338 
Ai & FEV1 %pred: 0.273 
Ao & FEV1 %pred: 0.195 
WA% & FEV1/FVC -0.192 
NA 
O'Donnel 2004 [40] %LAA-950, MLD %LAA-950 & FEV1 %pred: -0.45 
MLD & FEV1 %pred: 0.38 
%LAA-950 & FEV1 %pred: -0.52 
MLD & FEV1 %pred: 0.63 
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Ohara 2006 [74] %LAA-960, WA%, 
Ai, Ao, T/D ratio, 
etc. 
Separately reported by lung fields  
%LAA-960 & FEV1 %pred: -0.331 
(upper) 
%LAA-960 & FEV1/FVC: -0.222 (upper) 
%LAA-960 & FEV1 %pred: -0.487 
(lower) 
%LAA-960 & FEV1/FVC: -0.491 (lower) 
WA% & FEV1 %pred: -0.336 (upper) 
WA% & FEV1/FVC: -0.280 (upper) 
WA% & FEV1 %pred: -0.339 (lower) 
WA% & FEV1/FVC: -0.357 (lower) 
NA 
Ohno 2011 [30]* WA%, etc. WA% & FEV1 %pred: -0.69 
WA% & FEV1/FVC: -0.59 
NA 
Orlandi 2004 [15] %LAA-950, -910, 
MLD 
%LAA-950 & FEV1 %pred: -0.59 
%LAA-950 & FEV1/FVC: -0.65 
Separately reported by radiation dose 
%LAA-910 & FEV1 %pred: -0.91 (nor-
mal) 
%LAA-910 & FEV1/FVC: -0.81 (normal) 
MLD & FEV1 %pred: 0.77 (normal) 
MLD & FEV1/FVC: 0.78 (normal) 
%LAA-910 & FEV1 %pred: -0.87 (low) 
%LAA-910 & FEV1/FVC: -0.81 (low) 
MLD & FEV1 %pred: 0.57 (low) 
MLD & FEV1/FVC: -0.36 (low) 
NA 
Orlandi 2005 [75] %LAA-950, MLD, 
WA%, WA, T/D 
ratio 
%LAA-950 & FEV1 %pred: -0.42 
%LAA-950 & FEV1/FVC: -0.50 
MLD & FEV1 %pred: 0.40 
MLD & FEV1/FVC: 0.59 
WA% & FEV1 %pred: -0.04 
WA% & FEV1/FVC: -0.009 
NA 
Park 2008 [23]* %LAA-950 %LAA-950 & FEV1 %pred: -0.46 
%LAA-950 & FEV1/FVC: -0.67 
NA 
Patel 2008 [2] %LAA-950,  
%LAA-910,  
Visual score 
%LAA-950 & FEV1 %pred: -0.31 
%LAA-950 & FEV1/FVC: -0.41 
No reports on the correlation between 
%LAA-910 & FEV1 %pred or FEV1/FVC 
NA 
Pauls 2010 [24]* %LAA-950, LV %LAA-950 & FEV1 %pred: -0.360 
LV & FEV1 %pred: -0.162 
NA 
Pescarolo 2008 [76] Visual score No CT quantitative measurements NA 
Petersen 2010 [77] WA%, Ai, Ao No reports on the correlation with FEV1  
%pred or FEV1/FVC in COPD patients 
NA 
Sandek 2002 [78] %LAA-910, MLD %LAA-910 & FEV1 %pred: -0.69 
%LAA-910 & FEV1/FVC: -0.76 
MLD & FEV1 %pred: 0.36 
MLD & FEV1/FVC: 0.54 
%LAA-910 & FEV1 %pred: -0.83 
%LAA-910 & FEV1/FVC: -0.87 
Scichilone 2008 [79] MLD, etc No reports on the correlation between 
MLD & FEV1 %pred or FEV1/FVC 
NS 
Shaker 2005 [37] %LAA-910, 
Perc15, etc. 
%LAA-910 & FEV1 %pred: -0.62 
%LAA-910 & FEV1/FVC: -0.62 
Perc15 & FEV1 %pred: 0.62 
Perc15 & FEV1/FVC: 0.61  
NA 
Sorensen 2010 [80] Emphysema  
pattern 
No CT quantitative measurements NA 
Spiropoulos 2003 [81] %LAA-910 No reports on the correlation  
with FEV1 %pred or FEV1/FVC 
No reports on the correlation to 
FEV1 %pred or FEV1/FVC 
Torres 2011 [82] %LAA-960 %LAA-960 & FEV1 %pred: 0.14 
%LAA-960 & FEV1/FVC: -0.24 
NA 
Tsushima 2010 [83] %LAA-960,  
Visual score 
%LAA-960 & FEV1/FVC: -0.29 NA 
Van Der Lee 2006 
[84] 
%LAA-950, LV %LAA-950 & FEV1 %pred: 0.3
†
 
No reports on the correlation between 
LV & FEV1 %pred or FEV1/FVC 
NA 
Washko 2008 [12] %LAA-950, -910, 
MLD, Perc15, etc 
%LAA-950 & FEV1 %pred: -0.09 
%LAA-950 & FEV1/FVC: -0.09 
%LAA-910 & FEV1 %pred: -0.20 
%LAA-910 & FEV1/FVC: -0.19 
MLD & FEV1 %pred: 0.18 
MLD & FEV1/FVC: 0.21 
Perc15 & FEV1 %pred: 0.09 
Perc15 & FEV1/FVC: 0.12 
NA 
Washko 2009 [25]* %LAA-950, WA%, 
Ai, WT 
WA% & FEV1 %pred: -0.28 
WA% & FEV1/FVC: -0.014 
Ai & FEV1 %pred: 0.14 
Ai & FEV1FVC: 0.07 
WT & FEV1 %pred: -0.13 
WT & FEV1/FVC: -0.05 
NA 
Watanuki 1994 [85] MLD MLD & FEV1 %pred: 0.72 NA 
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Yamashiro 2010 [26]* %LAA-950, MLD, 
LV, etc. 
%LAA-950 & FEV1 %pred: -0.625 
%LAA-950 & FEV1/FVC: -0.713 
MLD & FEV1.%pred: 0.494 
MLD & FEV1/FVC: 0.562 
LV & FEV1 %pred: -0.010 
LV & FEV1/FVC: -0.198 
%LAA-950 & FEV1 %pred: -0.637 
%LAA-950 & FEV1/FVC: -0.729 
MLD & FEV1.%pred: 0.661 
MLD & FEV1/FVC: 0.743 
LV & FEV1 %pred: -0.406 
LV & FEV1/FVC: -0.588 
Yamashiro 2010 [28]* %LAA-950, WA%, 
Ai, etc. 
%LAA-950 & FEV1 %pred: -0.460 
WA% & FEV1 %pred: -0.470 
Ai & FEV1 %pred: 0.450 
NA 




No CT quantitative measurements No CT quantitative measurements 
Zampatori 1997 [87] %LAA-900, Visual 
score 
No reports on the correlation with  
FEV1 %pred or FEV1/FVC 
%LAA-900 & FEV1 %pred: -0.65 
Zampatori 2001 [88] Visual score No CT measurements NA 
Zampatori 2001 [89] %LAA-900, LV, 
Visual score 
LV & FEV1 %pred: -0.49 
LV & FEV1/FVC: -0.69 
NA 
Zampatori 2002 [90] %LAA-900,  
MLD, LV,  
Visual score 
%LAA-900 & FEV1%pred: -0.53(Scan 1) 
%LAA-900 & FEV1%pred: -0.56(Scan 2) 
%LAA-900 & FEV1/FVC: -0.79 (Scan 1) 
%LAA-900 & FEV1/FVC: -0.80 (Scan 2) 
No reports on the correlation between 
MLD, LV & FEV1 %pred or FEV1/FVC 
NA 
Zaporozhan 2005 [41] %-LAA-950, MLD, 
LV, etc 
No reports on the correlation with  
FEV1 %pred or FEV1/FVC 
No reports on the correlation to 
FEV1 %pred or FEV1/FVC 
Zhang 2008 [27]* %-LAA-950, -910, 
MLD 
 
%LAA-950 & FEV1 %pred: -0.520 
%LAA-950 & FEV1/FVC: -0.626 
MLD & FEV1 %pred: 0.416 
MLD & FEV1/FVC: 0.512 
%LAA-910 & FEV1 %pred: -0.437 
%LAA-910 & FEV1/FVC: -0.548 
NA 
NA = not available; %LAA = percentage low attenuation area; MLD = mean lung density; LV = lung 
volume; Perc = percentile point of lung density; WA% = airway wall area percentage; Ai = airway 






















Supplemental Table D   Assessment of Study Quality, by the Quality Assessment of Diagnostic 
Accuracy Studies (QUADAS) tool 






















































































































































































































































































































































































































Akira 2009 [13] Y Y Y Y Y Y Y Y Y U U Y Y Y 13.0 
Bon 2009 [18] Y Y Y U Y Y Y Y Y U Y Y Y Y 13.0 
Dransfield 2007 [19] Y Y Y U Y Y Y Y Y U U Y Y Y 12.5 
Hasegawa 2006 [20] Y Y Y Y Y Y Y Y Y Y U Y Y Y 13.5 
Hesselbacher 
2011[29] 
Y Y Y U Y Y Y Y Y U Y Y Y Y 13.0 
Iwasawa 2011 [31] Y Y Y Y Y Y Y Y Y Y U Y Y Y 13.5 
Leader 2008 [21] Y Y Y U Y Y Y Y Y U U Y Y Y 12.5 
Lee 2008 [22] Y Y Y Y Y Y Y Y Y Y U Y Y Y 13.5 
Ohno 2011 [30] Y Y Y Y Y Y Y Y Y U U Y Y Y 13.0 
Park 2008 [23]  Y Y Y Y Y Y Y Y Y U U Y Y Y 13.0 
Pauls 2010 [24] Y Y Y Y Y Y Y Y Y Y U Y Y Y 13.5 
Washko 2009 [25] Y Y Y U Y Y Y Y Y Y U Y Y Y 13.0 
Yamashiro 2010 [26] Y Y Y U Y Y Y Y Y U U Y Y Y 12.5 
Yamashiro 2010 [28] Y Y Y U Y Y Y Y Y Y U Y Y Y 13.0 
Zhang 2008 [27] Y Y Y Y Y Y Y Y Y U U Y Y Y 13.0 
Item number (Yes) 15 15 15 8 15 15 15 15 15 6 2 15 15 15  
Item number (No) 0 0 0 0 0 0 0 0 0 0 0 0 0 0  
Item number (Un-
known) 
0 0 0 7 0 0 0 0 0 9 13 0 0 0  
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Supplemental Table E   Bias analysis in the meta-analysis 
















       
%LAA-950 and 
FEV1%pred  
11.65 0.11 39.9 451 0.62 0.22 0.16 
%LAA-950 and 
FEV1/FVC 
10.22 0.12 41.3 614 0.45 0.31 0.71 
MLD and FEV1%pred 6.08 0.11 50.6 97 0.50 0.14 0.22 
MLD and FEV1/FVC 8.29 0.02 75.9 172 0.60 0.77 0.05 
WA% and FEV1%pred 8.50 0.04 64.7 255 0.73 0.60 IS 
Expiration        
%LAA-950 and 
FEV1%pred  
0.81 0.67 0 84 0.12 0.21 0.85 
%LAA-950 and 
FEV1/FVC 
0.38 0.54 0 IS IS IS IS 
MLD and FEV1%pred 3.55 0.17 43.6 122 0.12 0.15 0.56 
MLD and FEV1/FVC 0.05 0.82 0 IS IS IS IS 
FEV1 %pred = predicted forced expiratory volume in the first second; FEV1/FVC = FEV1 divided by 
forced vital capacity; %LAA-950 = percentage lower attenuation area than -950 HU; MLD = mean 
lung density; Perc 15 = 15 percentile point of lung density; WA% = wall area percentage; IS = insuf-
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The prevalence of chronic respiratory symptoms is high in smokers in lung cancer screen-
ing. The study-purpose is to compare CT-derived airway wall measurements between 
smokers with and without chronic respiratory symptoms.  
 
Materials and Methods 
50 heavy smokers with chronic respiratory symptoms (cough, mucus, dyspnea and wheez-
ing) and 50 without any respiratory symptom were randomly selected from the NELSON 
trial. This trial was ethically approved. All participants gave written informed consent. Im-
ages on thin-slice low-dose CT were evaluated using dedicated software for airway meas-
urements. Wall area percentage (WA%) and airway wall thickness (AWT) and were meas-
ured for airways with a luminal diameter ≥ 5 mm in five different bronchi in different pul-
monary lobes. Association between airway wall measurements and respiratory symptoms 
was analyzed using multiple linear regression, adjusted for age, body mass index, smoking 
status, emphysema and pulmonary function.  
 
Results 
After adjusting for relevant factors, a significant positive association between airway wall 
measurements and respiratory symptoms was found in airways with a 5 - 10 mm luminal 
diameter (p < 0.01), but not in ≥ 10 mm airways (p > 0.05). In the 5 - 10 mm airway level, 
mean WA% was 51.5 ± 7.9% and 48.1 ± 7.7% in symptomatic and asymptomatic group, re-
spectively. AWT was 1.54 ± 0.39 mm and 1.37 ± 0.35 mm, respectively.  
 
Conclusion 
Heavy smokers with chronic respiratory symptoms in lung cancer screening, who are of 
high-risk for chronic bronchitis, have bronchial wall thickening in airways with luminal 














Nearly half of smokers in lung cancer screening have chronic respiratory symptoms, i.e., 
chronic hyper secretion of mucus, combined with chronic cough, often accompanied by 
dyspnea and wheezing [1]. Smokers with these symptoms have a great chance to develop 
chronic bronchitis, a disease associated with an accelerated decline in pulmonary function 
– a major risk factor for chronic obstructive pulmonary disease (COPD) and all-cause mor-
tality [2,3]. During their lifetime, over 40% of smokers develop chronic bronchitis [2]. The 
clinical diagnosis of chronic bronchitis is commonly based on a combination of medical 
history, physical examination, spirometry and laboratory test [4]. The confirmative diagno-
sis relies on histopathology [5]. Despite the high prevalence, chronic bronchitis was often 
under-diagnosed or late-diagnosed [6].  
Chronic bronchitis is histopathologically found in a range of airways, commonly in 
large airways [7]. The morphological basis of chronic bronchitis is bronchial wall thicken-
ing and airway luminal narrowing, which subsequently result in airflow limitation [8]. 
Morphological changes are important to understand pathogenesis and effect of therapeutic 
interventions for chronic bronchitis [5,9]. Recent development of thin-slice multi-detector 
CT and dedicated software, allows accurate noninvasive quantification of airway dimen-
sions in large bronchi [10-12].  
In participants of lung cancer screening, it is important to know whether there are 
morphological changes of airway walls in subjects with chronic respiratory symptoms, 
since there would be substantial benefit to early detect airway remodelling of chronic 
bronchitis in this high-risk population. Airway wall thickening associated with some rele-
vant factors, such as age, body mass index, smoking status, emphysema and pulmonary 
function [13,14]. In the population of lung cancer screening, the adjusted association be-
tween CT-derived airway wall quantification and respiratory symptoms is still unclear. 
Therefore, the purpose of our study was to retrospectively compare the airway wall thick-
ness along the respiratory pathway between subjects with and without chronic respiratory 
symptoms, adjusted for relevant factors. 
 
Materials and methods 
 
Sample 
The study sample was randomly selected from the baseline round in one center of a popu-
lation-based Dutch-Belgian Randomized Lung Cancer Screening Trial (NELSON) (Figure 1). 
The symptomatic group contained 50 heavy smokers with four chronic respiratory symp-
toms, including chronic cough, chronic mucus hyper-secretion, dyspnea and wheezing 
lasting for at least three months during the last year before inclusion. The asymptomatic 
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group contained 50 smokers without any respiratory symptoms. Given the confidence level 
of 95%, a 50/50 sample size would provide a statistical power of > 0.90 in t-test when as-
sessing wall area percentage (WA%) in large airways between symptomatic and asympto-
matic groups [15]. 
 
Figure 1   Flow diagram of subject selection 
 
The NESON trial was approved by the Dutch Minister of Health and the ethics board 
in the participating center. All participants gave written informed consent. Detailed inclu-
sion and exclusion criteria and characteristics in this male population-based trial have 
been described elsewhere [16]. In short, current or former elderly smokers with a smoking 
history of at least 20 pack-years were included. Individuals in moderate or poor health with 
inability to climb two flights of stairs were excluded. Information about the presence of 
respiratory symptoms and smoking behavior (current or former smoker, pack-years, etc.) 









A 16-row multi-detector CT (Sensation 16, Siemens, Forchheim, Germany) was util-
ized with a low-dose acquisition protocol [17]. The protocol was: spiral acquisition at 120 
kV, 20 mAs, rotation time 0.5 s, pitch 1.5 and collimation 16 × 0.6 mm, field of view 350 mm, 
slice thickness 1 mm and slice increment 0.7 mm. The effective radiation dose is less than 
0.8 mSv. Contrast media was not used. The images were reconstructed to a pixel matrix of 
512 × 512 using a medium-smooth B30f kernel. The CT system was calibrated routinely. The 
image acquisition was performed during one breath-holding at full inspiration after appro-
priate instruction.  
 
Pulmonary function testing 
Standard pulmonary function testing was performed according to the European Respira-
tory Society guidelines [18] on the same day as the CT acquisition. In this population based 
trial, a bronchodilator was not administered. Forced expiratory volume in one second 
(FEV1) and forced vital capacity (FVC) were assessed. FEV1 was presented as a percentage of 
predicted (FEV1 %pred).  
 
Airway selection 
We investigated large airways with an internal luminal diameter ≥ 5 mm [19, 20], which 
were categorized into three categories (luminal diameter 5 ≤ Ø < 10 mm; 10 ≤ Ø < 15 mm; 
and Ø ≥ 15 mm). To measure the airway dimensions, we selected five bronchi of segmental 
level, each representing one pulmonary lobe: the apical bronchus (RB1) of the right upper 
lobe, the lateral bronchus (RB4) of the right middle lobe, the posterior basal bronchus 
(RB10) of the right lower lobe, the apicoposterior bronchus (LB1+2) of the left upper lobe, 
and posterior basal bronchus (LB10) of the left lower lobe. Those bronchi were selected 
because they are relatively free from cardiac motion artifacts. In the bronchial tree below 
segmental level, when there was more than one bronchus in each airway generation, we 
evaluated only one bronchus in each generation. Thereafter, the bronchial pathway was 















Quantitative image analysis 
The images were evaluated using dedicated software for airway measurement (Airway Ex-
aminer 1.0, Fraunhofer MEVIS, Bremen, Germany), which based on a three-dimensional 
(3D) algorithm of airway geometry [12], instead of the traditional full-width-at-half-
maximum (FWHM) algorithm. Briefly, wall thickness is estimated in 3D space using this 
3D algorithm, rather than 2D plane in FWHM method [12]. For airway wall thickness as 
small as 1 mm, the 3D algorithm showed much better accuracy and reproducibility than the 
FWHW method in phantom studies [12,21]. This software tool follows two principal steps. 
Firstly, the software automatically segments bronchial tree. Secondly, after clicking a bron-
chus in bronchial tree, the software automatically quantifies airway dimensions along tra-
chea to the chosen bronchus, presenting data per 1 mm along this respiratory pathway. A 
representative figure generated by the software package was shown in Figure 2. We col-
lected three airway quantitative measurements, including WA%, airway wall thickness 
(AWT) and airway luminal diameter. WA% was defined as (wall area) / (wall area + lumen 
area) × 100%.  
Figure 2   Reformatted images generated by 
the dedicated software. The bronchial tree 
was automatically segmented (a). A bronchial 
pathway from trachea to a selected bronchus 
was converted to a stretched multiple planar 






After randomization of all included subjects, one radiologist with nine years’ experi-
ences in thoracic diagnostic radiology evaluated the images, blinded to subject information 
on basic characteristics and respiratory symptoms during evaluation. Time duration of 
whole assessment processes for each subject was approximately three minutes. 
Emphysema quantification was performed using dedicated software (ImageXplorer, 
Image Sciences Institute, Utrecht, The Netherlands). This software automatically implies 
lung segmentation, image noise reduction, and CT density calibration to improve accuracy 
and reproducibility of evaluation [22,23]. The images were recalibrated by shifting CT den-
sity so that the density inside the trachea became -1000 Hounsfield unit (HU) [19]. We col-
lected three CT quantification parameters, including 15 percentile point of lung density 
(Perc 15), percentage of lung attenuation area under -950 HU (%LAA-950) and lung volume. 
Larger emphysematous tissues are indicated by lower Perc 15 or higher %LAA-950.  
 
Statistics 





 percentile) for nonnormally distributed data. Differences in characteristics 
between the symptomatic and asymptomatic group were assessed by independent-samples 
t-test for normally distributed continuous data, by Mann-Whitney U-tests for nonnormally 
distributed continuous data, and by Chi-square test for nominal data. The association be-
tween airway wall measurements (WA% and AWT) and potentially associated factors was 
evaluated by univariate linear regression. The association between airway wall measure-
ments and respiratory symptoms was analyzed using multiple linear regression, adjusted 
for age, BMI, smoking status, Perc 15, and FEV1 %pred. 
A p < 0.05 was considered as statistically significant. Statistical analyses were per-





Characteristics of the symptomatic and asymptomatic group are presented in Table 1. All 
subjects were male, with a mean age of 56.5 ± 5.4 years (range from 50 to 69 years). No 
diseases (pneumonia, atelectasis and heavy pulmonary fibrosis, etc.) affecting airway wall 
measurements were observed through reviewing CT images. No obstructive diseases (air-
way mass/tumor, external compression and bronchial stricture, etc.) causing airway wall 
thickening were found either. Airway walls were successfully evaluated in all the 100 sub-
jects, in which, 65,070 cross sections of airways were measured. WA% increased from 
proximal to distal airway, while AWT and luminal diameter decreased. WA% ranged from 
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14.6 to 75.5%. AWT ranged from 0.7 to 3.2 mm. Airway luminal diameter ranged from 5.0 to 
22.9 mm.  
 
Table 1   Characteristics of included subjects with and without chronic respiratory symptoms  
 Symptomatic  Asymptomatic p value 
Sample size, n 50 50  
Basic characteristics    
    Male, n  50 50  
    Age, years 56.0 ± 5.1 57.3 ± 5.7 0.190 
    Weight, kg 86.9 ± 13.6 83.9 ± 12.5 0.253 
    Height, m 1.79 ± 0.05 1.79 ± 0.06 0.628 
    Body mass index, kg/m2 27.0 ± 3.9 26.2 ± 3.3 0.282 
Smoking behavior    
    Current/former smoker, n 37 / 13 23 / 27 < 0.05 
    Pack-years 42.1 ± 15.5 39.9 ± 14.6 0.411 
    Smoking duration, years 8.3 ± 1.0 8.0 ± 1.1 0.130 
CT quantification    
    Wall thickness, mm 1.55 ± 0.44 1.42 ± 0.40 < 0.001 
    Wall area percentage, % 47.0 ± 12.1 43.3 ± 11.1 < 0.001 
    Lung volume, l 7.0 (6.3, 8.0) 6.6 (5.7, 7.5) < 0.001 
    Perc15, HU -922 (-933, -912) -915 (-928, -898) < 0.001 
    %LAA-950, % 3.2 (2.1, 5.5) 2.3 (1.0, 4.0) < 0.001 
Pulmonary function test    
    FEV1 %pred 80.3 (65.4, 110.4) 102.9 (95.6, 108.2) < 0.001 
    FEV1/FVC, % 65.5 (51.9, 72.4) 75.3 (69.6, 80.8) < 0.001 
COPD status    
    COPD, n 34 13 < 0.001 
    GOLD stage I, n 12 11  
    GOLD stage II, n 14 2  
    GOLD stage III, n 6 0  
    GOLD stage IV, n 0 0  
Data are reported as mean ± standard deviation for normally distributed data or median (25th, 75th 
percentile) for nonnormally distributed data. HU = Hounsfield unit; Perc15 = 15 percentile point of 
lung density; %LAA-950 = percentage of lung attenuation area under -950HU; FEV1 %pred = forced 
expiratory volume in the first second as percentage from predicted; FEV1/FVC = FEV1 divided by 
forced vital capacity; COPD = chronic obstructive pulmonary disease; GOLD = the Global Initiative 
for Chronic Obstructive Lung Disease. 
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The symptomatic group had more current smokers than asymptomatic group (74% vs. 
46%, p < 0.05). No significant differences were found for age, BMI, pack-years and smoking 
duration between those two groups (p > 0.05). 
In CT emphysema quantification, the symptomatic group had significantly lower Perc 
15 and higher %LAA-950 than the asymptomatic group (p < 0.001), indicating more emphy-





tile: 2.1, 5.5) and 2.3 (1.0, 4.0) in the symptomatic and asymptomatic group, respectively, 
indicating mild emphysema in those two groups [10]. The symptomatic group had signifi-
cantly worse pulmonary function (FEV1 %pred and FEV1/FVC) than asymptomatic group (p 
< 0.001).  
 
Table 2   Univariate regression analysis for factors associated with airway wall measurements 
Airway wall thickness  
 
 
Wall area percentage 
 
B p value  B p value 
Basic characteristics      
    Age, years -0.003 < 0.05  -0.132 < 0.01 
    Weight, kg 0 0.508  0.041 0.281 
    Height, m 0.151 0.373  1.940 0.667 
    Body mass index, kg/m2 0.012 < 0.05  0.160 < 0.05 
Smoking behavior      
    Current smoking  0.102 < 0.001  2.418 < 0.001 
    Pack-years 0.004 < 0.001  0.084 < 0.001 
    Smoking duration, years 0.021 < 0.001  0.233 < 0.01 
Respiratory symptoms      
    Presence of respiratory symptoms  0.124 < 0.001  3.742 < 0.001 
CT emphysema quantification      
    Lung volume, l 0.021 0.244  -0.163 0.361 
    Perc15, HU 0 0.259  0.021 0.132 
    %LAA-950, % 0.002 0.242  -0.041 0.430 
Pulmonary function test      
    FEV1 %pred -0.005 < 0.001  -0.120 < 0.001 
    FEV1/FVC, % -0.007 < 0.001  -0.164 < 0.001 
HU = Hounsfield unit; Perc 15 = 15 percentile point of lung density; %LAA-950 = percentage of lung 
attenuation area under -950 HU; FEV1 %pred = forced expiratory volume in the first second as per-
centage from predicted; FEV1/FVC = FEV1 divided by forced vital capacity.  
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Factors associated with airway wall measurements 
Univariate linear regression analysis showed that airway wall measurements positively as-
sociated with the presence of respiratory symptoms, and with BMI, current smoker, pack-
years and smoking duration (p < 0.05) (Table 2). Conversely, airway wall measurements 
negatively associated with age and pulmonary function parameters (FEV1 %pred and 
FEV1/FVC) (p < 0.001).  
 
 
Figure 3   Airway wall area percentage (a) and thickness (b) between symptomatic and asympto-
matic subjects of chronic respiratory symptoms, without adjusting for relevant factors. Significant 







Airway wall measurements between symptomatic and asymptomatic group 
Without adjustment for relevant factors, the symptomatic group showed overall higher 
WA% (47.0 ± 12.1% vs. 43.3 ± 11.1%, p < 0.001) and higher AWT (1.55 ± 0.44 mm vs. 1.42 ± 
0.40 mm, p < 0.001) than the asymptomatic group. In detail, in all the three categories of 
large airways (luminal diameter: 5 ≤ Ø < 10, 10 ≤ Ø < 15 and Ø ≥ 15), the symptomatic group 
showed significant higher WA% and AWT (p < 0.01) (Figure 3). The representative images 
of those two groups are showed in Figure 4. 
 
 
Figure 4   Cross-section images perpendicular to long axis of the bronchi. An image of a sympto-
matic subject (a). Wall area percentage (WA%) = 51%, airway wall thickness (AWT) = 1.4 mm and 
luminal diameter = 7 mm. An image of an asymptomatic subject (b). WA% = 43%, AWT = 1.1 mm 
and luminal diameter = 7 mm.  
 
However, using multiple linear regression, after adjusted for age, BMI, smoking 
status, Perc 15, and FEV1 %pred, a significant positive association between airway wall 
measurements (WA% and AWT) and respiratory symptoms was found only in airways with 
a luminal diameter from 5 to 10 mm (p < 0.01). In the airway level from 5 to 10 mm, mean 
WA% was 51.5 ± 7.9% and 48.1 ± 7.7% in symptomatic and asymptomatic group, respec-
tively. AWT was 1.54 ± 0.39 mm and 1.37 ± 0.35 mm, respectively. No significant associa-
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Table 3    Multiple linear regression for the association between airway wall measurements and 
Chronic respiratory symptoms, adjusted for age, BMI, current smoking status, Perc 15, and FEV1 
%pred 
Airway luminal diameter, mm 
5 ≤ Ø < 10 10 ≤ Ø < 15 Ø ≥ 15   
B p value B p value B p value 
Respiratory symptoms 0.091 <0.001 0.051 0.170 0.052 0.339 
Age 0.004 0.075 0.003 0.409 -0.013 <0.01 
BMI 0.014 <0.001 0.002 0.646 -0.009 0.186 
Current smoking  0.019 0.461 0.159 <0.001 -0.014 0.793 











FEV1 %pred -0.006 <0.001 -0.004 <0.001 -0.003 <0.01 
Respiratory symptoms 1.647 <0.01 0.054 0.944 0.551 0.500 
Age 0.042 0.348 -0.065 0.347 -0.164 <0.05 
BMI 0.333 <0.001 0.015 0.881 -0.131 0.219 
Current smoking  0.509 0.330 3.084 <0.001 -0.202 0.801 
















FEV1 %pred -0.130 <0.001 -0.076 <0.001 -0.059 <0.001 
BMI = body mass index; Perc 15 = 15 percentile point of lung density; FEV1 %pred = forced expira-


















Thin-slice CT and automated software are promising tools to quantify airway walls. Using 
these techniques, after adjustment for relevant factors, heavy smokers with chronic respi-
ratory symptoms have significant thicker airway walls in airways with luminal diameter 
from 5 to 10 mm, but not the larger airways. If not adjusted for, the thicker airway walls 
were in all ≥ 5 mm airways.  
The symptomatic group showed general thicker airway walls, up to the trachea. The 
common causes of bronchial wall thickening are inflammatory, congenital (e.g., cystic fi-
brosis, alpha-1 antitrypsin deficiency, etc.) and obstructive [24, 25]. Inflammation of the 
mucous membrane directly results in hyper-secretion of mucus, leading to respiratory 
symptoms, such as cough, dyspnea and wheezing [26]. Our sample was from a population-
based trial, and the prevalence of these congenital bronchial diseases is rare [27, 28]. An 
experienced radiologist reviewed the CT images, and did not observe obstructive bronchial 
diseases. Thus, the primary cause of bronchial wall thickening in our study is likely in-
flammatory. Chronic bronchitis is a disease associated with long-term inflammatory stimu-
lation [7].  
Using CT quantification in COPD population instead of heavy smokers, Patel, et al. 
observed a significant positive association between wall thickness and respiratory symp-
toms in approximately 6 mm airways in luminal diameter [29]. Mair, et al. found a signifi-
cant positive association in proximal airways (> 11 mm in luminal diameter), but not for 
distal airways (approximately 2 to 4 mm) [20]. In consistent with the histological evidence 
that inflammation and airway remodeling, associating with chronic bronchitis, is located in 
the more central airways [30], our results strengthened those previous noninvasive findings, 
in case of without adjustment for relevant factors.  
Importantly, we adjusted for five relevant factors to determine the adjusted associa-
tion between thicker airway walls and chronic respiratory symptoms. In accordance with 
the previous studies, where age, BMI, smoking status and pulmonary function associated 
with airway wall thickening [14, 31, 32], we found that thicker airway walls were signifi-
cantly associated with younger age, higher BMI, current smoking and worse pulmonary 
function by univariate linear regression. Inconsistent with the prior studies, where emphy-
sema associated with airway wall thickening [14, 33], we found a nonsignificant association 
between CT emphysema quantification and airway wall thickening. That inconsistent find-
ing might be explained by only mild emphysema in our sample, selected from a popula-
tion-based screening trial. Our symptomatic group has more current smokers. Smoking 
often causes more active airway inflammation [34], which is an important potential con-
founder in this study. After adjustment for these potential confounders, we found signifi-
Part 4   Emphysema and bronchial wall 
 174 
cant thicker airway walls in airways with luminal diameter from 5 to 10 mm, but not the 
larger airways. 
A recently introduced three-dimensional algorithm was used to assess airway walls in 
this study. With this algorithm, wall thickness is approximated by an integral based closed-
form solution, based on the volume conservation property of convolution [12]. In contrast, 
the traditionally utilized “full-width-at-half-maximum (FWHM)” algorithm calculates the 
X-ray attenuation values along rays placed from the lumen center to outward directions in 
cross section [11]. The former algorithm has shown much better accuracy and reproducibil-
ity than the latter, for wall thickness as small as 1 mm in phantom studies [12, 21]. Thus, we 
expected that our measurements were accurate, in case of the sub-millimeter thickness 
difference between symptomatic and asymptomatic group.   
CT quantification is associated with pathophysiological changes of airway remodeling. 
A number of CT-derived measurements have been used for airways quantification, such as 
thickness, area, perimeter, CT density and visual score [13, 29, 35]. We measured WA% and 
AWT, because those two measurements directly indicate, and pathologically reflect airway 
wall thickening [36]. Moreover, we utilized automated dedicated software to evaluate air-
way dimensions per 1 mm. Some prior studies used manual methods to quantify airway 
walls, where airway walls were noncontinuously measured on cross-sections in-between a 
large gap of up to 20 mm [15, 29]. Mair, et al. has quantified airway walls, as a function to 
airway generation [20]. In addition to that study, we evaluated airway walls as a function to 
airway luminal diameter, since the same airway generation in two bronchi might be of dif-
ferent size.   
We evaluated large airways of ≥ 5 mm in luminal diameter, because chronic bronchi-
tis commonly involves large airways. On the other hand, thickening of small airway walls is 
important for the pathogenesis of COPD and asthma [36, 37]. Increased CT-derived airway 
thickness of more peripheral airways, as small as 2 to 4 mm in luminal diameter, strongly 
correlated with airflow limitations in those diseases [19, 38, 39]. 
 
Clinical implications 
In lung cancer screening trials, the common participants are heavy smokers, with a high 
prevalence of chronic bronchitis [2, 16]. Despite the high prevalence, chronic bronchitis 
was often under-diagnosed or late-diagnosed [6]. One morphological manifestation of 
chronic bronchitis is bronchial wall thickening caused by chronic inflammatory stimula-
tion [7]. We found that heavy smokers with chronic respiratory symptoms had significant 
thicker airway walls, which represents airway remodeling in an inflammatory process. Our 
study shows that this airway remodeling can be detected using thin-slice CT and dedicated 
software, thus has potential benefit for early diagnosis of chronic bronchitis. 
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Currently, clinical symptoms and spirometry are commonly used for diagnosis and 
surveillance of chronic bronchitis [40]. Noninvasive CT quantification of airway walls has 
shown the potential for regional and morphological evaluation of the therapeutic response 
in treatment of chronic bronchitis [9]. In our study, significantly thicker airway walls are 
especially identified in large airways of 5 to 10 mm in luminal diameter in respiratory symp-
tomatic group. Thus, CT quantification of airway walls may provide additional morpho-
logical information beyond clinical symptoms and spirometry. When assessing airway wall 
thickening in symptomatic individuals, the airways of 5 to 10 mm in luminal diameter op-
timally reflect the presence of respiratory symptoms, but not the larger airways. 
The absolute increase of airway wall thickening in symptomatic subjects is commonly 
within a millimeter, thus is difficult to be perceptible to human eyes on CT images. Hence, 
dedicated software is essential to assess airway walls. Our results were based on 16-row 
multi-detector CT utilized in a long-standing screening trial, we expect the latest CT tech-
nique could provide higher spatial resolution thus improve airway wall assessment. For 
example, we used image matrix of 512 × 512 voxels, while 1024 × 1024 matrix has been avail-
able [41]. Thin-slice CT and automated software showed promising results in this study, it 
is interesting to know the strength of these techniques in diagnosis of chronic bronchitis.      
   
Limitations 
Firstly, inherent to a population-based lung cancer screening trial, histopathological results 
of bronchial wall are very hard to be available. At least, our results suggested that the 
chronic respiratory symptoms associated with airway remodeling in an inflammatory proc-
ess, which is a pathological basis for chronic bronchitis. Also, participants are only heavy 
male smokers with mild emphysema. Gender was not adjusted for in this study. We ex-
pected our included sample at least represent the common population in lung cancer 
screening. Secondly, a post-bronchodilator pulmonary function test was not performed to 
assess reversibility in airflow limitation, which is a criterion to exclude bronchial asthma 
[37]. However, our results might not be substantially influenced by that limitation. Asthma, 
whether or not coexisting with chronic bronchitis, generally involves only a small number 
of elderly heavy smokers [42]. Our sample was from a population-based trial, and the 
prevalence of asthma in elderly men is approximately 2 % in the Netherlands [43]. Thirdly, 
five bronchi from different pulmonary lobes were evaluated because they are relatively free 
from cardiac motion artifacts, instead of bronchi from all the pulmonary lobes. A large 
number of airway cross sections (650 per subject) were measured. We expected that five 








After adjustment for relevant factors, heavy smokers with chronic respiratory symptoms 
out of a population-based lung cancer screening trial have significantly thicker airway walls 
than asymptomatic smokers. Thus, heavy smokers with chronic respiratory symptoms do 
have airway remodeling. Thin-slice CT and dedicated software showed the potential to 
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Summary 
 
Part 1   Introduction 
Lung cancer is the most common cause of cancer-related death in the world. The Dutch-
Belgian Randomized Lung Cancer Screening Trial (Dutch acronym: NELSON) was 
launched in 2003, to investigate whether screening for lung cancer by low-dose multi-
detector computed tomography (CT) in high risk subjects will lead to a decrease of lung 
cancer mortality. The NELSON trial is the first lung cancer screening trial, in which lung 
nodule management is primarily based on nodule volume at first detection, and volume 
doubling time on follow-up examinations. Nodule volume and volume doubling time are 
quantitative imaging biomarkers. 
Aging and heavy smoking, two participant recruitment criteria in the NELSON trial, 
are also major risk factors for cardiovascular disease and chronic obstructive pulmonary 
disease (COPD). Cardiovascular disease is the leading cause of all-cause mortality, causing 
32.8% of the total death count in 2008, whereas COPD is the fourth, causing 5.8% of 
mortality cases. Apart from lung cancer biomarkers, lung cancer screening CT scans yield 
additional information: coronary calcium scoring and emphysema quantification, as 
biomarkers of cardiovascular disease and COPD, respectively, can also be performed.  
In Chapter 2, a practical approach to the radiological evaluation of CT lung cancer 
screening examinations is described, including assessment of pulmonary nodules and non-
nodular diseases. The high resolution images acquired in low-dose thin-slice CT can be 
used not only to evaluate nodule volume, but also to measure and interpret other thoracic 
structures, e.g., coronary calcium scoring, emphysema quantification and airway wall 
thickness. 
 
Part 2   Lung nodules 
In lung cancer screening, it is very important to distinct malignant nodules from the vast 
majority of benign lesions. Prerequisites for accurate distinction are sensitive observer-
detection of the pulmonary nodules that are present, and accurate evaluation of nodule 
growth during follow-up. As described in Chapter 3, an anthropomorphic thoracic 
phantom study was performed to assess the observer detection sensitivity of randomly 
placed spherical pulmonary nodules, and to determine the accuracy of nodule volumetry. 
This study shows that a lung cancer screening protocol by low-dose CT such as utilized in 
the NELSON trial is highly reliable for the detection of spherical pulmonary nodules of 5 
mm in diameter (65 mm
3
 in volume) and larger. Low-dose CT yields more accurate nodule 
volumetry when using a semi-automated software tool than in case of manual 
measurements, with negligible underestimation of actual size.  
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In addition to spherical pulmonary nodules, small irregular nodules are a common 
finding in lung cancer screening. The latter nodules have an increased likelihood of being 
lung cancer. We made a set of artificial spiculated and lobulated nodules to simulate 
irregular pulmonary nodules. In Chapter 4, the observer detection sensitivity and 
volumetry accuracy were further analyzed using these artificial nodules. This study shows 
that small irregular solid pulmonary nodules with an actual volume of at least 69 mm
3
 can 
be reliably detected, independent of the observer, CT system and nodule characteristics. 
However, the volume underestimation of small irregular nodules is larger than in case of 
spherical nodules. Thus, a lower measured volume threshold for irregular nodules may be 
needed, as the measured size of irregular nodules can be larger than expected. Also, there 
is a potential risk to misjudge the growth rate of a small nodule, when a nodule changes 
into another shape during follow-up.  
Repeated CT measurement of the volume of pulmonary nodules can yield different 
results. To differentiate real growth from measurement variability, a volume increase of at 
least 25% has been defined as the minimal change to determine nodule growth. In the 
current practice of lung cancer screening trials, multiple CT systems are involved, often 
from different vendors. In Chapter 5, we assessed the inter- and intra-scanner variability of 
volumetry for artificial spherical pulmonary nodules. The volume of nodules between 5 and 
12 mm diameter correspond well for different 64-multidetector CT scanners in low-dose 
setting, and when measured repeatedly. The inter- and intra-scanner variability is lower at 
larger nodule size. Specifically, variability decreases to a maximum of about 5% for ≥ 8 mm 
nodules. Our results suggest that the commonly accepted cut-off of 25% to determine 
nodule growth can be reduced for ≥ 8 mm nodules when using semi-automated volumetry. 
This offers potential to reduce the interval for repeated CT scans in lung cancer screening. 
An important conclusion from our phantom studies is that semi-automated volume 
measurements should be used in the setting of lung cancer screening, to obtain accurate 
volumetry.  
 
Part 3   Coronary artery calcification 
The amount of coronary calcification can be evaluated by a dedicated, electrocardiography 
(ECG)-triggered CT scan of the heart. The extent of coronary calcification, expressed as a 
coronary calcium score, is a strong predictor of cardiovascular risk. Nowadays, many CTs of 
the thorax are performed, such as in lung cancer screening. However, these latter scans do 
not involve ECG-triggering; this can cause motion artifacts of the coronary arteries and 
may affect the resulting coronary calcium score. Deriving the calcium score from the same 
examination as used in lung cancer screening may positively impact the cost-effectiveness 
of screening. In Chapter 6, we performed a systematic review and meta-analysis to 
determine the correlation in calcium scoring between nontriggered and ECG-triggered CT, 
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and to evaluate the prognostic performance of the calcium score derived from 
nontriggered CT. There is strong agreement in categorization of calcium scores between 
ECG-triggered and nontriggered CT techniques. Increasing calcium score categories, based 
on nontriggered CT, are associated with increasing risk of cardiovascular death or events.  
However, variability in coronary calcium quantification based on nontriggered CT is 
known to be considerable, mainly caused by coronary artery motion. We aimed to 
determine the influence of motion on the correlation between calcium scores obtained 
with nontriggered and ECG-triggered CT. For this purpose, an in-depth validation study 
regarding the impact of motion artifacts on calcium scoring was performed. In Chapter 7, 
the in-vitro agreement in coronary calcium scoring between these two CT techniques was 
evaluated. We used an anthropomorphic thorax phantom, containing calcifications of 
known size and density that moved at a controlled velocity. In general, the agreement in 
calcium scores between nontriggered and ECG-triggered CT is good, but not for large-size 
and high-density calcifications at higher coronary velocity. Nontriggered CT shows a lower 
sensitivity to detect small calcifications (calcium score < 25) than ECG-triggered CT.   
The results from our studies suggest that calcium scoring based on lung cancer 
screening CT examinations has potential to stratify individuals into broad calcium score 
categories, as indicator of cardiovascular risk. However, a zero-score in a screening setting 
does not reliably exclude presence of coronary calcification.   
 
Part 4   Emphysema and airway wall 
The pathogenesis of airflow limitation in COPD is mainly related to emphysema and small 
airway remodeling. The assumption is that emphysema and peripheral airway wall 
thickness, as detected by CT, are related to airflow obstruction in COPD patients. Previous 
studies have shown variable and sometimes conflicting results, and some individual studies 
have been small and underpowered. In Chapter 8, we performed a systematic review and 
meta-analysis to determine the correlation between CT measurements of emphysema or 
peripheral airways and airflow obstruction as assessed by lung function tests in COPD. CT 
measurements of emphysema or peripheral airway are indeed correlated with airflow 
obstruction parameters in COPD patients. Correlations were found for inspiratory and 
expiratory CT examinations. These results confirm a relationship between morphology and 
function in COPD patients. However, this finding is based on multiple measurements in 
distribution level. It is hard to use this finding on one-to-one relationship between CT 
parameters and lung function test results. Even so, we can conclude that CT provides a 
quantitative morphological method to investigate airflow obstruction by emphysema and 
peripheral airway disease in COPD. 
Over 40% of smokers develop chronic bronchitis (CB), a major risk for COPD and all-
cause mortality. CB is usually characterized by airway wall remodeling, commonly in large 
  184 
airways. The morphological changes of airway wall are important to understand the 
pathogenesis and effect of therapeutic interventions in CB. CT yields quantitative 
biomarkers of CB, namely different measures of airway wall thickening. In Chapter 9, we 
compare the airway wall thickening along the respiratory pathway between subjects with 
and without respiratory symptoms of CB, adjusted for relevant confounding factors. The 
airway wall thickness was higher for the symptomatic than for the asymptomatic group. 
After adjusting for confounders, respiratory symptoms were related to CT-derived airway 
wall measurements in airways with diameter of 5 to 10 mm, but not in airways of ≥ 10 mm. 
From this, we can conclude that airways of 5 to 10 mm diameter optimally reflect the 
presence of respiratory symptoms in CB, but not the larger airways. 
 
Conclusions 
Pulmonary nodule volumetry, coronary calcium scoring, and emphysema and bronchial 
wall quantification are CT-derived biomarkers for three major diseases: lung cancer, 
coronary artery disease and COPD, respectively. Firstly, this thesis shows that pulmonary 
nodule > 5 mm diameter can be reliably detected using low-dose CT. Semi-automated 
volumetry is more accurate and reproducible than manual assessment. The volumetry 
variability is lower at larger nodule size. These findings improve the nodule management 
protocol in lung cancer screening. Secondly, increasing calcium score categories, based on 
nontriggered CT, are associated with increasing risk of cardiovascular events. A high-risk 
score detected on nontriggered CT is fairly reliable; however, a zero-score does not reliably 
exclude the presence of coronary calcification. Thirdly, CT evaluation of emphysema or 
peripheral airway correlates with airflow obstruction parameters. CT measurement of large 
bronchial wall associates with respiratory symptoms. These findings confirm a 
morphological basis of function or symptoms. 
As a conclusion, an integrated evaluation of these CT biomarkers may enhance the 
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Samenvatting 
 
Deel 1   Evaluatie van longkanker screening CT scans 
Longkanker is de meest voorkomende oorzaak van overlijden aan kanker ter wereld. Het 
Nederlandse Leuvens Longkanker Screenings Onderzoek (NELSON) is gestart in 2003. 
Deze studie onderzoekt of screenen op longkanker in hoogrisico groepen leidt tot verla-
ging van de kankersterfte. Screening wordt verricht door middel van multi-detector com-
puter tomografie (CT) met lage stralingsdosis. De NELSON studie is het eerste longkanker 
screenings onderzoek dat nodulen beoordeelt aan de hand van nodule volume bij eerste 
detectie, en van volume verdubbelingstijd op vervolgonderzoeken. 
Voorwaarde voor deelname aan de NELSON studie zijn hogere leeftijd en fors roken. 
Dit zijn ook belangrijke risicofactoren voor cardiovasculaire ziekte en chronisch obstruc-
tieve longziekte (COPD). Cardiovasculaire ziekte is de meest voorkomende doodsoorzaak, 
terwijl COPD de vierde doodsoorzaak is. Op het CT onderzoek kunnen afwijkingen gede-
tecteerd worden die kunnen wijzen op longkanker, genaamd longnodulen. Maar ook ande-
re afwijkingen kunnen beoordeeld worden. Zo kunnen kransslagaderverkalkingen gemeten 
worden, een maat voor het risico op cardiovasculaire ziekte. Ook kunnen emfyseem en 
wandverdikking van de luchtwegen geëvalueerd worden, die zijn gerelateerd aan de aan-
wezigheid van COPD.  In hoofdstuk 2 wordt de aanpak van de radioloog bij de beoorde-
ling van de longkanker screening CT scans beschreven. De hoge resolutie CT beelden, ver-
kregen bij de NELSON studie, worden niet alleen gebruikt om de aanwezigheid van boven-
beschreven afwijkingen te beoordelen, maar ook om deze te meten. Zo wordt het volume 
van longnodulen berekend middels software, en wordt de hoeveelheid kransslagaderver-
kalking bepaald en uitgedrukt in een kalkscore. Ook de ernst van emfyseem en wandver-
dikking van de luchtwegen wordt kwantitatief beoordeeld. Al deze metingen zijn zoge-
naamde kwantitatieve imaging biomarkers.  
 
Deel 2   Longnodulen 
In longkanker screening is het belangrijk dat kwaadaardige nodulen (kanker) worden on-
derscheiden van overgrote meerderheid van goedaardige longafwijkingen. Een eerste ver-
eiste hiervoor is dat de beoordelaars de aanwezige longnodulen accuraat detecteren. Daar-
naast is nauwkeurige evaluatie van groei van longnodulen tijdens follow-up nodig. In de 
studie beschreven in hoofdstuk 3 wordt een thorax fantoom gebruikt waarin artificiële 
ronde longnoduli zijn verspreid. In dit validatie onderzoek is de gevoeligheid van het de-
tecteren van longnodulen bestudeerd, en is de  nauwkeurigheid van de volume meting van 
de nodulen beoordeeld.  Deze studie laat zien dat het NELSON screenings protocol waarbij 
gebruik wordt gemaakt van een lage dosis CT, een hoge betrouwbaarheid heeft voor het 
detecteren van ronde longnodulen van 5 mm diameter (65 mm
3
 in volume) en groter. De 
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accuratesse in nodule volume metingen is hoger als gebruik wordt gemaakt van semi-
automatische software in plaatst van handmatige metingen. Zo wordt het onderschatten 
van de werkelijke grootte verwaarloosbaar klein.  
Naast ronde nodulen worden op longkanker screenings scans ook vaak onregelmatig 
begrensde longnodulen gevonden, b.v. sprieterige nodulen. De kans op longkanker in deze 
nodulen is verhoogd. In hoofdstuk 4 is de gevoeligheid voor detectie, en accuratesse van 
volume meting van dit type nodulen onderzocht. Hetzelfde thorax fantoom is gebruikt als 
in hoofdstuk 2. Maar nu zijn met de hand gemaakte, onregelmatige nodulen in het fan-
toom geplaatst. Deze studie laat zien dat kleine onregelmatig begrensde longnodulen met 
een volume van tenminste 69 mm
3
 betrouwbaar kunnen worden gedetecteerd. De onder-
schatting van het volume van onregelmatige nodulen is wel aanzienlijk groter in vergelij-
king met ronde longnodulen. Misschien dat in de diagnostische strategie daarom een lager 
volume afkappunt nodig is voor onregelmatig begrensde nodulen. Daarnaast moet het risi-
co op foutieve berekening van de groeisnelheid in het achterhoofd gehouden worden wan-
neer kleine longnodulen van vorm veranderen op vervolg scans.  
Op herhaal scans verricht met verwaarloosbaar tijdsinterval kan de volume meting 
van longnodulen variëren. Om groei te onderscheiden van meetvariatie, is een volumetoe-
name van tenminste 25% gedefinieerd. Vanaf 25% volumetoename wordt uitgegaan van 
groei van de longnodule. In longkanker screening worden in het algemeen verschillende 
multi-detector CT scanners gebruikt. Dit zou variatie in volume meting tot gevolg kunnen 
hebben. Daarom is in hoofdstuk 5 de variabiliteit van volume metingen tussen verschil-
lende scanners en voor herhaald scannen met dezelfde scanner onderzocht. Hiervoor werd 
hetzelfde thorax fantoom gebruikt met hierin de artificiële ronde longnodulen. Volume 
metingen van nodulen met diameter tussen 5 en 12 mm blijken goed overeen te komen op 
lage dosis scans van verschillende 64-multi-detector CT scanners. De variabiliteit vermin-
dert bij grotere nodulen, vooral voor longnodulen met een afmeting van tenminste 8 mm. 
De studie toont dat het geaccepteerde afkappunt van 25% als definitie voor nodule groei 
mogelijk verlaagd kan worden voor nodulen met een diameter van 8 mm en meer. Dat zou 
kunnen betekenen dat het tijdsinterval tot een herhaal CT scan in longkanker screening, 
nu 3-4 maanden, verlaagd kan worden. De conclusie van de fantoom onderzoeken is dat 
voor betrouwbare volume metingen in longkanker screening semi-automatische software 
benodigd is.  
 
Deel 3   Kransslagaderverkalkingen 
De hoeveelheid kransslagaderverkalking, uitgedrukt in de kalkscore, is een sterke voorspel-
ler van het risico op cardiovasculaire ziekte. De kalkscore kan accuraat beoordeeld worden 
op een CT scan van het hart, gemaakt met elektrocardiografische (ECG) triggering. ECG 
triggering is nodig om beelden te verkrijgen op het moment in de hartcyclus waarop het 
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hart het minste beweegt, zodat de beelden niet bewogen zijn. Net zoals bij de klinische CT 
scan van de thorax, wordt bij de scans in het kader van longkanker screening geen ECG 
triggering toegepast. Hierdoor kunnen de kransslagaders op de beelden bewegingsartefac-
ten vertonen, en dit kan de meting van de hoeveelheid verkalking beïnvloeden. Als de 
kalkscore bepaald zou kunnen worden op CT scans verricht in het kader van longkanker 
screening, zou dit een positieve impact kunnen hebben op de kosten-effectiviteit van 
screening. Dan zou je namelijk met één scan zowel het risico op longkanker als op cardio-
vasculaire ziekte kunnen bepalen. In hoofdstuk 6 wordt een systematische review en me-
ta-analyse beschreven naar de accuratesse van kalkscore bepaling voor niet-getriggerde CT 
scans van de thorax. Hiervoor zijn de kalkscores in categorieën ingedeeld. Kalkscore cate-
gorieën gebaseerd op een CT scan van de thorax en die gebaseerd op een ECG-getriggerde 
CT scan van het hart tonen sterke overeenkomst voor de onderzoeksgroepen als geheel. 
Vervolgens is gekeken naar de voorspellende waarde van de kalkscore voor later optreden 
van cardiovasculaire ziekte. Het risico op hart- en vaatziekten is verhoogd in hogere kalk-
score categorieën, ook als de kalkscore op niet-getriggerde CT scans gebaseerd is.  
Het is bekend dat er aanzienlijke variatie in de meting van de hoeveelheid kransslag-
aderverkalking is, wanneer deze wordt bepaald op een niet-getriggerde CT scan van de 
thorax. Meestal wordt dit veroorzaakt door de beweging van kransslagaders, waardoor de 
beelden onscherp zijn. Om de invloed van bewegingsartefacten op de kalkscore uitkomst 
van een niet-getriggerde CT scan te bepalen is validatie onderzoek uitgevoerd, zoals be-
schreven in hoofdstuk 7. Middels een fantoom met verkalkingen, bewegend met toene-
mende snelheid, is de overeenkomst in kalkscore tussen niet-getriggerde CT en ECG-
getriggerde CT geëvalueerd. De twee CT technieken tonen een goede overeenkomst in 
kalkscore, behalve voor grote en zeer dense verkalkingen bij hogere snelheid. Ook is een 
niet-getriggerde CT scan minder gevoelig voor de detectie van kleine verkalkingen vergele-
ken met een ECG-getriggerde CT scan. De studies in dit proefschrift ondersteunen de be-
paling van de hoeveelheid kransslagader verkalking in longkanker screening trials voor 
indeling in kalkscore categorieën op populatie niveau. Echter een kalkscore van nul op een 
niet-getriggerde CT kan de aanwezigheid van kransslagader verkalking niet betrouwbaar 
uitsluiten.  
 
Deel 4   Emfyseem en wanddikte van de luchtwegen 
Emfyseem en veranderingen van kleine luchtwegen spelen een belangrijke rol in het ont-
staan van luchtwegobstructie in COPD. Maten van emfyseem en wandverdikking van de 
kleine luchtwegen gebaseerd op CT scans worden verondersteld samen te hangen met de 
mate van luchtwegobstructie in COPD patiënten. Eerdere onderzoeken op dit gebied heb-
ben verschillende en soms tegenstrijdige resultaten gevonden. Ook waren sommige studies 
erg klein. Hoofdstuk 8 beschrijft een systematische review en meta-analyse, waarin de 
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relatie wordt bepaald tussen CT kwantificatie van emfyseem en perifere luchtwegen ener-
zijds, en luchtwegobstructie in longfunctie onderzoek anderzijds. CT metingen van emfy-
seem en perifere luchtwegen hangen inderdaad samen met luchtwegobstructie gemeten 
middels longfunctie testen in COPD patiënten. Deze resultaten bevestigen de correlatie 
tussen morfologie en functie in COPD patiënten. Echter in principe betreft dit een verband 
dat gevonden is op populatie niveau. Deze bevindingen kunnen niet 1-op-1 toegepast wor-
den op individuele patiënten.  Hoe dan ook, geconcludeerd kan wel worden dat CT een 
kwantitatieve morfologische methode oplevert om luchtwegobstructie bij emfyseem en 
perifere luchtwegziekten in de COPD populatie te onderzoeken.  
Meer dan 40% van de rokers ontwikkelt chronische bronchitis, een risicofactor voor 
ontwikkeling van COPD en overlijden. Chronische bronchitis wordt in het algemeen geka-
rakteriseerd door verandering van de luchtwegwand, meestal van de grote luchtwegen. 
Begrip van de morfologische veranderingen van de luchtwegwand is belangrijk om de oor-
zaak en het effect van therapeutische interventies in chronische bronchitis te begrijpen. In 
hoofdstuk 9 is de wandverdikking van luchtwegen beoordeeld op CT vergeleken tussen 
personen met en zonder luchtwegsymptomen van chronische bronchitis. De aanwezigheid 
van luchtwegsymptomen hangt samen met de wanddikte van luchtwegen met diameter 
van 5 tot 10 mm, na correctie voor beïnvloedende factoren. Een soortgelijk verband werd 
niet gevonden voor grotere luchtwegen, met diameter van tenminste 10 mm. Hieruit kan 
afgeleid worden dat m.n. kleinere luchtwegen van 5-10 mm diameter de aanwezigheid van 
luchtwegsymptomen weerspiegelen, maar niet de grotere luchtwegen.  
 
Conclusie 
Volume meting van longnodulen, kalkscore bepaling, en evaluatie van emfyseem en wand-
dikte van perifere luchtwegen zijn kwantitatieve CT biomarkers voor de drie belangrijkste 
doodsoorzaken: longkanker, hart- en vaatziekten en COPD. Dit proefschrift laat ten eerste 
zien dat longnodulen met een diameter van 5 mm en meer betrouwbaar kunnen worden 
gedetecteerd bij longkanker screening met lage dosis CT. Semi-automatische evaluatie van 
nodule volume is accurater en beter reproduceerbaar dan meting met de hand, voor zowel 
ronde als onregelmatige nodulen. De variabiliteit in volume meting neemt af met de nodu-
le grootte, tot onder de afkapwaarde die op dit moment gebruikt wordt om groei van 
meetvariatie te onderscheiden. Deze bevindingen kunnen helpen om de management van 
bij CT screening gedetecteerde longnodulen te optimalizeren. Ten tweede wordt geconclu-
deerd dat toenemende hoeveelheid kransslagader verkalking, gebaseerd op niet-
getriggerde CT van de thorax, gerelateerd is aan verhoogd risico op hart- en vaatziekten op 
populatie niveau. Een hoge kalkscore, gedetecteerd op een screenings CT, is redelijk be-
trouwbaar; echter een kalkscore van nul sluit de aanwezigheid van kransslagaderverkalking 
niet uit. Ten derde, CT evaluatie van emfyseem correleert met resultaten van longfunctie 
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onderzoek op populatie niveau. Wanddikte meting van perifere luchtwegen op basis van 
CT hangt samen met de aanwezigheid van  luchtweg symptomen in rokers. Deze bevindin-
gen bevestigen een morfologische basis van longfunctie en symptomen. 
In conclusie, longkanker screening CT kan niet alleen aangewend worden voor evalu-
atie van longnodulen, maar levert ook de mate van kransslagaderverkalking, emfyseem en 
wanddikte van perifere luchtwegen op. Geïntegreerde evaluatie van deze CT biomarkers 
voor de drie grote doodsoorzaken in de westerse bevolking (longkanker, cardiovasculaire 
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